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Poster Discussion A
Autoantigens and Autoantibodies in RA
P1
Anti-keratin antibodies in juvenile idiopathic
arthritis
I Hromadnikova, P Vavrincova, K Stechova, D Hridelova and 
J Vavrinec
2nd Paediatric Clinic, University Hospital Motol, Prague , 
Czech Republic
We discuss the presence of anti-keratin antibodies (AKA) of the
IgG class in patients with defined juvenile idiopathic arthritis (JIA).
An indirect immunofluorescence test and rat oesophagus substrate
was used for the detection and quantification of AKA antibodies in
patients´ sera. Overall 33/60 patients with JIA had sera positive for
AKA (55 %, P = 0,0001) ranging from 1:10 to 1:160 dilutions. Fol-
lowing idiopathic arthritis of childhood classification criteria AKA
occurred in 2/7 patients with systemic disease (28,6 %), in 13/30
patients with RF negative polyarthritis (43,3 %, P = 0,008) and in
15/18 RF positive polyarthritis (83,3 %, P = 0,000002). AKA were
also found in a small cohort of patients with oligoarthritis (1/3) and
psoriatic arthritis (2/2). AKA positivity occurred in 3/26 healthy con-
trols at a 1:20 dilution. The presence of AKA was correlated as well
as with the severity of the disease. Our study revealed that AKA
was present overall in 18/29 patients (62%) with severe JIA and in
12/26 patients (46,2 %) with non-severe disease, however this did
not reach statistical significance (P = 0,18). We also observed that
AKA remained positive regardless of disease activity. AKA were
detectable in 55,6 % patients with active JIA and in 48,6 % patients
in the complete or near remission.
Acknowledgement: This research was supported by a European
Commission (Acronym: EUROBANK, contract no: QOL-2000-
14.1), web site http://www.ncl.ac.uk and by grant of 2nd Medical
Faculty, Charles University in Prague, VZ no. 111300003.
P2
The significance of antibodies to cyclic
citrullinated peptide, antikeratin antibodies, anti-
perinuclear factor, rheumatoid factor isotypes and
HLA shared epitope in prediction of erosive
disease in early rheumatoid arthritis patients
J Vencovsky, L Sedova, S Machacek, J Gatterova, V Pesakova, 
J Kafkova and O Krystufkova
Institute of Rheumatology, Prague, Czech Republic
Objectives: To evaluate a predictive value of autoantibody examina-
tions in development of erosive disease in early rheumatoid arthritis
(RA).
Patients and methods: One hundred and fourteen patients with
disease duration less than 2 years after the onset of symptoms were
investigated. Only patients who fulfilled the diagnostic criteria for
RA either at the beginning of the disease or during the follow-up
period were included. The antibodies to cyclic citrullinated peptide
(anti-CCP) (Immunoscan RA, Euro-diagnostica, The Netherlands),
IgM, IgA and IgG rheumatoid factors (RF) were measured by ELISA,
antikeratin antibodies (AKA) and antiperinuclear factor (APF) were
detected by indirect immunofluorescence, and the presence of HLA
shared epitope (HLA SE) was detected by PCR with sequence
specific primers. Patients were divided into two groups, either with
erosive or non-erosive changes present on the hand or/and feet
radiographs at the end of 24 months follow-up.
Results: Seventy-six (66.7%) patients developed bony erosion,
whereas 38 (33.3%) remained without destructive changes. The
initial anti-CCP, AKA, APF, IgM RF, IgA RF, IgG RF and HLA SE
were positive in 50 %, 46 %, 42%, 54%, 47%, 43% and 67 % in
erosive group, and in 19%, 14%, 22%, 30%, 27%, 24% and 65%
in non-erosive group, respectively. The significant differences
between erosive and non-erosive groups were detected for anti-
CCP, AKA, IgM RF and IgA RF. The levels of anti-CCP were signifi-
cantly higher in erosive early RA group (159.1±224.0 units) vs.
non-erosive one (85.8±164.8). Similarly, patients with erosive
disease had significantly higher levels of IgM RF, IgA RF and IgG
RF (3,1±2.8; 2.8±2.6; 2.8±2.6) in comparison with patients without
erosions (1.9±2.0; 1.8±2.6; 2.1±2.8).
Conclusions: The data showed that a measurement of anti-CCP,
individual isotypes of RFs and to a less extent AKA, could be useful
for prediction of disease development in the early cases of RA.
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P3
Clinical sensitivity of antibodies against cyclic
citrulinated peptide in patients with rheumatoid
arthritis
B Boz
vic
v, S C
v
uc
vnik, A Ambroz
vic
v, B Lestan, M Kos-Golja, 
B Rozman B and T Kveder T
University Medical Centre, Department of Rheumatology, Ljubljana,
Slovenia
The synthetic cyclic citrulinated peptide (CCP) is recognised by
rheumatoid arthritis (RA) associated antifilaggrin antibodies, previ-
ously determined as antikeratin antibodies or perinuclear factor.
Antibodies detected by ELISA using CCP as an antigen (anti-CCP)
seem to be of prognostic value in patients with RA.
The objective of our study was to determine the clinical sensitivity of
anti-CCP in patients with definite RA (according to ARA diagnostic
criteria). RF results were considered when measured in the same
serum as anti-CCP.
Sera from 97 RA patients (15 M, 82 F) were tested for anti-CCP in
duplicates by Imunoscan RA ELISA (Euro-diagnostica). RF was
tested in the same serum in 69/97 patients.
In all 4 assay runs, OD of all calibrators vs. their calculated values
completely corresponded to the figure in the manufacturer’s analy-
sis certificate. When the units of the lowest calibrator D were calcu-
lated by the equation of log calibration curve according to the
manufacturer’s protocol, they were always about 20% (7-17U)
above the defined value (50U). This inconsistency of the curve
fitting led to a wrong validation in 26/97 (27%) of the RA samples
whith OD below the OD of the calibrator D, but with calculated
results above the defined cut-off at 50U. Therefore, we calculated
results by the equtation of 3rd degree polynomal curve which fitted
perfectly the measured OD values to the defined units.
Out of 97 RA patients, 56 were anti-CCP positive (58%). From 69
patients simultaneously tested for RF and anti-CCP, both tests were
positive in 24/69 (35%) and both negative in 23/69 (33%). Anti-
CCP were positive in 15/38 (40%) patients with negative RF.
Despite lower anti-CCP positivity rate, 16% of samples in RF neg.
group exhibited high anti-CCP values:
Anti-CCP (U) <50 (neg) 50–200 201–800 801–3200 >3200
RF pos (n = 31) 7 (23%) 4 (13%) 6 (19%) 5 (16%) 9 (29%)
RF neg (n = 38) 23 (60%) 6 (16%) 3 (8%) 4 (11%) 2 (5%)
The clinical sensitivity of the anti-CCP test in our RA patients was
58%, which is lower than previously reported (68%). The discrep-
ancy might partially be due to different calculation of the results. We
believe that the introduction of polynomal standard curve could con-
tribute to a more consistent validation of samples exhibiting OD
bellow the lowest calibrator.
Our results support the idea that anti-CCP are of diagnostic value
especially in RF neg patients.
P4
Expression of citrullin-containing antigens in RA
synovium
TJ Smeets, ER Vossenaar, MC Kraan, WAM van Mansum, 
JM Raats, WJ van Venrooij, PP Tak
Academic Medical Center, Amsterdam and University of Nijmegen,
Nijmegen, The Netherlands
Introduction: The presence of autoantibodies directed to citrulli-
nated antigens in serum is highly specific for RA. The aim of this
study was to compare anti-CCP concentrations in paired serum/SF
samples of patients with RA and to investigate whether this is asso-
ciated with the expression of citrullinated antigens in RA synovium
and to study the nature of these antigens.
Methods: A recombinant single-chain variable fragment (scFv) mon-
oclonal antibody was selected against a cyclic citrullinated peptide
(CCP) from a patient antibody-fragment phage-display library. This
scFv and patient antibodies affinity purified with CCP, were both
used for immunohistochemical staining of synovial cryostat sections
of RA (30) and control patients (OA (13), ReA (9), and other arthri-
tides (28)). In addition, rabbit anti-citrullin antibodies (Biogenesis)
were used for immunohistochemistry of synovial cryostat sections of
RA (14), and control patients (OA (10), ReA (7), and other arthri-
tides (23)). IgG anti CCP titers were calculated with the quantitative
Rapscan RA ELISA kit (Eurodiagnostica). Total IgG concentrations
were determined on a cobas Fara-2 centrifugal analyzer.
Results: Citrullin containing antigens were observed in synovial
cryostat sections of anti-CCP positive and negative patients. Stain-
ing with ScFv monoclonal antibody was noted in synovial lining cells
and in (peri)vascular areas in 13/30 RA patients, 7/13 OA patients,
5/9 ReA patients, and 12/28 other arthritis patients. CCP positivity
was on average similar in all diagnostic groups. Staining was absent
in the negative controls using a control scFv antibody. Staining with
rabbit anti-citrullin polyclonal antibody was noted in 8/14 RA
patients, 3/10 OA patients, 2/7 ReA patients, and 6/23 other arthri-
tides. However, controls using irrelevant rabbit antibodies were also
positive in some patients in all groups. Anti-CCP concentrations
(expressed in Units per mg total IgG) were on average 1.34 times
higher in SF compared to serum (n = 20, P < 0.05) or 1.37 when
only positive samples were included (n = 11, P < 0.05)
Conclusion: Citrullinated antigens are present in the synovia of
both RA and control patients with similar prevalence. The presence
of anti-CCP autoantibodies in serum is not associated with the
expression of citrullinated antigens in the synovium.
The identity of the citrullinated antigens and potential differences
between RA and control synovia remain to be identified.
P5
Autoreactivity patterns in rheumatoid arthritis
S Behrens*, F Schumann*, S Adelt*, H Hofseß*, R Bergholz, 
GR Burmester*, JM Engel† and S Bläß*
*Department of Rheumatology & Clinical Immunology, Charité
University Hospital, Berlin, Germany; †Clinic for Rheumatology, Bad
Liebenwerda, Germany
Rheumatoid arthritis (RA) is characterized by the occurence of
autoreactive antibodies and T cells. RA is heterogneous disease also
with respect to these autoreactivities, since none of them is present
in every RA patient and they are additionally also present – although
to a considerably lesser extent - in other autoimmune diseases and
even in healthy individuals. It has now been analyzed if there are clus-
ters of autoreactivites that are absolutely specific for RA.
Therefore, the RA-associated autoantigens RA33 (hnRNP A2), cit-
rulline, rheumatoid factor (RF), the stress protein BiP (heavy chain
binding protein), calpastatin (Calp) and calreticulin (Calr) have
either been biochemically purified or used as a kit of of recombinant
antigen or chemically synthesized peptides. These antigens have
been applied to screen sera and PBMCs from RA and control
patients for reactivity and the data have subsequently been sub-
jected to cluster analyses.
Analyzing the reactivities of 100 RA and 100 control patients, the
following patterns of the three combined autoreactivities were
determined to be absolutly specific for RA: RF+Cit+BiP+, RF-
Cit+BiP+. RA-specific patterns composed of four autoreactivities
are RA33+RF+Cit+BiP+, RA33-RF+Cit+BiP+, RA33+RF+Cit+
BiP-, RA33+RF-Cit+BiP+, RA33+RF+Cit-BiP+, RA33-RF+Cit-BiP+.c
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RA-specific patterns composed of five autoreactivites are
RA33+RF+Cit+BiP+Calp+, RA33-RF+Cit+BiP+Calp+, RA33+
RF+Cit+BiP-Calp+, RA33+RF-Cit+BiP+Calp+, RA33+RF+
Cit+BiP+Calp-, RA33+RF+Cit+BiP-Calp-. RA-specific autoreactiv-
ities composed of six autoreactivities are RA33+RF+
Cit+BiP+Calp+Calr+, RA33-RF+Cit+BiP+Calp+Calr+, RA33+
RF+Cit+BiP-Calp-Calr+, RA33-RF+Cit+BiP-Calp+Calr+, RA33-
RF+Cit-BiP-Calp+Calr-. Other patterns also occured exclusively in
RA patients, but the differences did not reach statistical signifi-
cance. Patterns including p205-reactivity have yet to be analyzed
and will be presented. Summing up the RA-specific patterns that
are complementary to each other, the sensitivity of the analysis for
RA is 54%.
It appears evident that analyzing other known and unknown RA-
associated autoantigens will further increase the sensitivity of the
autoreactivity cluster analysis. The diagnostic confidence will
markedly improve by testing autoreactivity patterns that clearly dis-
tinguish RA from other rheumatic diseases. The composition of the
autoreactivity patterns will also improve our understanding of the
pathogenesis.
P6
Detection of rheumatoid arthritis-specific anti-
filaggrin antibodies by line immunoassay shows
complementarity to RF and corresponds to the
AFA-blot using natural antigen
A Union, R Humbel*, K Conrad†, G Steiner‡, P Schmit§, A Vos, 
K De Bosschere, S Dincq, H Pottel, L Meheus, L Nogueira§, 
G Serre§ and F De Keyser#
Innogenetics NV, Ghent, Belgium; *Centre Hospitalier de Luxembourg,
Luxembourg; †Universitats-klinikum, Dresden, Germany; ‡University
Vienna, Austria; §Hopital Purpan-CHU Toulouse, France; #University
Hospital Ghent, Belgium
Anti-filaggrin autoantibodies (AFA) are highly specific markers for
rheumatoid arthritis (RA) and can be detected by immunoblotting
using human epidermal protein extracts. Furthermore, it was demon-
strated that citrullination of the filaggrin epitopes is crucial for
epitope recognition and that citrullinated peptides are also recog-
nized by these specific autoantibodies. Based on these data, a line
immunoassay (LIA) was developed containing as individual markers
in vitro citrullinated recombinant filaggrin and two citrullinated syn-
thetic peptides.
Firstly, a comparison was made between this prototype LIA and the
AFA blot using natural filaggrin. A blind serum panel consisting of
25 early RA, 25 longstanding RA, and 25 disease controls was
selected. Results showed a similar performance of both tests at a
specificity level of 95%, while the LIA proved significantly better (P
= 0.035) than the AFA blot at 99% specificity. At the latter speci-
ficity level, 2 out of 17 RF negative samples were retrieved on LIA
but not on Western blot.
The LIA was further evaluated on sera obtained from 335 RA
patients and 254 patients with non-RA rheumatological disorders in
a retrospective study. The overall sensitivity of the LIA including
three markers (LIA3) was 65.1% versus 61.8% if only the reactivity
towards the citrullinated peptides was considered (LIA2). The
specificity of LIA3 was 97.6% versus 98.4% for LIA2, which corre-
lates with an estimated positive predictive value (PPV) of 87.3% for
LIA3 and 90.7% for LIA2. Thirty-seven percent (30/81) of the RF-
negative RA samples proved LIA2-positive, while 52 out of 55 RF
positive control samples were negative for anti-filaggrin. Higher
specificity and sensitivity was obtained for LIA2 in comparison with
anti-RA33 immunoblot, whereas good agreement could be
observed with anti-keratin antibody (AKA) testing.
In conclusion, anti-filaggrin autoantibodies can be readily detected
by a LIA test based on citrullinated peptides, resulting in a high
specificity and hence high PPV for RA. The assay can serve as a
user-friendly alternative for AKA immunofluorescent and immunoblot
techniques. Together with the RF complementarity, this test pro-
vides a valuable tool in the differential diagnosis of RA.
P7
ELISA detection of antifilaggrin autoantibodies
onto deiminated recombinant rat filaggrin: a highly
effective test for the diagnosis of rheumatoid
arthritis
C Vincent*, M Sebbag*, M Arnaud†, L Nogueira*, S Chapuy-
Regaud*, M Jolivet† and G Serre*
*Department of Biology and Pathology of the Cell, INSERM CJF 96-
02, Purpan Medical School, Toulouse; †Department of Immunoassays,
BioMérieux, Marcy L’Étoile ; France
We developped an ELISA using a deiminated recombinant rat filag-
grin (ArFA-ELISA) and assessed its diagnostic value for Rheuma-
toid Arthritis (RA). 714 sera from well characterised rheumatic
patients, including 241 RA, were analysed. The results were com-
pared to those obtained with another ELISA using a recombinant
filaggrin of human origin and with those of two reference tests.
Recombinant rat filaggrin was obtained by PCR amplification of
Wistar rat genomic DNA, cloning, production in E. Coli and purifica-
tion by metal chelate chromatography. The affinity-purified filaggrin
was deiminated with type II rabbit skeletal muscle peptidylarginine
deiminase. Deiminated and non-deiminated filaggrin were used as
immunosorbents and the difference between optical densities on
the two antigens were considered as the titer. The other tests were
performed following previously described methods : ‘AKA’ were
assayed by semiquantitative indirect immunofluorescence, antibod-
ies to human epidermis filaggrin by immunoblotting (AhFA-IB) and
by a recently described ELISA, using a deiminated recombinant
human filaggrin (AhFA-ELISA).
Whatever the chosen specificity threshold, the diagnostic sensitivity
of ArFA-ELISA was significantly higher than that of the three other
tests.
Specificity >=95% Specificity >=99%
‘AKA’ 0.51 (0.45 – 0.58) 0.40 (0.34 - 0.46)
AhFA-IB 0.59 (0.53 – 0.66) 0.37 (0.30 - 0.43)
AhFA-ELISA 0.52 (0.46 – 0.59) 0.31 (0.25 - 0.37)
ArFA-ELISA 0.75 (0.70 – 0.81) 0.61 (0.54 - 0.67)
As expected, the titres of ArFA-ELISA, ‘AKA’, AhFA-IB and AhFA-
ELISA were closely correlated (P < 10-5). However, among RA
sera, only 53% were concordant for the four tests, 25% being posi-
tive with only one test. Consequently, the successive use of ArFA-
ELISA, then ‘AKA’detection only when the first test is negative,
would allow a diagnostic sensitivity of 0.67 to be reached, keeping
a specificity close to 0.99.
This ArFA-ELISA appears as one of the most efficient among the
tests previously described for detection of antifilaggrin/anti-citrulli-
nated peptides autoantibodies, in terms of diagnostic accuracy for
RA.
Its diagnostic performance in early RA and its prognostic value are
currently under evaluation.
Available onlinehttp://arthritis-research.com/supplements/3/SAP8
Investigation of the epitopes of human
profilaggrin derived peptide targeted by antibodies
of patient with rheumatoid arthritis
M Brozik, J Szakonyi†, A Magyar‡, R. Tóbi‡, B Rojkovich‡, 
F Hudecz‡ and P Gergely†
National Institute of Rheumatology, †Central Laboratory of Immunology
Faculty of Medicine Semmelweis University, ‡Peptide Chemistry
Research Group, Eötvös Lóránd University, Hungarian Academy of
Science, Budapest, Hungary
Anti-filaggrin antibodies (AFA), directed against the 37-40 kD epi-
dermal protein filaggrin are one of the most specific markers of
rheumatoid arthritis (RA) and include anti-keratin antibodies (AKA)
and anti-perinuclear factor (APF). Although the antigen triggering
autoimmune response to filaggrin related proteins has not been
identified, recent studies confirmed that citrulline is essential con-
stituent of protein related antigenic determinats recognised by RA
specific autoantibody population.
The aim of our study was to identify epitopes of filaggrin derived-
peptides targeted by RA specific antibodies to provide further infor-
mation about the nature of the initial autoantigenic substance.
Citrullin containing peptides of human profilaggrin region (amio acid
residues 306-324) derived from known cDNA and on the basis of
the data published by Shellekens were synthetised by the multipin
peptide synthesis on solid support and were reacted in situ by
patient sera. Two 19-mer peptides were prepared with single cit-
rullin substitution at position 312 or 321 respectively and four addi-
tional ones with simultanious replacements of two Arg by Cit.
Shortened versions of the 306SHQESTCitGRSGRSGRSGR324
peptide were also produced by removal of 1-6 amino acid residues
from its N-terminal and the 14 -mer truncated one was further short-
ened from its C-terminal as well. The reactivities of these peptides
with RA sera and healthy controls were determined. The results
showed that substitution of arginine 312 by citrulline plays major
role in the anigenicity of filaggrin-derived sequences. Peptides not
containing Cit in position 312 almost lost their ability to bind anti-
bodies from RA sera. Replacement of one additional Arg by Cit in
different positions did not improved the antigenicity. When the
peptide with Cit in position 312 were shortened from its N-terminal,
the 14-mer one showed the highest reactivity. Further shortening of
this sequence from its C-terminal showed that TXGRS motif seems
to be essential to comprise the autoanigenic epitope.
In conclusion our results provide further evidence that not simply
the presence of citrullin but also the nature of its surronding amino
acids have important role in the creation of autoantigenic epitope
reactive with anti-filaggrin antibodies.
P9
Anti-skin anti-intercellular antibodies in juvenile
idiopathic arthritis
I Hromadnikova, P Vavrincova, K Stechova, D Hridelova 
and J Vavrinec
2nd Paediatric Clinic, University Hospital Motol, Prague, Czech
Republic
The aim of this work was to study the presence of anti-skin anti-
intercellular (ASA-IC) and anti-basement membrane (ASA-BM) anti-
bodies of the IgG class in patients with juvenile idiopathic arthritis
(JIA) without clinical features of chronic vesicular-bullous diseases
including pemphigus, pemphigoid and epidermolysis bullosa
acquisita (EBA).
No D-penicillamine was used for JIA management in this group due
to a risk of drug-induced pemphigus. Indirect immunofluorescence
antibody test (IIF) and dual substrates of monkey and guinea pig
esophagus sections were used for the detection and quantification
of ASA-IC as well as ASA-BM antibodies. Overall ASA-IC were
detected in 50 out of 57 studied patients´ sera samples (87,7 %, P
= 0,0003) ranging from 1:20 to £ 1:320 dilutions. Respective of the
classification criteria for idiopathic arthritis of childhood ASA-IC
were observed in 6/6 patients with systemic disease (100%, P =
0,029), 24/29 patients with RF negative polyarthritis (82,7 %, P =
0,01), 16/18 RF positive polyarthritis (88,9 %, P = 0,0077) as well
as in a small cohort of patients with oligoarthritis (2/2) and psoriatic
arthritis (2/2). However we have observed a high incidence of anti-
skin anti-intercellular antibodies in a cohort of patients with JIA we
suggest that subclinical pemphigus occuring in this group might be
exacerbated with different stimulus including pemphigus inducing
drugs. No ASA-BM antibody positivity was observed in a cohort of
57 studied patients.
Acknowledgements: This research was supported by a European
Commission (Acronym: EUROBANK, contract no: QOL-2000-
14.1), web site http://www.ncl.ac.uk and by grant of 2nd Medical
Faculty, Charles University in Prague, VZ no. 111300003.
P10
Correlation of the humoral immune answer to
selected bacterial antigens with presence of the
DNA specific to Salmonella enteritidis after
amplification by PCR
J Zabek, J Noworyta, M Kurowska, M Brasse-Rumin, J Gago, 
B Kwiatkowska and H Garwolinska
Department of Microbiology and Serology, Institute of Rheumatology,
Warsaw, Poland
Introduction: An infectious actiology has often been discussed as a
most compatible with both the clinical and pathological features of
rheumatoid arthritis /RA/. Until now, no single microorganism can
be showed as consistently associated with development of RA. In
our former serological and molecular studies we have shown that
the most common humoral immune answer in RA patients is
directed to Salmonella enteritidis /S. ent./ antigens, especially to
specific for Salmonella enteritidis 03 LPS.
The aim of the study was to proof the correlation between systemic
and local humoral immune answer to Salmonella enteritidis anti-
gens and the presence of DNA specific for Salmonella enteritidis
03 serotype.
Materials and methods: In the tested group, composed of 35 sera
and 20 synovial fluid, taken from 20 patients with connective tissue
diseases the presence of DNA after PCR amplification and antibod-
ies by ELISA method were estimated.
Results: In 10 of 35 /31%/ synovial fluids /bacteriologically nega-
tive/ we have found /after amplification by PCR/ double band of the
DNA, specific for Salmonella enteritidis, possessing mol. weight
390bp and 420bp respectively. Also in the same group of patients
the antibodies to OMP S. ent. in 30% of tested cases, to LPS S.
ent. in 78,9%, in 30% to ECA and none to peptydoglycan have
been found. Only in a few of the PCR-positive synovial fluid elevated
level of antibodies to S. ent. have been found.
Conclusions: No evident correlation, so far, between class and
specificity of humoral antibodies and the presence of specific for S.
ent. DNA after PCR amplification have been found.
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Aberrant expression of the autoantigen hnRNP-
A2/RA33 in the joints of patients with rheumatoid
arthritis and TNF-alpha transgenic mice: a clue to
autoimmunity?
S Hayer, M Tohidast-Akrad, G Schett, K Skriner, D Plows, 
S Haralambos, G Kollias, J Smolen and G Steiner
Division of Rheumatology, University of Vienna; L. Boltzmann Institute
of Rheumatolgy, Vienna, Austria; Institut Pasteur Hellenique, Athens,
Greece.
Autoantibodies to the nuclear antigen hnRNP-A2/RA33 are present
in sera of RA patients and also in TNFa transgenic (tg) mice which
develop severe erosive arthritis similar to human disease. Further-
more, autoreactive T cells have recently been found in peripheral
blood of 60% of RA patients suggesting hnRNP-A2/RA33 to be
also a major T cell autoantigen.
To investigate the pathway leading to loss of tolerance, expression
of hnRNP-A2/RA33 was investigated by immunohistochemistry in
synovial tissue derived from patients with RA and osteoarthritis
(OA) as well as in joint sections of TNFa tg and control mice. These
analyses revealed the antigen to be considerably overexpressed in
RA as compared to OA tissue, particularly in macrophages of the
lining layer and in fibroblasts of the sublining areas, whereas no or
very little expression was observed in areas of lymphocyte infiltra-
tion. Remarkably, the antigen was not only located in the nucleus
(as in cultured cells) but also abundantly detectable in the cyto-
plasm. Similar observations were made in TNFa tg animals in which
strong hnRNP-A2/RA33 expression could be also observed at carti-
lage-pannus junctions. Interestingly, anti-A2/RA33 aab were not
detectable in 8 animals treated with tissue inhibitor of metallopro-
teases 1 (TIMP 1) suggesting that metalloproteases may be
involved in breakage of tolerance to hnRNP-A2/RA33. To elucidate
the biological mechanisms leading to aberrant expression of
hnRNP-A2/RA33 peripheral blood monocytes and T lymphocytes
as well as cultured synovial fibroblasts and HeLa cells were treated
with various stimulating agents including LPS, PHA, anti-CD3, IL-1,
TNFa and IFNg or exposed to heat stress. However, none of these
stimuli was able to induce upregulation or nucleocytoplasmic
translocation of the antigen.
Taken together, these findings suggest that the state of chronic
inflammation in the rheumatoid synovium causes aberrant expression
of hnRNP-A2/RA33 (and possibly other autoantigens). This may lead
to increased uptake and (aberrant) degradation and presentation by
macrophages and other antigen presenting cells subsequently acti-
vating autoreactive T cells which then may drive or enhance the
inflammatory and destructive processes characteristic of RA.
P12
Autoantibodies to the mRNA destabilizing protein
hnRNP-D/AUF1 in patients with systemic
autoimmune diseases
K Skriner, W Hueber, E Süleymanoglu, E Höfler, JS Smolen 
and G Steiner
Division of Rheumatology and Institute of Biochemistry, University of
Vienna, 2nd Department of Medicine, Lainz Hospital, Vienna, Austria
The heterogeneus nuclear ribonucleoprotein (hnRNP) D, which is
also known as AU-rich element binding factor 1 (AUF1), decreases
stability of many short-lived mRNAs (including mRNAs of IL-1 and
TNFa) by binding to adenosine and uridine rich sequences (ARE)
contained in their 3´-untranslated regions. Previous studies had indi-
cated this protein to be recognized by sera from patients RA, SLE
and MCTD.
To investigate this autoimmune response in greater detail 356 sera
from patients (pts) with various rheumatic disorders were tested by
immunoblotting employing the recombinant 45 kDa variant of
D/AUF1 (the largest of the 4 known D/AUF1 proteins). Autoanti-
bodies (aab) were detected in 20% of RA pts (n = 105), 34% of
SLE pts (n = 70), 17% of MCTD pts (n = 31) and in 25% of pts
with primary Sjoegren´s syndrome (n = 21), but in less than 5% of
129 pts with other rheumatic disorders and not at all in healthy con-
trols. Importantly, anti-D/AUF1 aab were already present in 25% of
60 patients with early RA of less than 6 months duration, whereas
only one of 40 non-RA patients with other forms of early arthritis
showed this antibody. Epitope mapping studies showed the aab to
be directed to conformational epitopes in the N-terminal part of
hnRNP-D/AUF1 known to be indispensable for the protein´s func-
tion. However, aab did not interfere with RNA binding as assessed
by gel shift assays employing the ARE of the TNFa mRNA. Instead,
they were able to supershift protein-RNA complexes indicating
binding sites for RNA and aab to be distinct.
Thus, these findings suggest that anti-D/AUF1 aab target the
mRNA decay complex which may form another large ribonucleopro-
tein target structure in systemic autoimmunity. We are tempted to
speculate that increased formation of such complexes (e.g. due to
overexpression of instable mRNAs such as those for IL-1 and TNFa
as seen in RA) may lead to pathologic autoimmune reactions
against D/AUF1 and other proteins of mRNA decay complexes.
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The stress protein BiP is a major autoantigen in
rheumatoid arthritis
U Neuhaus-Steinmetz*, A Union†, J Raymackers†, F Schumann*,
S Behrens*, W Schmid‡, JM Engel§, GR Burmester* and S Bläß*
*Department of Rheumatology & Clinical Immunology, Charité
University Hospital, Berlin, Germany; †Innogenetics N.V., Ghent,
Belgium; ‡Clinic for Rheumatology, Berlin-Buch, Germany; §Clinic for
Rheumatology, Bad Liebenwerda, Germany
BiP (heavy chain binding protein) is the major chaperone of the
endoplasmic reticulum that interacts transiently with most of the
proteins of the secretory pathway and assists in their folding. BiP´s
function under stress conditions is essential for cell viability and
constitutively increasing or decreasing the BiP levels is detrimental
to cell growth or to survival. Here, we present the RA autoantigen
formerly designated “p68” as identical to BiP and that autoreactivity
against BiP is a specific feature of RA.
p68 was isolated and proven to be identical to BiP by two different
approaches (Edman sequencing and MALDI-TOF mass spectrome-
try). Using tissue sections, BiP has been shown to be overex-
pressed in the RA as compared to the OA joint. Applying
immunoblots, BiP-reactive autoantibodies were present in 63% of
400 RA patients, in 7% of 200 patients with other rheumatic dis-
eases and in 1 of 150 healthy individuals. In patients with early
arthritis approximately 50% are positive. An ELISA was established
to quantify anti-BiP antibodies and the data of 400 RA and 400
control patients will be presented. The majority of RA sera was
found reactive with a posttranlationally modified form of BiP and the
major epitope was O-linked N-acetylglucosamine.
Furthermore, we present evidence that BiP-specific T cell reactivity
is pathogenically altered in RA. Overt BiP-specific T cell reactivity as
determined by T cell proliferation assays could be observed in two
thirds of patients with RA, but neither in healthy individuals nor in
patients with other rheumatic diseases. Blocking anti-HLA-DR anti-
bodies expectedly decreased T cell proliferation indicating the pres-
ence of HLA-DR restricted effector T cells.
A subset of RA patients exhibited a BiP-specifically suppressed T
cell reactivity. Blocking anti-HLA-DR antibodies in these assays
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Available onlinehttp://arthritis-research.com/supplements/3/SAovercame the suppressive effect and allowed an increased prolifer-
ation. This argues strongly for the presence of BiP-specific regula-
tory T cells restricted for HLA-DR and BiP-specific effector T cells
restricted for HLA-DP and -DQ in this subset of RA patients. These
effects could not be mimicked by blocking anti-IL-10 or anti-TGF-b
antibodies, implicating that other factors or also direct cell-cell-
contact are required.
Apparently, the healthy immune system views BiP as a component
to which autoreactivity is either avoided or tightly regulated. In RA
this general principle appears to have lost control. BiP-reactive may
serve as a new diagnostic marker in RA, while regulatory T cells may
provide means for a specific therapy.
P14
Lysozyme and its biological value in rheumatoid
arthritis (RA)
J Smirnow and M Wislowska
Central Clinical Hospital, 137 Woloska Street, Warsaw, Poland
Lysozyme or muramidase catalyzes the hydrolysis of 1,4-beta-link-
ages between N-aacetylmuramic acid and N-acetyl-D-glucosamine
residues in peptidoglycan. A basic enzyme that is present in saliva,
tears, egg white and many animal fluids. Its function is an antibacter-
ial agent. Lysozyme is well known for the ability to hydrolize the cell
wall of bacteria.
Objective: The aim of study was to measure the concentration of
lysozyme in synovial fluid in RA patients.
Methods:  We measured the lytic activity of lysozyme towards
micrococcus lysodeikticus (1, 2, 3 ), bacteria which are highly sus-
pectible to lysis by lysozyme by the turbidometric method 30 syn-
ovial fluid of RA patients. In order to obtain a method covering a
wider range of lysozyme concentrations, Osserman and Lawlor
worked out the so-called lyso-plate method (4).
The test measured the zone of clearing by lysozyme in an agar plate,
in which microccocus lysodeikticus is embedded. After about 18
hours the diameter of the zone of clearing is measured.
Results: In all our RA synovial fluid we observed increased level of
lysozyme.
Conclusions: The increased levels of lysozyme in synovial fluid in
RA could indicate of monocyte/macrofage activity and might be
used to study disease activity in RA.
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Differential effect of corticosteroid therapy on the
cytoplasmic cytokine expression in CD4 and CD8
positive T cells from lupus patients
E Kiss, M Aleksza, P Antal-Szalmás, S Sipka and Gy Szegedi
3rd Department of Internal Medicine, Medical and Health Science
Center, University of Decrecen, Hungary
Due to their different antiinflammatory and immunmodulatory effects
corticosteroids are widely used in the treatment of SLE. Literature
data support both Th1 and Th2 dominance in lupus. There are only
few reports about cytokine profile of CD8+ T cells in SLE.
In the present study we examined by flow cytometry the cytoplasmic
IFNg, IL-4 and IL-10 expression in CD4+ and CD8+ T cells from six
active, untreated, newly diagnosed SLE patients, who received after
that 1 mg/kg methylprednisolon. Pretreatment expression of IFNg
was lower, while IL-4 and IL-10 expressions were higher in CD4+,
but not in CD8+ T cells of patients than in control cells. Corticos-
teroid treatment increased IFNg and decreased IL-4 and IL-10
expressions in patients’ CD4+ cells, but had no significant effect on
the cytoplasmic cytokine expression of CD8+ cells.
In conclusion, present results indicate that corticosteroid therapy
does not influence INFg, IL-4 and IL-10 expression in CD8+ T cells
of lupus patients, and it may have pathogenic significance.
P16
Elevated IL-16 level is a non-genetic characteristic
of patients with severe systemic lupus
erythematosus
LR Lard, BO Roep* and TWJ Huizinga
Departments of Rheumatology and Immunohaematology and
Bloodbank*, Leiden University Medical Center, Leiden, The
Netherlands
Introduction: IL-16, origanilly named lymphocyte chemoattractant
factor, is a cytokine which is mainly produced by CD8+ T cells.
Several reports have described that increased levels of IL-16 are in
part responsible for T cell abnormalities in SLE patients. It is
unknown if the previously reported increased levels of IL-16 is a
characteristic underlying susceptibility to SLE or is a characteristic
of the disease itself.
Methods: Accumulated organ damage was measured with the
SLICC/ACR Damage Index. Twenty-five severe (SLICC/ACR: 4.9 ±
2.5) and ten non-severe (SLICC/ACR: 1.0 ± 0.8) SLE patients
were included in this study. Also 11 first degree relatives and 12
healthy volunteers were included in this study. Plasma IL-16 levels
were measured by ELISA.
Results: No significant difference in the IL-16 levels of the first
degree relatives of patients with SLE (38.3 ± 11.1 pg/ml) were
observed when compared to controls (31.2 ± 10.1 pg/ml). In order
to analyze characteristics of the SLE in relation to concentration of
IL-16, IL-16 was measured in severe SLE patients (71.3 ± 87.4
pg/ml; P = 0.025) compared to healthy controls. On the other hand,
no significant differences were observed between the non-severe
SLE patients (37.8 ± 26.1 pg/ml) and controls.
Conclusion: No evidence for increased IL-16 levels in first degree
relatives of the SLE patients was observed. IL-16 is enhanced in
SLE patients with a severe disease, but not in patients with non-
severe disease, thereby suggesting that IL-16 is associated with
disease severity, and not with susceptibility for SLE.
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Functional and biologic evaluation of
immunoregulatory cytokines in the
immunopathologic lesion of Sjogren’s syndrome
DI Mitsias, AG Tzioufas, CI Veiopoulou, HM Moutsopoulos, 
G Thyphronitis
Department of Pathophysiology, Medical School, University of Athens
Autoimmune diseases are commonly considered to involve a
Th1/Th2 imbalance in favor of Th1. Studies in mice suggest that the
Th1 cytokines overexpression may be implicated in the pathogene-
sis of autoimmunity. Recent results, though, in humans challenge
this notion.
Conflicting data have been published on the cytokine profile in
patients with Sjogren’s syndrome (S.s.). These data were mainly
obtained using PCR based techniques and in-situ hybridization.
Some of them indicate that a Th1 response is prevalent. To clarify
this issue, small salivary glands (SGL) from patients with S.s. with
different grades of infiltration as well as patients without S.s. but
with sicca manifestations, were cultured in RPMI plus 40 IU/ml of
recombinant IL2. IL4, IL13 and IFNgamma production in the culture
supernatants (SN) was evaluated with a sensitive ELISA and, in par-
allel, mRNA levels for the same cytokines were evaluated with a
quantative RT-PCR.
Within a period of a week, lymphocytes were evident in the cultures
in numbers depending on the infiltration of the gland. The pheno-
type of these lymphocytes, as determined by flow cytometry, was
similar to that published previously from SGL immunochemistry,
suggesting that these cells derive from the salivary gland. SN were
collected on various time intervals and mRNA was extracted from
the lymphocytes on day 12 of the culture. Interestingly, IL13 mRNA
was detected in almost all (17/19) of the samples, and both
IFNgamma and IL4 on the majority (16/19 and 14/19, respectively).
The cytokine production in the culture SN was examined in a set of
8 biopsies. IL 4 couldn’t be detected ( <4 pg/ml), may be due to its
binding on the IL4R. Both IFNgamma and IL13 were present and
the ratio of IFNgamma/IL13 was related to the grade of infiltration (p
<0.05), indicating that the balance of Th1 vs Th2 changes in favor
of the former along with the severity of the disease. Finally, it was
demonstrated that the Th2 cytokines IL4 and IL13 are functional
since IgE was present in 12 out of 28 SN of cultured biopsies. IgE
was present in greater quantities in those biopsies that had low
grade infiltration (0-0.3 according to Chisholm’s score) compared
to those with medium grade (0.3-0.6), while in biopsies with infiltra-
tion >0.6 it was undetectable.
These results show that in Sjogren’s syndrome the distinction
between Th1 and Th2 doesn’t apply as both play a role to its patho-
genesis. Moreover it seems that Th2 response prevails at the early
stages whereas Th1 gradually augments as the disease progresses.
P18
High spontaneous CD40 expression by salivary
gland epithelial cells in Sjogren’s syndrome:
possible evidence for intrinsic activation of
epithelial cells
ID Dimitriou, G Xanthou, EK Kapsogeorgou, RF Abu-Helu, 
HM Moutsopoulos and MN Manoussakis
Department of Pathophysiology, Medical School, University of Athens,
Greece
CD40 is a surface protein originally identified on B cells. Its interac-
tion with CD40L on T cells plays an important role in the activation,
proliferation and differentiation of B cells. During the recent years,
CD40 has been identified in an expanding list of hemopoietic and
nonhemopoietic cells and has received an increased interest based
on its role in a variety of cell-mediated responses and its potential to
participate in the pathogenesis of chronic inflammatory disorders.
Sjogren’s Syndrome (SS) is an autoimmune exocrinopathy, which is
characterized by chronic lymphocytic infiltration of exocrine glands
and aberrant activation of epithelial tissues.
To investigate the participation of CD40 in the pathogenesis of SS,
the expression of this protein was studied in cultured non-neoplastic
salivary gland (SG) epithelial cell (SGEC) lines as well as in minor
SG biopsies obtained from 17 SS patients and 12 controls.
Immunocytochemical and flow cytometric analysis has revealed the
occurrence of constitutively expressed CD40 molecules on the
surface of our long-term cultured SGEC lines, which could be
further induced by IFNg and IL-1b, but not TNFa, IL-4, IL-6, GM-
CSF and IFNg. In SGEC lines derived from SS patients, the sponta-
neous expression of membranous CD40 was significantly higher
compared to controls (P < 0,001), which is likely suggestive of their
activated status. In SG biopsies, CD40 was constitutively
expressed by B cells, ductal epithelial cells and endothelial cells but
not by other glandular cell types, such as acinar cells, myoepithelial
cells and fibroblasts. In addition, CD40L staining was also detected
in 30-50% of the infiltrating T cells in the biopsies of SS patients.
Our results possibly reveal the immunoregulatory potential of SGEC
and lend further support to a model of intrinsic activation in salivary
epithelia in SS, whereby these cells actively participate in the induc-
tion and maintenance of lymphocytic infiltrates of patients.
Acknowledgement: Supported by grants from the Hellenic Secre-
tariat for Research and Technology, the Lilian Voudouri Foundation
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Substance P and its cleavage products: effects on
interleukin-1 secretion of rheumatoid arthritis
monocytes/macrophages
E Wagner, G Partsch* and A Dunky
5th Medical Department, Wilhelminenspital, Vienna, Austria; *Ludwig
Boltzmann Institute of Rheumatology and Balneology, Vienna, Oberlaa,
Austria
Introduction: Clinical observations in man and experimental studies
support the importance of neurogenic mechanisms in the initiation
and perpetuation of inflammation. A leading role is attributed to sub-
stance P (SP), a tachykinin that besides its role in pain transmission
in the central nervous system is also secreted antidromically from
peripheral nerve endings into tissue in response to various stimuli.
Since SP might be cleaved into several cleavage products (CLP) in
the synovial fluid, we determined the effects of SP and its CLPs on
the production of IL-1 by monocytes/macrophages (MO) from
patients with rheumatoid arthritis.
Methods: MO from venous blood were separated and stimulated
with SP and its CLPs in various concentrations without and with
LPS stimulation (1mg/ml). The IL-1 concentration in the supernatant
was determined by ELISA. The CLPs SP 1-4, SP 4-11, SP 6-11,
SP 7-11 were applied in the experiments.
Results: SP and its CLPs (without LPS) had only weak and low (in
pM range) effects on IL-1 secretion. The stimulating effect of SP
and SP 7-11 was pronounced at lower concentrations, at higher
concentrations inhibition was observed. The other CLPs did not
show significant effects.
The same result was observed in MO with prior LPS stimulation.
However, with LPS there was an increase of IL-1 in the nMolar range.
Discussion: In contrast to the findings of other authors SP and SP
7-11 at higher concentrations inhibited IL-1 release from MO . The
effects were similar in LPS stimulated and LPS unstimulated MO,
therfore not due to full LPS stimulation at the concentration of
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Available onlinehttp://arthritis-research.com/supplements/3/SA1mg/ml. This could point to a mechanism of action different from the
classical neurokinin receptor of SP and CLPs on MO regarding
cytokine secretion.
P20
Human neutrophil production and cleavage of IL-
18: potentiating inflammatory arthritis?
SE Robertson, J Young, FY Liew, IB McInnes and JA Gracie
CRD/Department of Medicine, and Department of Immunology,
Glasgow Royal Infirmary, Glasgow, G31 2ER, Scotland
We have recently demonstrated the presence and involvement of
IL-18 in rheumatoid arthritis (RA) synovitis. Moreover, blockade of
IL-18 in vivo is protective in arthritis models. We sought to demon-
strate for the first time the production and intracellular processing of
IL-18 by human neutrophils. Thereafter we investigated novel pro-
cessing pathways and potential regulatory mechanisms for IL-18
bioactivity that could operate in synovium.
Methods: Matched peripheral blood (PB) and synovial fluid (SF)
neutrophils were isolated by ficoll density gradients. IL-18 was
detected in neutrophil total protein lysates by western blotting.
Serum free neutrophil culture supernatants were incubated with
recombinant IL-18 prior to HPLC fractionation and assessed for
biological activity using IL-18 sensitive KG-1 cells.
Results: Western blotting of neutrophil lysates isolated from PB
and SF of rheumatoid and psoriatic arthritis patients demonstrated
the presence of a number of IL-18 specific bands ranging in molec-
ular weight from 22 to 6 kD in size, representing pro, mature and
possible IL-18 cleavage products. HPLC purified culture super-
natants from PB and SF neutrophils contain heat sensitive enzy-
matic activity capable of in vitro cleavage of both recombinant pro
and mature IL-18. This caspase independent cleavage of IL-18
resulted in the generation of biologically active fragments capable of
modulating IL-18 induced IFN-g production by KG-1 cells.
Conclusions: These data demonstrate for the first time that modi-
fied fractions of IL-18 may be biologically active, suggesting the
existence of a novel regulatory mechanism in the IL-1 cytokine
family. In light of their rapid accumulation in large numbers within RA
joints, our data further suggest that both neutrophils and IL-18 play
important roles in disease pathogenesis.
P21
Intracellular expression of CXCR3 on rheumatoid
arthritis synovial tissue cells
O Krystufkova, J Vencovsky, S Ruzickova, J Sinkora*, J
Niederlova, CA Power†, C Plater-Zyberk†
Institute of Rheumatology, Prague, *Institute of Microbiology, Novy
Hradek, Czech Republic, †Serono Pharmaceutical Research Institute,
Geneva, Switzerland.
Introduction: Inflammatory cell infiltration and synovial activation are
important processes in rheumatoid arthritis. Chemotactic gradients
of various chemokines are responsible for cell attraction and possi-
bly for their activation. We have previously detected strong expres-
sion of chemokine receptor CXCR3 in the rheumatoid joint by
immunostaining.
Aim:  Characterization of the cells expressing CXCR3 in RA synovial
membrane.
Methods: Synovial tissue samples were obtained from RA patients
undergoing synovectomy or a total joint replacement. Cells were
released by digestion with collagenase, DNAse and briefly with
hyaluronidase. A three colour fluorescence analysis was performed
with FITC conjugated anti-CXCR3 mouse MAb (R&D) and with a
panel of phycoerythrin (PE) conjugated MAb (anti-CD3, CD4, CD8,
CD19, CD55, CD31, CD68, CD14 and CD45). Live cells were
identified by propidium iodide. PBCs were stained using the same
protocol.
Results: As expected, a proportion of CD3+ and CD4+ blood and
synovial cells were CXCR3 positive. In addition, CXCR3 was also
seen in synovial cells positive for CD55, CD14, CD8 and to a lesser
extent CD31. However, in contrast to the surface staining of cells
from peripheral blood, synovial cells displayed only intracellular
staining for CXCR3. No CXCR3 staining could be detected on the
surface of any type of viable synovial cell, including CD3 positive
lymphocytes.
Conclusions: Flow cytometry identifies synovial cells that display
intracellular CXCR3 staining. These cells are comprised of T lym-
phocytes, macrophages, possibly synovial fibroblasts and endothe-
lial cell populations. The intracellular presence of CXCR3 suggests
a possible internalization of this molecule, which may be a conse-
quence of ligand binding. The significance of this phenomenon and
of CXCR3 expression in cell types other than leukocytes remains to
be determined.
Acknowledgement:  This work is supported by a grant NI/6459
from IGA MZ CR.
P22
Interleukin-13 (IL-13) in autoimmune rheumatic
diseases: relationship with autoantibody profile
T Rinaldi, A Spadaro, V Riccieri, E Taccari and G Valesini
Dipartimento di Terapia Medica, Unità di Reumatologia, Università “La
Sapienza”, Rome, Italy
The production of rheumatoid factor (RF) and antinuclear antibody
by B-cells could depend on different cytokines action. We evalu-
ated IL-13 serum levels in 230 patients with autoimmune rheumatic
diseases including rheumatoid arthritis (RA) [M/F=22/62; mean
age=55.2 (25-76) yrs; mean disease duration = 116 (5-605)
months], SLE [M/F=17/97; mean age=38.3 (15-70) yrs; mean
disease duration = 77 (1-456) months], Sjögren’s syndrome (SS)
[M/F=2/50; mean age = 55.2 (26-81) yrs; mean disease duration =
82 (3-540) months], and systemic sclerosis (ScS) [M/F = 1/31;
mean age=50.6 (20-73) yrs; mean disease duration = 113 (12-
276) months], in order to investigate the relationship of this cytokine
with the autoantibody profile.
Serum levels of IL-13 (pg/ml) were significantly increased in patients
with RA (P < 0.00003), with SLE (P < 0.03), with SS (P < 0.0007),
with ScS (P < 0.025) as compared to controls. IL-13 serum levels
correlated with those of RF in RA (P < 0.00001), SLE (P < 0.003)
and ScS (P < 0.03). IL-13 levels were higher in RA (P < 0.0002),
SLE (P < 0.004) and ScS (P < 0.05) patients with RF than patients
without RF. SS patients with anti-SSA/Ro antibodies had signifi-
cantly higher IL-13 levels than SS patients without this autoantibody
(P < 0.036). No statistically significative correlation was found
between IL-13 levels and any other antinuclear autoantibody or total
immunoglobulin levels or main clinical features of each disease.
This study suggests that IL-13 may be involved in the pathogenesis
of autoimmune rheumatic diseases, with a relevant role on RF pro-
duction. In SS, the lack of correlation between IL-13 and RF is prob-
ably due to the peculiar characteristics of this antibody in the
disease. We can conclude that the mechanisms involved in RF syn-
thesis recognise different pathways depending on the underlying
autoimmune disease.
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Mice deficient in leptin (ob/ob) or in liptin receptor
(db/db) have a milder form of antigen-induced
arthritis
N Busso, A So, V Péclat and C Gabay*
Service de Rhumatologie, CHUV, 1100 Lausanne, Switzerland;
*Division de Rhumatologie, HUG, 1211 Geneve 14, Switzerland.
Leptin, the product of the ob gene, is synthesized exclusively by
adipocytes to regulate the body weight in a central manner through
its interaction with long isoform of leptin receptor ob-Rb. However,
Ob-Rb is also expressed in lymphoid tissues and leptin has been
shown to play an important role in cell-mediated immunity. We
therefore decided to examine the role of leptin in vivo by analyzing
the phenotype of mice deficient in leptin (ob/ob) or in ob-Rb (db/db)
during antigen-induced arthritis (AIA). Arthritis was induced by an
intraarticular injection of methylated bovine serum albumin (mBSA)
in the knees of previously immunized ob/ob, db/db, control litter-
mates and wild-type mice, all in C57BL/6 background. The severity
of arthritis was determined by 99m Technetium (99m Tc) uptake. In
addition, the degree of articular inflammation was also determined
after sacrifice by histology scoring. Levels of circulating
immunoglobulins and antibodies against mBSA were measured by
ELISA. The responses of isolated lymph node cells to mBSA were
also examined. The results showed that joint inflammation, as mea-
sured by 99m Tc uptake, was significantly reduced in ob/ob mice
as compared with control littermates and wild-type mice (on day 1
of arthritis: P < 0.002 and P < 0.001, respectively; on day 3: P <
0.03 and P < 0.02, respectively). In addition, histology studies
showed that ob/ob mice had markedly less synovial inflammation
than lean controls (P < 0.04). In contrast, there was no difference in
proteoglycan content within the articular cartilage as assessed by
Safranin-O staining. The in vivo production of antibodies against
mBSA was significantly decreased in ob/ob mice as compared with
controls (P < 0.03). Circulating levels of IgG2a were also signifi-
cantly lower in ob/ob mice than in controls, whereas levels of IgM
were not different. In vitro lymph node cell proliferation in response
to mBSA was significantly reduced in ob/ob mice as compared with
controls. In addition, production of interferon-g by cultured lymph
node cells was significantly lower in ob/ob than in control mice,
whereas opposite results were observed for IL-10. Experiments per-
formed in db/db mice confirmed the findings in leptin-deficient mice.
In conclusion, leptin appears to regulate both the cellular and
humoral components of the immune response against mBSA and to
contribute to the mechanisms of joint inflammation in AIA. In addi-
tion, these results demonstrate that the effects of leptin on the
immune system are mediated through its interaction with ob-Rb.
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Temporal expression of cytokines and chemokines
in rat adjuvant-induced arthritis
Z Szekanecz, MM Halloran, JM Woods, MV Volin, GK Haines
and AE Koch
Third Department of Medicine, University of Debrecen, Hungary and
Northwestern University, Chicago, Illinois, USA
Adjuvant-induced arthritis (AIA) in rats is a relevant model for human
rheumatoid arthritis (RA). In this study, th expression of the cytokines
TNF-alpha, IL-1 and IL-6, as well as the chemokines MIP-1-alpha,
MCP-1 and ENA-78 in the sera and joint homogenates of AIA and
control, sham-injected rats was studied over a 47-day period. All of
these cytokines and chemokines showed increased production in
AIA. In addition, TNF-alpha, IL-1, ENA-78 and MIP-1-alpha could be
termed as “early” mediators, as their production increased in the first
14-21 days and it correlated with early events in synovitis, such as
neutrophil ingress, joint swelling and general symptoms. TNF-alpha
may have mostly systemic, while IL-1 mainly local synovial effects. IL-
6 and MCP-1 were found to be “late” inflammatory mediators, as
their secretion was up-regulated after 2 weeks post-adjuvant injec-
tion and remained high during the observation period. Also, signifi-
cant correlation was found between the production of TNF-alpha
and that of chemokines. In conclusion, the differential expression of
“early” and “late” cytokines and chemokines may account for various
events underlying synovitis in AIA.
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Dynamics of early synovial cytokine expression in
rodent collagen-induced arthritis: a therapeutic
study
K Palmblad*, H Erlandsson Harris*, K.J Tracey†
and U Andersson*
*Rheumatology research unit, Karolinska Hospital, CMM L8:04, 171
76 Stockholm, Sweden; †North Shore University Hospital, Manhasset,
NY, USA
This study was performed to elucidate pathophysiological events
prior and during the course of collagen-induced arthritis (CIA) in DA
rats. Kinetic studies of local cytokine responses were determined
using immunohistochemisrty and computer-aided image analysis.
We also investigated the effect of the macrophage-pacifying com-
pound CNI-1493 on proinflammatory cytokine expressions. Synovial
cryosections were analysed at various time points for the presence
of IL-1b, TNF and TGF-b. Unexpectedly, an early simultaneous TNF
and IL-1b expression was detected in resident cells in the lining
layer, preceding disease onset by more than one week. The pre-
dominant cytokine synthesis by synovial (ED-1+) macrophages
coincided with clinical disease. TNF-production greatly exceeded
that of IL-1b. CNI-1493 treatment did not affect the early TNF and
IL-1b synthesis, while disease-associated TNF and IL-1b production
was greatly reduced. Furthermore, CNI-1493 significantly up-regu-
lated synthesis of the anti-inflammatory cytokine TGF-b and thereby
shifted the balance of pro-inflammatory and anti-inflammatory
cytokines in the arthritic joint in a beneficial way.
P26
Comparison of arthritogenic and nonarthritogenic
Eubacterium aerofaciens cell walls
X Zhang, M Rimpiläinen, E Simelyte and P Toivanen
Department of Medical Microbiology, Turku Immunology Center,
University of Turku, Turku, Finland
We have recently reported that cell walls (CWs) of two closely
related E. aerofaciens strains appear arthritogenic or nonarthrito-
genic when injected i.p. into the rats (Zhang et al. Rheumatology
2000). These strains have different structures of the CW peptido-
glycan (PG). To further define what determines the arthritogenicity
of these human intestinal bacteria, the tissue distribution of their
CWs was compared. Muramic acid (MurNAc), a component of
PG, was selected as a marker for bacterial CW as it is not synthe-
sized by eukaryotic cells. Gas chromatography-mass spectrometry
was applied to identify and quantify MurNAc. The results obtained
indicate that the amount of MurNAc was much higher in the spleen
and liver after injection of the arthritogenic CW than after injection
of the nonarthritogenic CW. MurNAc was detected in synovial
tissues and fluids from day 1 to day 28 after injection of the arthri-
togenic CW, but not after injection of the nonarthritogenic CW.
This is probably due to the resistance of the arthritogenic CW
against biodegradation; lysozyme and mutanolysin degraded the
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Available onlinehttp://arthritis-research.com/supplements/3/SAarthritogenic CW only by 21-34%, whereas the nonarthritogenic
CW was degraded by 77-78%, both after 24h incubation. Further-
more, degradation by mutanolysin significantly increased the
capacity of the arthritogenic PG to stimulate rat macrophages to
secrete TNF-a and MCP-1, whereas it dramatically decreased
such a capacity of the nonarthritogenic PG, suggesting that pep-
tides with proinflammatory activity are released from the arthrito-
genic PG. These results, obtained with an arthritogenic and
nonarthritogenic strains of E. aerofaciens, indicate that capacity to
resist biodegradation, leading to persistence in the tissues, and to
release proinflammatory PG peptides, are crucial factors determin-
ing arthritogenicity or nonarthritogenicity of a bacterial CW.
P27
Immune complex stimulation of peripheral blood
mononuclear cells result in enhancement of
suppression of IL-12 production dependent on
soluble serum factors
A Tejde, K Nilsson Ekdahl, B Nilsson and J Rönnelid
Department of Clinical Immunology, University Hospital, Uppsala, Sweden
Immune complexes can induce the production of various cytokines
in vitro. Both IL-10 and IL-12 could be induced by addition of heat-
aggregated immunoglobulins to mononuclear cells in serum-free
cell culture systems. Addition of native serum to the cell cultures
influenced the effects on IL-10 and IL-12 in opposite ways. While
IL-10 levels were increased in cell cultures with native human
serum, IL-12 production was inhibited as compared to cultures with
monomeric IgG. Two series of experiments suggested that the
effects of immune complexes on IL-12 production depended on the
activity of the classical complement pathway in the serum: 1.) Heat-
inactivation of serum reverted the inhibitory effect of immune com-
plexes on IL-12 production. 2.) C4 deficient serum behaved as a
heat-inactivated normal serum concerning the effects on IL-12 pro-
duction, and this effect could be reversed by addition of C4. The
effects of neutralizing IL-12 had modest effect on immune complex-
induced IL-10 production, and the effects of neutralizing IL-10 had
no effect on IL-12 production. IL-10 production in the presence of
immune complexes could be partially blocked by anti-FcgammaRII
antibodies, while the immune complex-mediated effects on IL-12
not changed by blocking FcgammaRII or FcgammaRIII.
Opposite and complement-dependent effects on the production of
IL-10 and IL-12 can be of importance in cytokine-dependent
autoimmune diseases like rheumatoid arthritis or systemic lupus ery-
thematosus, where local or systemic activation of the classical com-
plement pathway participate in the disease processes. Blocking of
complement activation or receptors for activated complement com-
ponents might gain increased attention as potential targets for
immune therapies in the light of such cytokine-deviating effects.
P28
Inflammatory arthritis, hypoxia and vascularity
PC Taylor, A Steuer, P Etherington, D Cosgrove and RN Maini
Kennedy Institute of Rheumatology at Imperial College School of
Medicine, London, W6 8LH, UK
We have employed novel technology to investigate the relationship
between synovial tissue oxygen levels and vascularity in human
inflammatory arthritis. Silver microelectrodes were used to measure
synovial tissue oxygen levels in knee joints of 15 patients with
inflammatory arthritis (6 RA, 2 SLE, 1 psoriatic, 1 crystal, 2 reactive
and 2 seronegative oligo-arthritides). Synovial membrane cells were
obtained from tissue biopsies and ex-vivo production of vascular
endothelial growth factor (VEGF) was measured. In RA patients, 50
ml N/Saline was injected into the joint and the electrode positioned
in the cavity such that the rate of oxygen consumption could be
measured. Microelectrodes were also used to assess synovial pO2
levels in a single metacarpophalngeal (MCP) joint in 5 RA patients.
These joints were simultaneously imaged by high resolution ultra-
sound and power colour doppler to determine the relationship
between joint architecture, vasculature and tissue pO2.
In knees, synovial tissue pO2 levels were significantly lower in
patients with active RA (mean = 7 mm Hg) than in patients without
RA (mean = 40 mm Hg; P = 0.002). In RA, oxygen was consumed
from N/Saline introduced into the cavity at a rate of 20.5 mm
Hg/min. Production of VEGF from synovial cells was greater for
patients with RA (mean = 868pg/106 cells) than from synovial cells
from patients without RA (mean = 84pg/106 cells; P < 0.01).
In the 5 MCP joints studied, a total of 9 vascular areas were sampled.
The mean pO2 at these sites was 97 mmHg. In 19 non-vascular
areas sampled, the mean pO2 was 34 mm Hg (range 6-73). In a vas-
cular erosion the tissue pO2 was measured as 41 mm Hg.
In conclusion, marked hypoxia is observed in selected regions of
inflamed synovium and is a likely stimulus for local VEGF production
and angiogenesis. However, the increased vascularity associated
with erosive damage is insufficient to restore oxygen homeostasis at
the site of joint destruction.
P29
Cartilage-derived morphogenetic protein-1 and -2
are endogenously expressed and stimulate
proteoglycan synthesis in healthy and
osteoarthritic human articular chondrocytes
K Bobacz, A Soleiman*, W Graninger and L Erlacher
Department of Rheumatology, University of Vienna, Austria;
*Department of Pathology, University of Vienna, Austria
Objective:  Cartilage-derived morphogenetic protein-1 and -2
(CDMP-1 and -2) form a subgroup within the Bone morphogenetic
protein family. While they are essential during embryonic joint and
limb development, their role in postnatal articular cartilage is not fully
clear. In this study we examined the stimulatory effects of CDMP-1
and -2 on proteoglycan synthesis and cell proliferation on postnatal
human articular chondrocytes and investigated the hypothesis that
osteoarthritic chondrocytes lose their responsivness to CDMP-1
and -2 compared to healthy cells and thus lead to a decrease in
proteoglycan synthesis that impairs maintenance of matrix integrity.
Methods: Chondrocytes were isolated from human articular carti-
lage from patients with and without osteoarthritic lesions. Cell
number was assessed directly after collagenase digestion and chon-
drocytes were cultured as monolayers for a period of seven days in a
chemically defined serum-free basal medium (BM) with and without
the addition of recombinant CDMP-1 and -2. The proteoglycan-syn-
thesis rate was measured by [35S]sulfate incorporation into newly
synthesized macromolecules. Growth factors influence on cell prolif-
eration was investigated by [3H]thymidin incorporation. Using RT-
PCR the endogenous expression of CDMPs and their respective
type I and type II receptors was examined.
Results: Cell number per mg tissue of osteoarthritic cartilage was
significantly reduced, on an average by 45%, compared to healthy
controls (P < 0.007). CDMP-1 and -2 stimulation markedly
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology Researchincreased proteoglycan synthesis in postnatal human articular chon-
drocytes (P < 0.05). A comparison of the biosynthetic activity
between healthy and osteoarthritic samples revealed no difference,
neither in stimulated nor in unstimulated cultures. [3H]thymidine
incorporation showed that CDMP-1 and -2 treatment had no effect
on cell proliferation. RT-PCR results indicated that CDMPs and their
respective receptors are endogenously expressed not only in
healthy but also in osteoarthritic cartilage.
Conclusion: The present study shows that CDMPs are potent stim-
ulators of proteoglycan synthesis in postnatal articular chondrocytes
and exert their anabolic effects on both healthy and osteoarthritic
cartilagenous tissue. This data and the finding that CDMPs and
their receptors are endogenously expressed in healthy and
osteoarthritic cartilage suggest that osteoarthritis is not associated
with a loss of responsivness to CDMP-1 and -2. Moreover the
decrease in cell number seems to be important for the limited tissue
repair capacity in osteoarthritis.
P30
Effects of cartilage-derived morphogenetic
proteins and osteogenic protein-1 on
osteochondrogenic differentiation of periosteum-
derived cells
R Gruber*†, C Mayer*, K Bobacz*, M-T Krauth*, W Graninger*, 
FP Luyten‡, L Erlacher*
*Clinic of Internal Medicine III, Department of Rheumatology, Vienna,
Austria; †School of Dentistry, Department of Oral Surgery, University of
Vienna, Austria; ‡Division of Rheumatology, University Hospitals, KU
Leuven, Belgium
Localization studies and genetic evidence have implicated Cartilage-
derived morphogenetic proteins-1, -2 (CDMP-1 and CDMP-2) and
osteogenic protein-1 (OP-1) in the osteochondrogenic differentiation
of mesenchymal progenitor cells during embryonic development and
in postnatal life. Based on their expression pattern and the evidence
that periosteum contains mesenchymal cells in the cambium layer
that can undergo bone and cartilage formation, we hypothesized that
CDMPs and OP-1 may be involved in long bone development and
fracture healing. To test this hypothesis, periosteum-derived cells
from young calves were cultured as monolayers under serum-free
conditions with and without the addition of recombinant CDMP-1,
CDMP-2 and OP-1. Phenotypic analysis indicate that periosteum-
derived cell populations prepared, expanded and cultured under the
conditions described below, constitutively express mRNAs for the
bone markers osteocalcin, osteopontin and collagen type I, and the
chondrogenic markers collagen type II and aggrecan as determined
by reverse transcription (RT)-PCR. Moreover, histologic examinations
showed positive staining for alcian blue and alkaline phosphatase
(AP). Treatment of periosteum-derived cells with CDMPs and OP-1
resulted in a dose-dependent increase of cell proliferation; CDMP-2
was less active in this regard. Furthermore, all growth factors
enhanced osteogenic differentiation as assessed by a time- and
dose-dependent stimulation of AP activity and OP-1 increased
mRNA expression for osteocalcin and collagen type I. We further
examined the effects of CDMPs and OP-1 on chondrogenic differen-
tiation of periosteum-derived cells. Both CDMPs and OP-1 stimu-
lated 35S-sulfate incorporation into newly synthesized
macromolecules with OP-1 having a more pronounced stimulatory
effect when compared with CDMP-1 and CDMP-2. Our results indi-
cate that distinct members of the BMP-family act on periosteum-
derived cells to increase their mitotic and metabolic activity. The
enhancement of both the chondrogenic and osteogenic differentia-
tion suggests that these growth factors might contribute to the post-
natal local regulation of bone formation and fracture repair.
P31
TNFa, IL10 and TGFb1 gene polymorphism in
myositis and mixed connective tissue disease
(MCTD)
A Hassan, I Lundberg and L Padyukov
Rheumatology Unit, Dept. of Medicine, Karolinska Institutet, S-171 76
Stockholm, Sweden
Background: The polymorphisms in the regulatory regions of
cytokine genes have been considered as potential markers for
disease susceptibility. Some of these polymorphisms are proved to
have functional roles. These could be important for understanding
the pathogenesis of myositis and MCTD, which are inflammatory
diseases of unknown genetic background. Our aim was to investi-
gate whether ¡V308 TNFA, -1082 IL10 and codon 25 TGFB1 gene
polymorphisms associate with myositis and/or MCTD or with
certain clinical and immunological parameters in these disorders.
Patients and Methods: 72 patients with myositis and 24 patients
with MCTD were genotyped for the above markers and compared
with a control group from the same population. Gene specific PCR
with restriction endonuclease mapping was used for the detection
of polymorphisms.
Results: Our preliminary data suggested that the frequency of T2
allele of TNF was significantly increased in myositis patients com-
pared to the controls. There were 28 homozygous TNF1/TNF1
(39%), 39 heterozygous TNF1/TNF2 (54%) and 5 homozygous
T2/T2 (7%) with frequency alleles 39 and 61% (TNF1 and TNF2
respectively). Regarding the MCTD patients there was a tendency
for those patients who had high serum levels of TNF-a to carry the
TNF2 allele (P value was 0.08). The frequencies of IL10 and
TGFB1 alleles were not different in myositis or MCTD compared to
the control group.
Conclusion: An increased frequency of the TNF2 allele which may
be associated with high production of TNF-a levels was observed in
myositis patients. This may be of importance for the pathogenesis of
this disorders.
P32
Association between TNF –308A and systemic
lupus erythematosus in relation to HLA-DR3 and
six microsatellite markers on the short arm of
chromosome VI
MW van der Linden*†, A van der Slik‡, E Pieterman†, E Zanelli‡,
MJ Giphart‡, FC Breedveld†, RGJ Westendorp§
and TWJ Huizinga†
Departments of *Clinical Epidemiology, †Rheumatology,
‡Immunohaematology and Blood Transfusion, and §General Internal
Medicine, Leiden University Medical Center, Leiden, The Netherlands
Allelic imbalance at polymorphic loci within the human HLA-DRB1
and TNF genes has been observed in association with increased
susceptibility to systemic lupus erythematosus. We investigated
whether the association of HLA-DRB1*0301 (HLA-DR3) and TNF-
308A with SLE could be attributed to linkage to six polymorphic
microsatellites between HLA-DRB1 and HLA-C. Ninety-one con-
secutive Caucasian patients with SLE and 253 controls (organ
donors) were typed for HLA-DRB1, D6S1014, D6S273, TNFa,
MIB, C-1-2-5 and C-1-3-2 and for TNF promoter polymorphisms.
Independent contribution of alleles to disease susceptibility was
estimated by crosstabulation and multivariate regression.
Results: Carriership of TNF-308A was associated with susceptibil-
ity to SLE (odds ratio [95% confidence interval], 3.70 [2.24-6.11]).
This remained present after stratification on carriership of HLA-DR3
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Available onlinehttp://arthritis-research.com/supplements/3/SA(pooled odds ratio, 2.53 [1.37-4.70]). Stratification further revealed
a possible association of carriership of C-1-2-5*192 with protection
from SLE beyond the effects of HLA-DR3 and TNF-308A. Gene
dose effect was observed for -308A only (homozygotes, 7.75[3.01-
20.0], heterozygotes, 3.15[1.85-5.37]). In multivariate analysis, the
association between HLA-DR3, TNF-308A, and C-1-2-5*192
remained independently associated with susceptibility to SLE (2.58
[1.29-5.18], 2.76 [1.43-5.31], and 0.26[0.10-0.66], repsectively).
Conclusion: An association of carriership of TNF-308A with sus-
ceptibility to SLE can not be attributed to linkage to HLA-DR3, nor
to other polymorphic markers in the vicinity of the TNF gene. Further
loci that are independently associated with SLE might be located in
the vicinity of marker C-1-2-5.
P33
A single nucleotide polymorphism on the IL-10
locus defines an expression polymorphism and a
possible risk factor to develop RA
LR Lard, JJM Schonkeren, E Pieterman, R Westendorp*, 
FC Breedveld and TWJ Huizinga
Departments of Rheumatology and *Clinical Epidemiology, Leiden
University Medical Center, Leiden, The Netherlands
Introduction: IL-10 production differs between individuals. We have
evaluated the IL-10 production in whole blood cultures with/without
LPS. The comparison of monozygotic twins, sibs and unrelated indi-
viduals yielded an estimate of heritability of 70% (Lancet 98). More-
over the ex-vivo IL-10 production was associated with haplotypes
defined by alleles of CA-repeats (PNAS 98). In line with these results
we have demonstrated that the interindividual differences in produc-
tion of mRNA encoding IL-10 are similar than the interindividual dif-
ferences in IL-10 protein production (Rheumatology 2000).
Aim: A) to define SNPs associated with common haplotypes. B) to
study the association of IL-10 production with haplotypes/SNPs. C)
to measure the distribution of IL-10 SNPs in RA versus controls.
Methods: DNA of high and low IL10 producers were sequenced.
Subsequently, the association between LPS-induced IL-10 produc-
tion and previously described (Lancet 98) panel was analyzed.
Results: The following SNPs were identified: -3575 A to G, -2849
A to G, -2763 A to C and -1330 A to G. Previously (Genes and
Immunity 99) we have identified 4 ancestral IL-10 haplotypes. The
current SNP’s on: IL10.1 R3-AAAA-(IL10G)-GCC, IL10.2 R2-
TGCG-(IL10G)-ACC, IL10.3 R2-AGAA-(IL10G)-GCC, and IL10.4
R2-TGCC-(IL10G)-ATA. To investigate whether these SNP’s were
functional we analyzed the LPS-induced IL-10 production of 161
healthy donors with a specific genotype: -3575: AA (n = 38) 1896
ng/ml, AT (n = 76) 3232 ng/ml, TT (n = 47) 3195 ng/ml. -2849: AA
(n = 21) 2115 ng/ml, AG (n = 75) 2950 ng/ml, GG (n = 65) 3111
ng/ml (Mann-Whitney test both P < 0.05). Next, the analysis was
repeated in a different group of donors: 135 partners of patients
with SLE/MS: -3575: AA (n = 29) 4190 ng/ml, AT (n = 71) 4521
ng/ml, TT (n = 35) 4401 ng/ml (MW-test P = 0.6).
-2849: AA (n = 26) 3845 ng/ml, AG (n = 41) 4577 ng/ml, GG (n =
68) 4543 ng/ml (MW–test P = 0.04, for G carrier versus non G: P
= 0.02). Next, the distribution of -2849 SNP was compared in RA
patients compared to controls. Control-Panels were 1) partners of
MS-SLE patients (n = 135) and 2) organ donors (n = 168). RA-
patients were: 1) incident RA cases, 2) outpatient consecutive RA
and 3) RA patients from our early arthritis cohort.
Conclusion: We (Eskdale et al, Lancet 98) have previously found
that the allele IL-10R3 microsatellite was less frequent in three
ethnic groups of RA patients (Afro-americans P < 0.01, English P <
0.008 and Scottish P < 0.02). The SNP that defines the haplotype
on which R3 is located is also less prevalent in three groups of 
Control RA Patients
(1) (2) (1) (2) (3)
AA 27 16 3 24 16
AG 42 64 38 141 74
GG 71 88 51 152 91
Total chi-square: P = 0.0014
dutch RA compared to two groups of dutch controls. These data
suggest that a high innate IL-10 production is a risk factor for RA.
This may be due to the B-cell stimulating properties of IL-10.
P34
Elevated levels of soluble intercellular adhesion
molecule –1 in systemic lupus erythematosus
N Kljukvina, S Shekshina, E Alexandrova, A Novicov and E
Nassonov
Moscow Medical Academy, Institute of Rheumatology of RAMS,
Russia
Objective: To assess the value of measuring serum levels of soluble
intercellular adhesion molecule 1 (sICAM-1) in systemic lupus ery-
thematosus (SLE).
Material and methods: We studied 35 patients (pts) (7 female, 28
male), satisfying the ACR criteria for SLE. Mean age of pts was
31,4±12,0 years (range 17-63), mean disease duration was
81,8±70,5 month (range 2-240). Disease activity was assessed by
disease activity indices (SLAM, SLEDAI). Enzyme-linked
immunosorbent assay was used to measure levels of sICAM-1
(R$D, USA). The results were compared with 18 healthy subjects.
Results: Levels of sICAM-1 were found elevated (more than 2 SD
above the mean in normal controls, 443 ng/ml) in 7 of 35 (20%) pts
with SLE. The relations between positive sICAM-1 and some clini-
cal manifestations of SLE have been detected. We found significant
correlation between individual sICAM-1 serum level and the
SLEDAI (r=043) and SLAM (r=0,56) scores, and ESR (r=0,53).
Parameters, Positive sICAM-1 Negative sICAM-1
(%) or mean ±SD (n = 7) (n = 28) P
ICAM-1, ng/ml 512,3±45,5 284,3±85,0 <0,001
Malar rash 28,6% 14,2% NS
arthritis 42,8% 25% NS
nephritis 57,2% 32,1% NS
CNS involvement 71,4% 39,3% NS
Serositis 42,8% 14,3% NS
ESR, mm/h 38,0±24,8 21,2±16,1 <0,05
SLAM, score 16,0±7,4 9,03±5,7 <0,05
SLEDAI, score 18,0±12,4 10,2±7,75 <0,05
Conclusion: Elevated serum levels of sICAM-1 can be found in SLE
and correlate with disease activity. Longitudinal studies may estab-
lish their clinical value in the monitoring or the prognosis of patients.
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Spontaneous activation of JNK-1 and PI-3 kinase
can be induced in lupus-like chronic GVHD in the
P->F1 model
F Niculescu, P Nguyen, V Rus, H Rus and CS Via
University of Maryland School of Medicine and VA Medical Center,
Baltimore, MD 21201, USA
Abnormalities in intracellular signaling pathways have been
described in human SLE however, it is not clear whether they are
primary, predisposing events or secondary to SLE expression. To
address this question, we used a murine model of SLE (chronic P-
>F1 GVHD) and compared the function of a broad range of intracel-
lular signaling pathways. In this model, SLE-like disease is induced in
normal F1 mice by injection of parental CD4+ T cells and is medi-
ated predominantly by Th2 cytokines. In contrast, acute GVHD is a
cell-mediated anti-host response induced by CD4 and CD8 donor T
cells and both Th1 and Th2 cytokines. Spleen cell lysates from
control and GVHD mice (day 10 and 21) were immunoprecipitated
with antibodies to Raf-1, ERK-1, JNK-1, p38 MAPK and PI-3 kinase
and the function of the precipitated kinases determined using a spe-
cific substrate for each kinase. Raf-1 and ERK1 were selectively
increased in acute GVHD (2-fold) only, whereas JNK-1 and PI-3
kinases were increased in both acute and chronic GVHD. This
increase was approximately two fold greater for acute vs. chronic
GVHD mice for both kinases. p38 MAPK was not increased over
control in either form of GVHD and may reflect the earlier peak of IL-
2 (day 3) in this model. The data suggest that Raf-1 and ERK-1 may
be important in CD8 driven cell mediated immune responses
whereas JNK-1 and PI-3 kinase signaling may be important in CD4
driven antibody mediated immune response. Studies are under way
using purified T cell subsets to confirm this hypothesis. However
these data support the idea that the signaling abnormalities reported
in human SLE may be secondary to a continuous immune activation
rather than indicative of a primary predisposing event.
P36
T lymphocytes of patients with SLE lack Stat4
M Aringer, GH Stummvoll, G Steiner, CW Steiner, I Radda, 
JS Smolen and WB Graninger
Department of Rheumatology, Internal Medicine III, University of
Vienna, Austria
Background: Signal transducers and activators of transcription
(Stats) are essential for cytokine receptor signaling. Stat4 is found
in lymphocytes and activated monocytes, where it is tyrosine-phos-
phorylated after IL-12 or (human) interferon-alpha bind their respec-
tive receptors. Stat4 plays a significant role in the development of
Th1 cells: Stat4-/- mice lack such cells and are Th2-shifted. More-
over, Stat4 expression is known to be influenced by lymphocyte
activation. We therefore investigated the expression of Stat4 in
human SLE.
Methods: Peripheral venous blood was drawn from 9 patients fulfill-
ing ACR criteria for SLE and 7 healthy controls. Protein lysates
were prepared from highly enriched T cells and standardized for
protein, electropheresed on polyacrylamide gels and electrotrans-
ferred. Stat4 was detected using polyclonal antibodies, peroxidase-
conjugated secondary antibodies and chemoluminescence.
Results: Stat4 protein was clearly detectable in 5 out of 7 healthy
controls. In contrast, the T cells of only 1 of 9 SLE patients con-
tained Stat4. This difference was statistically significant (P = 0.035
in Fisher’s exact test). This result was independent of disease activ-
ity or therapy. Lysates from crude PBMC lysates gave similar
results, which would be expected, given the normal cellular distribu-
tion of Stat4, but some SLE lysates contained additional bands of
similar size.
Conclusion: The lack of Stat4 protein in SLE T lymphocytes may
have immunological consequences by hampering Th1 answers. It is
unclear at the moment whether the differences observed are due to
constant immune stimulation.
P37
Global analysis of gene expression in unseparated
and CD8+ cells from bronchoalveolar lavage of
patients with scleroderma lung disease
IG Luzina, SP Atamas, R Wise, FM Wigley and B White
University of Maryland School of Medicine and Johns Hopkins Medical
Institutions, Baltimore, MD, USA
The molecular mechanisms that lead to lung fibrosis following lung
inflammation in patients with scleroderma are unknown. The objec-
tive of this study was to identify patterns of abnormal gene expres-
sion in unfractionated bronchoalveolar lavage (BAL) cells from
scleroderma patients. DNA microarrays were used to assess expres-
sion of over 4000 genes in BAL cells from 17 scleroderma patients
and 7 controls. Hierarchical matrices were constructed and showed
that BAL cell samples from patients with lung inflammation segre-
gated into one cluster, whereas BAL cell samples from patients
without lung inflammation and controls clustered in another. Next,
372 genes were identified that were expressed at least two- fold
higher or lower in BAL samples from patients without lung inflamma-
tion, compared to controls. These genes, which may represent a
scleroderma phenotype independent of tissue inflammation, clus-
tered into eight groups. One cluster of note included receptors for
several chemokines,IL-1, IL-13, IL-18,and IFN-gamma receptors, as
well as IL-10, IL-12, macrophage stimulating factor, VEGF, IGF
binding protein and TXK tyrosine kinase. Fibroblast growth factors,
other cytokines, and intracellular signaling molecules were among
the genes in other clusters. Finally, 238 genes were identified that
were over- or under- expressed in BAL cells from patients with
greater risk of lung fibrosis, that is, patients with lung inflammation,
compared to both patients without lung inflammation and controls.
These genes clustered into 3 groups which included genes induced
by stress (such herne oxygenase, complement components, and
heat shock proteins), multiple chemokines (such as MCP-1, MIP-1,
and PARC), and genes associated with several intracellular signaling
pathways (such as JNK2 kinase, diacylglycerol kinase, and phos-
phatidylinositol 4,5 bisphosphate 5-phosphatase). Similar studies of
global gene expression have begun with CD8+ T cells isolated from
BAL samples. Preliminary data suggest abnormal expression of lym-
photoxin beta, endothelin-2, fibroblast growth factors, and TGF-beta
RII. In summary, scleroderma patients with lung inflammation have
distinct patterns of gene expression in BAL cells, compared to
patients without lung inflammation and healthy controls. Cluster
analyses of genes that are abnormally expressed in different patient
groups may shed light on new mechanisms that contribute to the
development of the scleroderma phenotype, including genes likely to
be involved in the inflammatory process and subsequent develop-
ment of fibrosis in this autoimmune illness.
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Redox-sensitive changes in conformation and
cellular localization of LAT and downstream TCR
signaling lead to hyporesponsiveness of synovial
fluid T cells in rheumatoid arthritis
SI Gringhuis, PHJ Remans, EAM Papendrecht-van der Voort, A
Leow, EWN Levarht, FC Breedveld and CL Verweij
Department of Rheumatology, Leiden University Medical Center, P.O.
Box 9600, 2300 RC Leiden, The Netherlands
In rheumatoid arthritis (RA), the synovial fluid (SF) T lymphocytes
present in the inflamed joints, display hyporesponsiveness upon
engagement of the TCR/CD3 complex despite phenotypic evi-
dence of former activation. We have previously shown that the
central and crucial adaptor protein LAT (linker for activation of T
cells), which plays a central and crucial role in the T cell receptor
(TCR)-mediated signaling pathways, exhibits deficient phosphoryla-
tion due to displacement of the integral membrane protein from the
plasma membrane in SF T lymphocytes. SF T lymphocytes exhibit
several features of chronic oxidative stress, e.g. severely decreased
intracellular levels of glutathione (GSH), and our previous studies
have indicated that the subcellular localization of LAT is sensitive to
changes in the intracellular GSH levels. The cysteine-to-serine sub-
stitutions of several cysteine residues (C26/29 or C117) within LAT
creates LAT mutants that are resistant to reduced intracellular GSH
levels and remain membrane-anchored in GSH-depleted cells.
In this study, we have used the redox-insensitive LAT mutants to
study the effect of redox balance alterations, like in SF T lympho-
cytes, on TCR signaling pathways downstream from LAT and on
CD28 signaling pathways. In co-transfection experiments, we show
that the presence of the redox-insensitive LAT mutants allows for
the partial restoration of the TCR-mediated signaling pathways, but
not the signaling pathways induced through the CD28 receptor.
The data are indicative that the Raf1-ERK and the calcium-cal-
cineurin pathways leading to transcriptional activation of AP-1 and
NFAT, respectively, are very sensitive to reduced intracellular GSH
levels, while the activation of the p38/Mpk2 pathway leading to AP-
1-mediated transcription is mostly unaffected by chronic oxidative
stress. A very proximal event in the CD28-mediated signaling path-
ways seems to be extremely sensitive to GSH depletion since cos-
timulation did not affect the transcriptional activity of either AP-1 or
NF-kappaB.
We conclude that the signaling pathways in SF T lymphocytes from
RA patients are affected at several levels by chronic oxidative
stress, all contributing to the observed hyporesponsiveness of these
cells.
P39
Peripheral corticotropin releasing hormone
signaling is mediated by Type 1a a receptors in early
human inflammatory arthritis
A McEvoy, B Bresnihan, O FitzGerald and E Murphy
Department of Rheumatology, St Vincent’s University Hospital, Dublin,
Ireland
Corticotropin Releasing Hormone (CRH) is essential for modulating
the effects of the inflammatory response in vivo. Elevated levels of
CRH are produced locally in inflamed human synovial tissue and
observations indicate a role for CRH in the pathogenesis of inflam-
matory joint disease. CRH action is initiated by two distinct sub-
types of CRH receptors, CRH-R1 and CRH-R2, which are
approximately 68% homologous. Each subtype exhibit spliced vari-
ants (a and b), displaying pharmacologically and functionally dis-
tinct isoforms.
To further elucidate the peripheral biological role for CRH we exam-
ined the expression of known CRH receptors subtypes in inflamed
human synovium (n = 14) and compared the expression patterns to
normal synovium. Immunohistochemistry and RT-PCR confirmed
enhanced expression of CRH-R1 receptors in rheumatoid (RA) and
psoriatic (PsA) arthritis synovial tissue. In all tissues studied CRH
R1a mRNA was identified, however, we were unable to detect
other CRH R1 or CRH R2 isoforms in the same cohort of patients.
Immunoreactive CRH-R1 is abundantly expressed on vascular
endothelial cells and discrete perivascular cell populations, posi-
tively identified as mast cells. In contrast, in normal synovial tissue,
neither CRH receptor subtype is expressed.
Selective up-regulation of CRH receptors in inflamed synovial tissue
indicates that CRH functions locally, in an autocrine/paracrine
receptor-mediated response. Our findings suggest that CRH signal-
ing, via CRH-R1a, may play a role in both vascular changes and
pathologic mechanisms associated with joint inflammation.
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Detection of the “Kreisler” (maf B) gene by
combination of in situ-hybridization and
immunohistochemistry of RA-, osteoarthritis- and
normal controls-synovial tissue samplings as a
potential significant marker for early RA
U Vigna*, B Ostendorf*, T Pauly*, T Giel*, U Jeffry†, R Murray†, 
M Schneider*
*Multipurpose Arthritis Center, Heinrich-Heine University Duesseldorf,
Germany; †EOS-Biotechnology, San Francisco, USA
Introduction: By analyzing gene expression profiles of arthritic
tissue on DNA microarrays (EOS) compared to the “Body Atlas”, a
reference database of 13 normal human tissues, we found the
RAB3 “Kreisler” (maf B) gene (member of the maf gene family and
encoding for a transcription activator specific for mesenchymal and
neuronal organogenesis) highly expressed in early rheumatoid
arthritis (RA) (< 2 years disease duration).
Objective: To investigate the functional “Kreisler” gene expression
in RA-, osteoarthritis- and normal controls- synovial samplings by
combination of in situ-hybridization and immunohistochemistry.
Methods: We analyzed synovial biopsies (n = 12; 7f/5m) from 5
RA- (3 early RA, 2 RA), 4 osteoarthritis-patients and 3 normal con-
trols, which were taken by arthrotomy by various indications and
miniarthroscopy of MCPs (2 early RA). Samples were analyzed by in
situ-hybridization with the “Kreisler” (maf B) gene-mRNA and
immunohistochemistry (e.g. Ki 67, CD 68).
Results: We detected increased “Kreisler”-mRNA levels in 3 early
RA samples in the synovial lining layer and no signals in the control
and compared samples. At higher concentrations (>1ng/ml) of
RNA-oligonucleotides unspecific hybridization-signals prevailed in
tissues of all diseases (even in normal controls). The combination of
both methods (in situ-hybridization and immunohistochemistry) iden-
tifies the single cells inside the synovial lining layer which contains
the highly expressed RAB3 “Kreisler” (maf B) gene.
Conclusion: Based on the gene expression profiles through
oligonucleotid-microchip-array-analysis by EOS and the detection of
the increased “Kreisler” (maf B) gene expression in combination of
in situ-hybridization and immunohistochemistry of RA-synovial tissue
samplings we discuss the “Kreisler”-gene as a potential inducing
element in the pathogenesis of early RA. Further serial studies are
needed to clarify the significance of “Kreisler” especially for early
RA and the molecular pathogenesis of this disease.
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Defective Rap1 activation in synovial fluid T cells
from patients with rheumatoid arthritis.
PHJ Remans*, SI Gringhuis*, K Reedquist†, FC Breedveld*, 
JM van Laar* and CL Verweij*
*Rheumatology, LUMC, 2300 RC Leiden, The Netherlands; †Dept.
Physiological Chemistry, and Center of Biomedical Genetics, UMC,
3584 CG Utrecht, The Netherlands
Background: Rap1 is a small G-protein, member of the Ras
GTPase family. Rap1 has been linked to T cell anergy and it is sug-
gested that Rap1 has the potential to inhibit Ras-mediated onco-
genic or growth promoting activity. Synovial fluid (SF) T cells from
patients with rheumatoid arthritis (RA) display a defective phospho-
rylation pattern of several pivotal signaling proteins and severe
hyporesponsiveness upon antigenic stimulation. Our previous data
showed that the hyporesponsive state of the SF T cells in RA corre-
lates with markers of oxidative stress and replenishment of the intra-
cellular level of the anti-oxidant glutathione (GSH) by treatment with
N-acetyl-L-cysteine (NAC) restores the observed signaling defects.
Objective: To determine Rap1 activation and its correlation with
oxidative stress in T cells from healthy controls compared to periph-
eral blood (PB) and SF T cells isolated from RA patients.
Methods: T cells from healthy donors and PB and SF T cells from 5
RA patients were isolated and after 5 minutes of stimulation with
either anti-CD3 antibodies or PMA+ionomycin, whole cell lysates
were prepared in Ral lysis buffer. GTP-bound Rap1 was isolated
using the bacterial expressed fusion protein GST-RalGDS and
detected by ECL Western blotting. In whole cell lysates, total Rap1,
rapGAP and Spa1 were detected by ECL western blotting as well.
Results: Our data show that in T cells isolated from healthy con-
trols, Rap1 was activated in a redox-dependent way. Upregulation
of intracellular GSH levels by incubation with 10 mM NAC for 48 h
resulted in diminished Rap1 activation, while depletion of GSH by
pre-incubation for 48h with 200 mM BSO resulted in enhanced
Rap1 activation. We also observed that treatment of T cells with
H2O2 led to the rapid activation of Rap1.
Despite an environment of oxidative stress in the inflamed joints of
RA patients, we found that in SF T cells Rap1 was present in its
inactive GDP-bound state. Furthermore, upon stimulation Rap1
remained inactive in SF T cells while in contrast Rap1 could be acti-
vated in PB T cells from RA patients. The defective Rap1 activation
was not due to increased levels of the Rap1 GTPase activating pro-
teins RapGAP or Spa1. While restoration of the intracellular redox
balance does reverse the hyporesponsiveness of the SF T cells, the
replenishment of GSH with NAC had no effect on the defective
Rap1 activation.
Conclusions: 1. In healthy T cells the small GTPase Rap1 is acti-
vated by H2O2; 2. Rap1 activation after T cell stimulation is redox-
dependent; 3. Rap1 activation is defective in SF T cells from RA
patients, and cannot be restored by the replenishment of GSH with
NAC.
P42
The RIIbeta-subunit of protein kinase A (PKA)
inhibits c-fos synthesis in T cells
N Mishra, M Tolnay*, MR Elliott, DR Brown, GC Tsokos* and GM
Kammer
Wake Forest University School of Medicine, Winston Salem, NC;
*Walter Reed Army Institute, Silver Spring, MD, USA
In human primary T cells, the type II isozyme of protein kinase A
(PKA-II) is localized to cytoskeletal elements or organelle mem-
branes. Stimulation of T cells via the T cell receptor/CD3 complex
or by addition of the cAMP analog, 8-Cl-cAMP, activates PKA-II,
resulting in nuclear translocation of the RIIbeta-subunit from the
cytosol and apparent RIIbeta DNA-binding. In current experiments,
we demonstrated that recombinant RIIbeta forms a heterodimer
with recombinant CREB, a nuclear transcription factor, as shown
both by EMSA and immunoprecipitation/ immunoblotting. We found
no evidence of direct binding of RIIb to c-fos-defined CRE oligonu-
cleotides by EMSA. Although the RIIbeta-CREB heterodimer binds
to the c-fos cAMP response element (CRE), phosphorylation of
both RIIbeta and CREB by PKA enhances binding to c-fos CRE
oligos. In vivo, phorbol myristate acetate (PMA)-induced synthesis
of c-Fos protein is inhibited by DNA-binding of RIIbeta-CREB com-
plexes. Taken together, these data suggest that, in addition to its
primary function as an inhibitor of catalytic-subunit activity, the
RIIbeta-subunit also acts as a transcription factor that can modulate
the activity of the c-fos promoter. Therefore, we propose that
RIIbeta may be a transcriptional repressor of c-fos.
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Invasion of synoviocytes is inhibited by gene
transfer of TNF-BP or IL10 in an in vitro invasion
model
E Pieterman*, PH Goossens*, WH van der Laan†, 
AL Huidekoper*, MJM Rabelink‡, RC Hoeben‡, JH Verheijen†, 
FC Breedveld*, TWJ Huizinga*
*Department of Rheumatology, Leiden University Medical Centre,
Leiden; †Gaubius Laboratory, TNO Prevention and Health, Leiden;
‡Department of Molecular Cell Biology, Leiden University Medical
Centre, Leiden, The Netherlands
In RA fibroblast like synoviocytes (FLS) degrade and invade into
adjacent cartilage. An in vivo model is the SCID-mouse/ Human
cartilage /synoviocyt model (S. Gay). Previous studies indicate that
the invasive behaviour of fibroblast like synoviocytes can be tested
in vitro in a matrigel transwell system. Matrigel, mainly composed of
laminin and collagen IV, serves as a model for cartilage.
The aim of this study was to compare the invasive behaviour of FLS
from RA and osteoarthritis (OA) patients and to investigate the
effect of adenoviral (Ad) transfer of genes encoding IL-10 and TNF-
binding protein (p55) (TNF-BP) on the invasive behaviour of FLS
from RA patients.
FLS from 43 RA and 28 OA patients obtained from synovial tissue
harvested at joint replacement surgery, were seeded at confluency in
serum free medium on top of a matrigel coated transwell filter with 8
mm pores. Medium with 10 % Fetal Calf Serum and 10 % Human
Serum was used in the lower compartment. Three days post incuba-
tion cells were fixated, stained and the invaded synoviocytes on the
lower side of the filter were counted. To test the effect of IL10 and
TNF-BP, RA synoviocytes were infected overnight with 5, 10, 50 and
100 plaque forming units (pfu)/cell of Ad.IL10, Ad.TNF-BP or
Ad.luciferase (negative control) and then tested in the invasion model.
Significantly more RA synoviocytes invaded through the matrigel
(median = 4035 cells) as compared to OA synoviocytes (median =
1900 cells; P < 0.001). IL10 and TNF-BP gene transfer both
resulted in a dose dependent inhibition of invasion with a maximal
inhibition of 93.7% (± 10.7) and 86.6% ( ± 14.5) respectively,
while luciferase gene transfer showed a maximal inhibition of 17.6%
(±1.7).
In conclusion, the invasive behaviour of FLS can be studied in the
matrigel transwell system. This assay discriminates between the
invasive behaviour of RA and OA FLS. The invasive behaviour of RA
synoviocytes can be strongly inhibited by IL10 indicating that IL10
is able to downregulate the proteins involved in invasive growth. The
inhibitive effect of TNF-BP indicates that continuous production of
TNF is involved in invasive behaviour of synoviocytes.
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Specific suppression of the transcription factor
AP-1 by mepacrine
KM Stuhlmeier, C Linnert and H Bröll
Ludwig Boltzmann Institute for Rheumatology and Balneology, Vienna-
Oberlaa, Austria
Mepacrine has been used for decades and the beneficial effects of
this drug are well described. Since endothelial cells (EC) are in
many cases the first cells to come in contact with drugs, the effect
of mepacrine on certain aspects of EC biology were studied. First,
our data demonstrate that at high doses mepacrine can have a
marked impact on the integrity of the EC monolayer without grossly
interfering with cell viability. The described impact of mepacrine on
EC might explain, at least in part, the negative effects of this drug
observed in the past. More importantly, mepacrine profoundly
effects gene regulation in EC and fibroblasts. Mepacrine binds to
DNA in a sequence specific manner. While NF-kB-DNA interactions
are not effected, AP-1-DNA binding is blocked by mepacrine. Such
differential effects are presumably due to sequence specific interca-
lation of mepacrine into the AP-1 consensus element. Pre-incuba-
tion of oligonucleotides resembling this sequence blocked the
subsequent binding of nuclear extract containing AP-1 protein(s).
Consequently, mepacrine prevents the upregulation of genes which
depend mainly on the activation of AP-1. One of the few genes
which have been found to depend heavily on the activation of this
transcription factor is metalloproteinase-1 (MMP-1). We demon-
strated by western blot that treatment of fibroblasts with mepacrine
completely prevented subsequent upregulation of MMP-1. Since
MMP-1 plays an important role in the propagation of rheumatic dis-
eases, we suggest that the beneficial effect of mepacrine seen in
the past is due, at least in part, to the described mechanisms.
P45
Patterns of differentially expressed genes in
synovial tissue from RA and OA patients and from
normal joints
U Ungethüm, T Häupl, J Zacher*, A Gursche*, Förster†, P
Reutermann‡, A Prub, V Krenn and G-R Burmester
Department of Rheumatology, Charité, Berlin; *Dept. of Orthopedics,
Klinikum Buch, Berlin; †Department of Orthopedics Waldkrankenhaus
Bad Düben; ‡Department of Orthopedics, KMG Kliniken, Kyritz;
Germany
Objective: To identify key genes in the pathomechanism of rheuma-
toid arthritis (RA), synovial tissues from RA, osteoarthritis (OA) and
from normal joints (ND) were compared by a subtractive hybridiza-
tion technique, the representational difference analysis (RDA).
Methods: Synovial tissues from 3 RA, 3 OA patients and 5 normal
joints were selected according to their disease-characteristic
immunhistochemical findings and to their expression of high versus
low levels of inflammatory (IL-1b, TNF-a) and destructive markers
(MMP-1, MMP-3) as determined by semiquantitative RT-PCR.
Pooled mRNA from RA, OA and normal tissues was transcribed,
digested by a 4-base-cutter, ligated to adapter-primers and ampli-
fied to form representational amplicons. Subtractive hybridizations
were performed by different protocols: 1. the OA amplicon (driver)
was subtracted from the RA representation (tester); 2. the RA
(driver) from the ND (tester) and 3. the ND (driver) from the OA rep-
resentaion (tester). Using primers specific for the corresponding
tester, the difference-products were selectively amplified, cloned,
sequenced and compared to published sequences in the
Genebank. Differential expression of identified genes was validated
by semiquantitative RT-PCR.
Results: Approximately 150 genes were found to be differentially
expressed in RA synovial tissue as compared to OA or ND tissues
respectively, or in OA tissues as compared to ND. Interestingly,
some genes were identified to be overexpressed in both groups:
RA (i.e. difference-product from RA minus OA) and OA (OA minus
ND), indicating rather an association to general joint destruction
than to RA-specific mechanism. Other genes were found to be dif-
ferentially expressed only in the RA representation. 30 of the differ-
entially expressed genes identified from each disease group were
analyzed in synovial tissues from further 20 RA, 20 OA patient and
20 normal joints. The expression of some genes showed either a
significant correlation to those of inflammatory genes (IL-1b and
TNF-a) or to those of destructive markers (MMP-3).
Conclusions: The analysis of differential gene expression in chronic
joint diseases is a promising approach to identify deregulation of the
inflammatory network to explain the inappropriate immune response
with autoaggessive outcome. Furthermore a pattern of genes is
generated which is specifically or preferentially expressed in RA.
Such patterns will be of diagnostic value, especially for disease
characterization, longitudinal studies and analysis of therapeutic
effects.
P46
MMP-1, MMP-3 and MMP-10 are involved in the
degradation of cartilage
TCA Tolboom*, E Pieterman*, WH van der Laan*†, AL
Huidekoper*, RGHH Nelissen‡, FC Breedveld* and TWJ
Huizinga*
*Departments of Rheumatology and ‡Orthopaedic Surgery, Leiden
University Medical Centre, Leiden; †Gaubius laboratory, TNO
Prevention and Health, Leiden, The Netherlands
Rheumatoid arthritis (RA) is characterised by degradation of carti-
lage and invasion of fibroblast-like synoviocytes (FLS) into adjacent
cartilage. Several families of proteinases are involved in the degra-
dation of cartilage, especially the matrix metalloproteinases (MMP’s)
and cathepsin K. However, it is not known which MMP’s are
responsible for the degradation of cartilage and the invasiveness of
FLS. In this study, the expression of MMP’s 1 to 20 and cathepsin K
in cultured FLS obtained from joint replacement surgery from RA,
osteo-arthritis (OA) and other non-destructive arthropathies are
investigated and compared to the invasiveness of the FLS in a
matrigel transwell system. In this matrigel transwell system previous
studies have shown that FLS from RA patients were significantly
more invasive than FLS from patients with OA or other non-destruc-
tive arthropathies.
FLS from synovial tissue of 32 RA, 18 OA and 14 patients with
other non-destructive arthropathies were obtained from joint
replacement surgery. The FLS were grown to confluency and RNA
was isolated at passage 1 or 2. cDNA was synthesized using oligo-
dT and reverse transcriptase. Expression of MMP’s and cathepsin K
was investigated using RT-PCR. For MMP’s 2, 3, 7-12, 14-17, 19,
20 and cathepsin K RT-PCR was performed with primers for the
MMP under investigation and primers for beta-actin in one mix. For
MMP-1 and 13 no primers for beta-actin were in the mix. The inten-
sity of the bands were compared and given a number from 0 (no
expression) to 3 (intensity more than beta-actin). These numbers
were related to the invasiveness (number of cells) in a matrigel tran-
swell system.
FLS that expressed MMP-1, MMP-3 or MMP-10 were significantly
more invasive (median number of invasive cells: 3970, 4525, 4998,
respectively) than cells that did not express MMP-1, MMP-3 or
MMP-10 (1826, P = 0.02; 3081, P = 0.01; 2537, P = 0.01,
respectively). Expression of the other MMP’s and cathepsin K did
not show a significant relationship with invasive growth. Expression
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology Researchof MMP-9 showed a trend with higher expression in more invasive
cells (P = 0.09). From this study it can be concluded that a correla-
tion exists between expression of MMP-1, MMP-3 and MMP-10 and
invasiveness of FLS in a matrigel transwell system.
P47
The release of an ERK-activating factor from
cartilage explants in response to trauma
T Vincent, M Bolton and J Saklatvala
Kennedy Institute of Rheumatology, Aspenlea Road, London W6, UK
Mechanical injury to cartilage predisposes to premature degenera-
tive arthritis but little is understood of the chondrocytic response to
injury at the cellular and molecutar level. We have shown that the
extracellular regulated kinase (ERK), the original mitogen activated
protein (MAP) kinase, is strongly activated in porcine articular carti-
lage upon scarification in vivo, or following cutting of rested carti-
lage explants in vitro. Activation occurs within minutes and is
sustained for 24-48h. It appears to be mediated by a soluble factor
which is released into the culture medium by damaged cartilage.
The factor is thermolabile and retained by dialysis membrane
(10kDa cut-off). We have purified the factor through a series of
chromatography steps (anion and cation exvhange, gel filtration and
agarose-heparin columns), and are awaiting identification. It repre-
sents a potential homeostatic mechanism in response to injury, and
could play a role in normal metabolism and degenerative arthritis.
Poster Discussion D
Cellular Immunity
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In vitro autoreactivity against autologous
keratinocytes in patients with rheumatoid and
juvenile idiopathic arthritis
K Štechová, P Vavrincová, H Reitzová and I Hromadníková
2nd Dep.of Paediatrics, University Hospital Motol, Prague, Czech
Republic
In patients with rheumatoid arthritis or juvenile idiopathic arthritis we
observed the tendency of peripheral blood mononuclear cells to
induce graft versus host disease like histhopathological changes of
grade II or above (evaluated according to standard Lerner´s classifi-
cation)when co-cultured in vitro with autologous skin explants. The
aim of this study was to verify if observed skin damage was really of
an autoimmune origin and we also tried to compare results with
autoreactivity directed against autologous synovium. We suppose
that humoral as well as cellular autodestructive mechanisms may be
involved in the pathogenesis of observed skin damage.
Methods:To prove this hypothesis (cellular autodestruction)we
used 51Cr release cytotoxic test where peripheral blood mononu-
clear cells were co-cultured with autologous synovial cells as well
as with autologous keratinocytes.
Results: We found that patient´s peripheral blood mononuclear
cells lysed both autologous keratinocytes (specific lysis 60%) as
well as autologous synovial cells (59% specific lysis). No specific
lysis of autologous keratinocytes and synovial cells was observed in
healthy controls.
We suppose that peripheral blood mononuclear cells might recog-
nise similar autoantigen(s) expressed on epidermal cells that might
give rise an autoimmune response in synovium.
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Enrichment of CD8+ CD28- cytotoxic T cells in
circulating lymphocytes of patients with
ankylosing spondylitis
M Schirmer, C Goldberger, C Duftner, J Clausen, A Falkenbach
Department of Internal Medicine, University of Innsbruck, and
Gasteiner Heilstollen Hospital, Bad Gastein-Böckstein, Austria
Introduction: In patients with ankylosing spondylitis (AS), HLA-B27
restricted cytotoxic T lymphocytes (CTLs) exist with specificity for
arthritogenic bacteria, viral peptides or autoantigens. These MHC-
class I restricted CTLs could maintain the inflammatory process
even after the bacterial pathogen itself had been eradicated by
antibacterial immune responses and thus be directly involved in the
pathogenesis of spondylarthropathies. Phenotypically they are char-
acterized by CD28-negativity and CD57/CD11a high-positivity. This
study was performed to directly compare the relative number of
CD8+ CTLs from AS patients with age-matched healthy controls.
Until now only few data are available for the incidence of
CD8+CD28- T cells in autoimmune diseases.
Methods: AS patients were recruited and examined at the
Gasteiner Heilstollen Hospital. Controls were preselected by evalu-
ating the proband’s history and physical examination excluding an
inflammatory or autoimmune diseases. Peripheral blood mononu-
clear cells were isolated by Ficoll density gradient centrifugation,
triple-stained for CD3, CD4, and CD28-antigens and analyzed on a
FACScan flow cytometer.
Results: Peripheral blood was analyzed from 95 AS patients and 53
age –matched healthy controls (49,1 +/- 11,4 and 48.0 +/- 14.0
years old, respectively). In AS patients CD8+CD28- T cells are
expanded more than in the age-matched population (41,2 +/- 17,7%
and 18,6 +/- 7,6% (P < 0,0001), with regression lines y = 0,23x +
29,85 (R2 = 0,02) and y = 0,03x + 17,03 (R2 = 0,004), respec-
tively). The percentage of CD8+CD28- T cells does not increase over
the decades in healthy controls. Trends are described for increased
percentages of CD8+CD28- T cells in patients with severe disease.
Conclusions: These data suggest that the fraction of CD8+CD28-
T cells is not only increased in certain infectious diseases but also in
patients diagnosed with AS. Increased percentages of
CD8+CD28- T cells during ageing might be an artificial effect of
undiagnosed infectious or autoimmune diseases. This finding
further supports the hypothesis that increased levels of
CD8+CD28- T cells can be considered pathogenic, comparable to
benign monoclonal gammopathy.
P50
Differences in B cell regulation in DRB1 shared
epitope positive and negative rheumatoid arthritis
U Wagner, M Pierer, S Kaltenhäuser, B Wilke, S Arnold 
and H Häntzschel
Department of Medicine IV, University of Leipzig, Härtelstr. 16-18,
04107 Leipzig, Germany
Introduction: Aim of the study was the analysis of systemic B cell
activity and of the size of the B lymphocyte compartment in patients
with rheumatoid arthritis (RA)
Material and methods: In 94 patients with RA according to the
1987 ACR criteria, clinical, radiographic and laboratory data were
gathered in a cross-sectional, retrospective study. Besides standard
laboratory test, concentration of serum IgM and IgG were determined.
In peripheral blood mononuclear cells, the percentages of CD4+,
CD8+ and CD19+ lymphocytes were determined by dual-color flow
cytometry. For all patients, the presence of the RA associated shared
epitope (SE) was determined by HLA DRB1 genotyping.
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Available onlinehttp://arthritis-research.com/supplements/3/SAResults: The analysis of CD19+ B cell frequencies of RA patients
revealed a bimodal distribution in the study population separating
one group of patients with B cell counts below 8.5 % of all lympho-
cytes (B cell low patients, 62 % of the study population) from a
second group with more than 8.5 % B cells (B cell high, 38 %).
HLA genotyping revealed, that the two groups were immunogeneti-
cally distinct. B cell low patients were more frequently SE positive
than B cell high patients (84.5 % vs. 50 %, P < 0.001), and SE
positive patients had lower CD19 percentages in the rank-sum
analysis when compared to SE negative ones (6.3 % vs. 14.0 %, P
< 0.001). Comparative analysis of a healthy control group showed,
that B cell frequencies were diminished in SE positive and
increased in SE negative patients.
B cell low patients were found to have significantly lower concentra-
tions of RF IgM, RF IgA, and serum IgM, but not of serum IgG, when
compared to the B cell high group. Multivariate analysis revealed
the presence of low B cell counts to be associated with the pres-
ence of the shared epitope sequence, RF IgM seronegativity and
low concentrations of serum IgM, but not with disease activity,
gender, age at disease onset or disease duration.
Conclusion: We have found a diminished size of the peripheral B
cell pool in SE positive RA patients, that is associated with lower RF
IgM titers and a suppression of the parameters of polyclonal IgM,
but not IgG secretion. Suppression of polyclonal autoreactivity in
SE positive RA patients by clonal deletion of autoreactive, IgM+ B
lymphocytes is one possible explanation for decreased B cell
counts in RA.
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In adjuvant-induced arthritis the disease-triggering
adjuvant squalene accumulates in draining lymph
nodes but not affected joints
BC Holm*, L Svelander*, A Bucht*† and JC Lorentzen*‡
*Department of Medicine, Unit of Rheumatology, Karolinska Institute,
Stockholm, Sweden; †Department of Biomedicine, Division of NBC
Defense, Defense Research Establishment, Umeå, Sweden;
‡Department of Genetics and Pathology, Uppsala University, Uppsala,
Sweden
Nonspecific stimulation of the immune system by adjuvants can
cause joint-specific inflammation in rats, as exemplified by arthritis
induced with the endogenous cholesterol precursor squalene
(C30H50). To determine the uptake and distribution of injected
adjuvant, and more specifically to determine whether adjuvant accu-
mulates in affected peripheral joints, tritium-labelled squalene was
used to induce arthritis in arthritis-prone DA rats. All organs, includ-
ing hind paws and the site of injection, were collected at different
stages of disease development. The deposition of oil was subse-
quently quantified by dissolving the tissues followed by scintillation
counting.
The majority of injected oil never leaves the injection site, and no
adjuvant oil is accumulated in the peripheral joints. Organ samples
taken early prior to clinical disease and after arthritis onset dis-
played a similar distribution of oil, except for the draining lymph
nodes and the intestines. In the draining lymph nodes, the deposi-
tion of oil accumulated over time, whereas the reverse was the case
for the intestines.
A passive transfer of squalene-induced arthritis with lymph node
cells was successfully accomplished, both with cells from draining
inguinal lymph nodes and cells from lymph nodes not draining the
injection site (axillary). Since uptake of squalene was minimal in axil-
lary lymph nodes, this result indicates that the oil need not be
present for passive transfer of the disease.
In conclusion, we report an accumulation of the arthritis triggering
squalene in the draining lymph nodes but not in the peripheral joints
from the time of injection to the disease onset. This uptake evokes a
systemic immune activation of unknown mechanisms that subse-
quently lead to a joint specific inflammation.
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p205 induces the production of rheumatoid factors
F Schumann*, U Ungethüm*, S Adelt*, H Hofseß*, A Gursche†, J
Zacher†, JB Natvig‡, J-M Engel§, G-R Burmester* and S Bläß*
*Department of Rheumatology & Clinical Immunology, Charité
University Hospital, Berlin; †Orthopedic Clinic Berlin Buch; ‡Institute of
Immunology, Rijkshospitalet Oslo, Norway; §Rheumaklinik Bad
Liebenwerda, Germany
The p205 autoantigen is the strongest stimulatory antigen for T
cells known in rheumatoid arthritis (RA). It contains an 11 aminoacid
stretch identical to a sequence (278-288) located in the CH2
domain of immunoglobulin G. This domain contains the major epi-
topes of rheumatoid factors. This study aimed to analyze if the
p205-specific T cell responses are also directed against RF epi-
topes and to analyze the role of p205 in the production of rheuma-
toid factors in general.
p205 was enriched from synovial fluid as described earlier. p205-
derived peptides were chemically synthesized. T cell proliferation
assays were performed with cells obtained from RA and control
patients and healthy individuals.
Sequencing and mass spectrometry by matrix assisted laser des-
orption-time of flight (MALDI-TOF) of p205 revealed that it con-
taines sequences with similarity and identity to IgG and other
members of the immunoglobulin superfamily. p205 was detected in
the synovial membrane of RA patients by antisera specific for p205-
derived peptides. Cells staining positive for p205 were also positive
for the macrophage marker CD68. p205 staining did never occur in
B cell clusters staining positive for CD19 or in T cell infiltrates stain-
ing positive for CD3. No B and T cells were detected in the highly
p205-positive lining and sublining of the synovial membrane. p205
could react with monoclonal rheumatoid factors (RF). Those RF that
reacted also with p205 tended to be of a binding specificity charac-
teristic of RA. Those RF that did not react with p205 tended to be
of a binding specificity that is also observed in healthy immunized
donors or patients with Waldenström´s macroglobulominia.
Synovial fluid (SF), SF-derived p205 and p205-derived peptides
were used as antigens in T cell proliferation assays. As control anti-
gens, a mock peptide and PHA were used. SF, p205 and p205-
derived peptides stimulated T cells from two thirds of RA patients,
but not from patients with other rheumatic diseases or from healthy
individuals. SF, p205 and the 11aa p205 peptide with sequence
identity to IgG were extremely high stimulators of proliferation in the
majority of RA patients and were often in the range of the mitogen
PHA. Two other p205-derived peptides were also stimulatory for
RA-derived T cells, but to a lesser degree and at a lower frequency
of patients. None of these peptides induced T cell proliferation in
patients with other rheumatic diseases or healthy individuals. No
reactivity was observed with the mock peptide in any of the patients.
T cells specific for p205 cocultured in the presence of IgG-specific
B cells induced the production of rheumatoid factors upon stimula-
tion with cognate antigen and the 11mer peptide 3. RFs could also
be induced upon immunization of rabbits with peptide 3.
p205 is a major target of autoreactive T cells in RA and appears to
be a novel member of the immunoglobulin superfamily. It contains
an IgG-identical stretch and p205 is targeted by RFs. The IgG-iden-
tical peptide 3 stimulates T cells such that they can provide cross-
help for RF-secreting B cells in vitro and in vivo. p205 may thus
likely be the trigger of RF production in RA and may thus be of path-
ogenic importance.
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Responses of the rat immune system to
arthritogenic adjuvant-oil
L Svelander*, BC Holm*, A Bucht†* and JC Lorentzen*‡
*Department of Medicine, Unit of Rheumatology, Karolinska Institutet,
Stockholm, Sweden; †Department of Biomedicine, Division of NBC
Defense, Defense Research Establishment, Umeå, Sweden;
‡Department of Genetics and Pathology, Uppsala University, Uppsala,
Sweden
T-cell mediated inflammatory joint diseases with similarities to
rheumatoid arthritis can be triggered in arthritis-prone rat strains by
intradermal injection of adjuvant-oils. The pathogenesis of oil-
induced arthritis (OIA) remains elusive, and a largely unresolved
question concerns how the rat immune system responds to arthrito-
genic oils, such as incomplete Freund’s adjuvant (IFA). Here we
report that IFA induces increased plasma levels of the APR (acute
phase reactants) fibrinogen and AGP (a1-acid glycoprotein) already
at day 4 post-injection (d.p.i.). In contrast, no early responses were
detected in the joints before infiltration of T-cells, which coincided
with arthritis onset at 11-14 d.p.i. The infiltrating cells were possibly
derived from draining lymph nodes (LN), which contained dramati-
cally increased cell numbers from 4 d.p.i. onwards. The magnitude
of the early increase in cell numbers and APR was regulated by
non-MHC genes, as determined by comparison between arthritis-
susceptible DA rats and arthritis-resistant but MHC-identical
LEW.1AV1 and PVG.1AV1 rats. These resistant strains had high
plasma AGP at 4 d.p.i. whereas DA rats did not - possibly reflecting
a deficient anti-inflammatory response in this strain. Furthermore,
the relative increase in LN cell numbers was largest in DA rats,
which is intriguing considering that LN T-cells can transfer arthritis.
Analysis of LN after in vivo labelling with BrdU revealed increased
numbers and proportions of proliferating lymphocytes. Furthermore,
PCR-analysis of LN cytokine mRNA revealed up regulation for IL-1b
at 4 d.p.i. When an immunogen (ovalbumin) was added to the adju-
vant an immune response was clearly traced as increased mRNA
for IL-4, IFN-g and IL-1b, and in increased numbers of proliferating
lymphocyte in vivo.
In summary, we provide evidence that arthritogenic oil induces an
early systemic inflammatory response, as well as activation of cells
and lymphocytes in draining lymph nodes, but no signs of cell acti-
vation in the joints before onset of arthritis.
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Characterization of autoreactive T cells to the
autoantigens hnRNP-A2/RA33 and filaggrin in
patients with rheumatoid arthritis and controls
R Fritsch, D Eselböck, B Jahn-Schmid, C Scheinecker, B Bohle,
K Skriner, J Neumüller, J Smolen and G Steiner
Division of Rheumatology, Institute of Biochemistry, Institute of
Experimental Pathology and Institute of Histology, University of Vienna,
Austria
In an attempt elucidate the role of autoimmune processes in the
pathogenesis of rheumatoid arthritis (RA) we investigated the T cell
responses to two autoantigens targeted by autoantibodies of
patients with RA, (i) the heterogeneous nuclear ribonucleoprotein
(hnRNP) A2/RA33 and (ii) filaggrin which is one of the target struc-
tures recognized by anti-citrulline antibodies.
Stimulation assays were performed with peripheral blood mononu-
clear cells of 50 RA patients, 20 patients with osteoarthritis and 21
healthy control individuals using recombinant hnRNP-A2/RA33 as
well as some fragments thereof and recombinant filaggrin both in
unmodified and citrullinated form. Antigen-specific T cell clones
(TCC) were obtained by cultivating T cell lines in the presence of
antigen and IL-2 followed by limiting-dilution cloning.
Proliferative responses to hnRNP-A2/RA33 were seen in 60% of
the RA patients with a mean stimulation index (SI) of 3.5±2.8 and
were significantly higher than those observed in the control group
(mean SI=1.7±1, P < 0.00005). There was no correlation with the
presence of anti-A2/RA33 autoantibodies nor with MHC genes,
although more than 60% of the responsive patients carried the
shared epitope. Results obtained with recombinant fragments indi-
cated a major T cell epitope to be located in the N-terminal first
RNA binding domain of the protein. Anti-A2/RA33 specific TCC (n
= 16) derived from RA patients were almost exclusively
CD4+/CD8-, whereas only 7 of 12 TCC derived from controls
showed this phenotype, and secreted high amounts of IFNg upon
antigen stimulation as did all TCC derived from controls. Prolifera-
tive responses to filaggrin in either form were seen in only 25% of
the RA patients tested and did not differ from those observed in the
control group indicating that filaggrin-reactive T cells do presumably
not drive the autoantibody response to citrullinated antigens.
Taken together, a Th1 type autoimmune response to hnRNP-
A2/RA33 was commonly observed in RA patients suggesting this
nuclear protein to constitute a major T cell autoantigen which might
be fuelling one of the pathological autoimmune reactions that drive
the destructive processes effective in RA.
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Leflunomide leads to inhibition of transendothelial
migration
J Grisar, GH Stummvoll and JS Smolen
Division of Rheumatology, Department of Internal Medicine III,
University of Vienna, Austria
Leflunomide is a new disease modifying drug that is widely used in
the therapy of rheumatoid arthritis (RA). The active metabolite of
leflunomide A771726 leads to inhibition of dihydroorotate dehydro-
genase, an enzyme necessary for pyrimidine de-novo synthesis.
Since activated lymphocytes expand their pyrimidine pool,
A771726 leads to a decrease of their proliferation. A771726 also
suppresses TNF mediated nuclear factor kappaB activation. We
were therefore interested if A771726 also would be capable to
influence transendothelial migration (TEM) of peripheral mononu-
clear cells (PBMC).
We investigated the TEM of PBMC, which migrated through
endothelial cell monolayers in an in-vitro model. Human umbilical
vein endothelial cells (EC) were cultured to confluence on collagen
gels and then incubated with human PBMC of healthy blood
donors. PBMC were recollected in three groups: 1) cells that did
not adhere to the endothelium, 2) cells that bound to the endothe-
lium, 3) cells that had migrated through the endothelium, and then
counted by microscope. Experiments in which PBMC as well as EC
were treated with A771726 (in the absence or presence of uridine)
were compared to simultaneously performed control experiments.
No increased toxicity on the PBMC treated with the doses of
A771726 used in our experiments, was observed.
24 hour incubation of PBMC and EC with 30 mg/ml A771726 led
to a significant decrease in TEM (11±3 % vs. 6±3 % migrated
cells,  P = 0.016, paired T test). Uridine partly reversed the decrease
in TEM when incubating PBMC and EC with both uridine and
A771726.
Our results demonstrate that leflunomide may have direct anti-
inflammatory effects by inhibiting the extravasation of PBMC. These
data suggest, that leflunomide, besides its influences on lymphocyte
proliferation, also reduces accumulation of cells at inflammatory
sites.
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Immune response to hn and snRNP in
autoimmune mice. A model for the development of
lupus autoimmunity by a single initiator T helper
epitope?
F Monneaux, H Dumortier, J-P Briand, G Steiner* and S Muller
UPR 9021, CNRS, IBMC, Strasbourg, France; *Vienna University,
Vienna, Austria
Systemic lupus erythematosus is characterised by the presence of
high titers of autoantibodies reacting with various components of
the small and heterogeneous nuclear ribonucleoprotein particle. It
has been suggested that these antibodies are produced by an
antigen-driven mechanism under the dependence of antigen-spe-
cific T cells. To investigate the role of T cell help in this process, we
sought with twenty overlapping peptides the Th epitopes on the U1-
70K snRNP in unprimed H-2k MRL/lpr lupus mice and immunised
CBA normal mice. The peptide 131-151 was recognized by both
IgG autoantibodies and CD4+ T cells from 7-9 week-old MRL/lpr
mice. In this test, APCs from MRL/lpr mice were required, APCs
from naive CBA mice failed to stimulate CD4+ cells from MRL/lpr
mice. Peptide 131-151 bound both I-Ak and I-Ek class II molecules
and favoured an IL-2 positive T cell response but not IFN-g, IL-6 and
IL-10 secretion. Segment 131-151 is localised within the RNP80
motif and contains residues that are highly conserved in many
nuclear, nucleolar and cytoplasmic RNA binding proteins. In parallel,
we studied the Ab response to the A2/B1 hnRNP in different
murine models of lupus, and found in residues 50-70 a major
epitope recognized very early during the course of the disease by
Abs from most of MRL/lpr mice. Peptide 50-70 generated in CBA/J
mice an effective Th cell response with IL-2 and IFN-g secretion.
Interestingly, this peptide also contains the highly conserved
sequence present in peptide 131-151 of the 70K protein. It is pos-
sible that starting from a single Th epitope, the sequence of which is
repeated in several self-proteins involved in the same complex or
close cellular components, a larger, diversified Th response is gen-
erated, which extends via intra-and inter-molecular spreading of the
T and B cell responses.
1. Monneaux, F., Briand, J. –P. and Muller, S., Eur. J. Immunol. 2000.
30: 2191-2200.
2. Dumortier, H., Monneaux, F., Jahn-Schmid, B., Briand, J. –P.,
Skriner, K., Cohen, P. L., Smolen, J. S., Steiner, G. and Muller, S., J.
Immunol. 2000. 165: 2297-2305.
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Persistence of plasma cells in the kidneys of
autoimmune NZB/W mice
G Cassese*, S Lindenau*, B de Boer*, S Arce*, A Hauser*, 
G Riemekasten†, C Berek*, F Hiepe†, A Radbruch* 
and RA Manz*
*Deutsches Rheuma-Forschungszentrum, Berlin, Germany;
†Department of Medicine, Rheumatology and Clinical Immunology,
Charité University Hospital, Humboldt University, Berlin, Germany
NZB/W mice develop a disease similar to human systemic lupus
erythematosus (SLE), including autoantibody production, hyper-
gammaglobulinaemia and inflammation of the kidneys. It is known
that large numbers of lymphocytes infiltrate the kidneys of these
mice but the role of this organ for the production of antibodies is not
clear. Here, we compare the role of bone marrow, spleen and
inflamed kidneys of NZB/W mice for the activation of B cells and for
the persistence of antibody secreting cells (ASC). ASC are present
in the kidneys of mice with full blown disease, as many as in the
spleen and bone marrow, and 50 times more than in the kidneys of
normal mice. In the kidneys, ASC are located mainly in the outer
medulla, close to B- and T cell infiltrates. The specificity of the ASC
in the inflamed kidneys is not restricted to self-antigens. After immu-
nization of NZB/W mice with Ovalbumin (OVA), the antigen-specific
ASC are found initially exclusively in the spleen. Weeks later, during
a period of at least 3 months, OVA-specific ASC are found in stable
and high numbers within the bone marrow and the kidneys of these
mice, but no longer in the spleen. As determined by FACS, B cells
with a germinal center phenotype (B220+/PNA+) are found only in
very low numbers in the kidneys, but in high numbers in the spleen
of NZB/W mice. By histology, germinal centers could not be
detected in the kidneys, but in the spleen. The lack of B cell activa-
tion and the kinetics of the appearance of OVA-specific ASC
suggest that in autoimmune NZB/W mice kidneys, plasma cells
generated during an immune reaction in secondary lymphoid
organs, later accumulate and persist, like in bone marrow. These
experiments identify the inflamed kidneys of NZB/W mice as site of
prime relevance for the homeostasis of plasma cells, irrespective of
their specificity, suggesting that chronically inflamed tissue attracts
plasma cells as such and extends the overall capacity of the body
for plasma cells, allowing autoreactive plasma cells to survive for
long times within the inflamed tissue and to provide exorbitant titers
of antibodies locally.
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In vivo preactivated autoreactive Th cells in healthy
individuals
A Radbruch, S Nitsch, B Holzknecht, E Gromnica-Ihle, 
S Schneider, F Hiepe, A Thiel
Deutsches Rheuma-Forschungszentrum Cell Biology, Berlin, Germany
The direct analysis of autoantigen-specific Th-cells has been ham-
pered so far by the lack of appropiate methods to directly determine
their frequency or functional capabilities. We have applied a set of
new techniques to directly identificate and analyze autoantigen-spe-
cific T-cells in both affected and healthy people according to their
effector functions (e.g. effector cytokine production) after provoca-
tion with antigen.
We have used these technologies to analyze Th-cells specific for
SLE-associated autoantigens, in particular nucleosomes and the
ribonucleoprotein La. Suprisingly, in vivo pre-activated autoantigen-
specific Th-cells secreting IFNgamma and TNFalpha, could be
detected not only in SLE-patients, but also in normal healthy
persons, with frequencies ranging from 0.02% to 0.1%. Preactiva-
tion of these cells in vivo was confirmed by the fact that they
expressed CD45RO but not CD45RA. Some of them had down-
regulated expression of CD45RB and CD27. We also detected in
healthy donors in vivo preactivated Th-cell specific for the self-
antigen alphaB-Cristallin, a small heat shock protein. Up to 0.5% of
peripheral Th cells specifically react with IFNgamma secretion upon
short term stimulation, a hallmark of a recall response, i.e. in vivo
preactivation.
The fact that in vivo pre-activated, autoantigen-specific Th-cells can
be detected at comparable frequencies and with similar cytokine
secretion patterns in blood of normal persons and patients suffering
from a disease in which such Th cells are suspected to play a
pivotal role, points to mechanisms other than central and peripheral
tolerance that control the initiation of those autoimmune reactions.
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Characterization of RA33 (hnRNP-A2/B1)-
autoreactive T cells in SLE-patients
R Fritsch, D Eselböck, B Jahn-Schmid, J Neumueller, B Bohle, 
K Skriner, J Smolen and G Steiner
Rheumatology Department, Institute of Genetics and Experimental
Pathology, University of Vienna, Austria
SLE is a systemic autoimmune disease with distinct immunological
characteristics including defective T cell functions, especially con-
cerning IL2 production and proliferation. Furthermore, B-cell hyper-
activity is observed leading to the formation of several characteristic
autoantibodies (ab), among them ab to the heterogenous nuclear
ribonucleoprotein A2/B1 (hnRNP/RA33). These antibodies are
known to occur in over 20% of SLE patients.
In order to elucidate the role of T cells and their influence in anti-
body production in SLE, we studied proliferation of PBMC to puri-
fied hnRNP-A2/B1 in 34 SLE patients and 21healthy controls.
While the stimulation indices (SI) in the healthy control group
ranged from 0.5 to 3.5 (mean SI: 1.5 ± 0.9), the proliferative
response of PBMC of the patient group ranged from 0.7 to 17 with
a mean SI of 4.8± 4.0 (only 6 of 34 patients had an SI<2; P <
0.00004).
We then proceeded to draw RA33-specific T cell clones (TCC) by
cultivation and limiting-dilution cloning of T cell lines. The generated
30 TCC derived from SLE patients and 19 TCC from healthy con-
trols did not reveal a significant difference in SI and produced either
more IFNg than IL4 or none of these cytokines at all, suggesting that
these TCC were of T1 or T0, but not T2 phenotype. Interestingly
though, while only 11% of healthy control patients showed a CD4-
/CD8+ subtype and 16% displayed a CD4+/CD8+ phenotype,
37% of TCC derived from SLE patients were CD4-/CD8+ (and 20
% expressed CD4 as well as CD8).
Our data reveal that more than 80 % of SLE-patients have a signifi-
cant T cell reactivity (SI ³ 2) to the nuclear protein hnRNP-A2/B1
indicating that the antibody response might be T cell driven. Further-
more, almost 60% of TCC derived from SLE patients were CD8+,
which supports the importance of these T cells in SLE. Further
studies will have to elucidate the pathogenetic implications of these
findings.
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Signalling via T cell receptor (TCR) in patients with
SLE
M Cebecauer*, L Cebecauer, D Kozáková, J Rovenský, J Lukáè, 
J Bartùòková†
Research Institute of Rheumatology, Pieštany, Slovak Republic;
*Institute of Microbiology, Academy of Sciences of the Czech
Republic, Prague, Czech Republic; †Institute of Immunology, 2nd
School of Medicine, Charles University, Prague, Czech Republic
Aim: Dominating defects in SLE are demonstrated in humoral
immune response, however, various T cell defects were observed.
Recently, some authors referred to about the abnormalities in sig-
nalling after TCR activation and about CD3z chain deficiency of
some SLE patients (1,2,3). The reports differed in many details and,
therefore, we decided systematically to test these results and to
study molecular architecture of such signalling complex.
Methods: Isolated periferal blood lymphocytes (PBL) from SLE
patients and controls were analyzed for the presence of CD3z chain
using immunoblot assay with mouse monoclonal anti-CD3z chain
antibody and secondary antibody conjugated with peroxidase fol-
lowed by chemiluminiscence. Lysis of PBL was performed either fol-
lowing the method of American authors (1,2) or by the method used
in the laboratories studying the molecular aspects of TCR signaliza-
tion (e.g. Dr. V. Hoøejší, Prague). T cell signallization was stimulated
by cross-linking TCR with monoclonal antibody against CD3z
(MEM-92) and tyrosine phosphorylated proteins were detected
using monoclonal antibodies (P-TYR1 and P-TYR2) by immunoblot-
ting.
Results: The defect of CD3z chain was found in 17 of 45 SLE
patients (38 %) using the protocols published by American group
and was never found in 15 controls (healthy or not SLE patients).
But, we could not find this defect using the improved protocol in 59
SLE patients, including all of the previous group. Signalling was dif-
ferent in patients compared to controls in that unstimulated cells
from patients showed the pattern observed in stimulated controls
but the results were dependent on the conditions by which PBL
were brought to the so-called “inactive” or quiet state.
Conclusion: Conflicting results show that the published CD3z
chain deficiency in SLE patients could be caused by the methodical
approach. Defect in signalization must be defined more precisely
under strictly controlled conditions.
References
1. Liossis SN, Ding XZ, Dennis GJ, Tsokos GC. Altered pattern of
TCR/CD3-mediated protein-tyrosyl phosphorylation in T cells fiom
patients with systemic lupus erythematosus. Deficient expression
of the T cell receptor zeta chain. J Clin Invest 1998; 101: 1448-
1457.
2. Brundula V et al. Diminished levels of TCR zeta chains in peripheral
blood T lymphocytes from patients with systemic lupus esythe-
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Impaired T-cell rsponse to subsequent TCR-
stimulation after anti-CD3 induced proliferation
MD Köller, HP Kiener, M Aringer, W Graninger, Y Samstag*, 
S. Meuer* and JS Smolen
Department of Internal Medicine III, Division Rheumatology, University
of Vienna, Austria; *Department of Immunology, University of
Heidelberg, Germany
Introduction: Defects of T-cell (TC) proliferation and in TC-receptor
(TCR) signaling have been demonstrated in several autoimmune
diseases. The detailed mechanisms governing activation and prolif-
eration of activated TC, however, are still not completely known.
Here, we will show that under certain conditions human peripheral
blood (PB) TC, once activated by anti-CD3 monoclonal antibody
(mab) in vitro, fail to respond to a subsequent re-stimulation via the
TCR. This unresponsiveness is caused at the transcriptional level by
an impaired production of IL-2, and this defect is temporary.
Methods: PB mononuclear cells (MC) from healthy donors were
pre-stimulated (PS) by anti-CD3PS for 96 h following restimulation
by IOT-3, IL-2, or IL-15, as well as other mitogens. In control experi-
ments (NS), PBMC were cultered in medium alone for the first 4
days. Restimulation of both populations was also performed in the
presence of freshly isolated monocytes (MO). Furthermore, after the
first incubation T-cells and MO from PS and NS cultures were
seperated by magnetic beads and incubated for re-stimulation in a
criss-cross design. Surface immunophenotype of both, TC and MO
were analysed by flow cytometry. Cytokine production was deter-
mined by rtPCR and intracellular signaling protein content of TC in
PS and NS cultures were compared by western blotting.
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a good proliferation to subsequent stimulation with anti-CD3 mab,
whereas IL-2 induced only little proliferation. Unresponsive TC fail to
produce IL-2 as demonstrated at transcription level by rt-PCR. In
contrast, PS cells responded only minimally to subsequent stimula-
tion with anti-CD3, but the addition of IL-2 induced a strong prolifer-
ation, comparable to IL-15. Both, PS and NS TC responded well to
re-stimulation by PHA, whereas Con A induced proliferation mainly
of NS cells and thus had similar effects as anti-CD3. In the pres-
ence of 10% freshly isolated MO PS cells were able to respond sig-
nificantly to subsequent TCR challenge. But the addition of MO
from NS cultures to PS-TC did not fully restore proliferation. Inter-
estingly, when cells were allowed to rest for 168 h, the responsive-
ness of PS lymphocytes was restored. Surprisingly, immunoblots
revealed that PS cells had a higher intracellular content of z-chain
and p56lck. Both, PS TC and MO show higher expression of differ-
ent activation associated surface molecules (HLA-DR, CD25,
CD69, and costimulatory molecules).
Discussion: Our results show a mechanism leading to a temporary
unresponsiveness to TCR ligation of preactivated TC although
adaequate costimulatory support seems available. The rate limiting
events for IL-2 production can be overcome by bypassing the TCR
via mitogens or addition of freshly isolated MO. Although we have
not been able to fully define the rate limiting events we have been
able to exclude various possibilities. TC pre-activated via the TCR
can continue to produce and express a variety of molecules such as
IFN-g, IL-2R, and cell surface molecules. Thus, their effector function
in G1-phase, but not their progression into a mitotic cell cycle
seems to be sustained.
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Effect of CD154-CD40 interactions on collagen
production by fibroblasts
VV Yurovsky and B White
University of Maryland and the VA Maryland Health Care System,
Baltimore, MD 21201, USA
Interactions of T cells and fibroblasts appear to be important in the
development of fibrosis, for example, the restrictive lung disease
that follows the inflammatory process of alveolitis in scleroderma
(systemic sclerosis, SSc). The intermolecular interactions mediating
fibroblast activation are not well characterized. CD154 (CD40
ligand) is an activation-induced T-cell surface molecule which
counter-receptor is CD40 expressed on target cells, including
fibroblasts. We have found CD154 expression on a number of acti-
vated CD8+ T cell clones derived from bronchoalveolar lavage
(BAL) fluids from SSc patients. To begin investigating the potential
role of CD154-CD40 interactions in fibroblast activation, we co-cul-
tured CD154+ Jurkat D1.1 cells or CD154– Jurkat E6-1 cells with
fibroblast lines derived from dermal biopsies or BAL fluids from SSc
patients and control donors. Collagen a2(I) mRNA expression in
fibroblasts was measured by RT-PCR, with ribosomal protein S9 as
an internal standard. Total soluble collagen was measured in co-
culture supernatants, using Sircol Biocolor assay. In fibroblasts co-
cultured for 6 h with CD154+ cells, but not CD154– cells,
normalized collagen mRNA expression and total soluble collagen
production were 2 times higher than in fibroblasts cultured alone.
Intracellular fluorescent staining did not detect IL-4, IL-10, IFNg, or
CD95 ligand expression in either D1.1 or E6-1 cells. These data
suggest that CD154-CD40 interactions may enhance collagen pro-
duction in fibroblasts. As this process continues uncontrolled, it may
lead to the development of fibrosis.
Acknowledgement: This work was supported by a VA Type II Merit
Review award.
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Enhanced transendothelial in vitro migration of
scleroderma lymphocytes
GH Stummvoll, M Aringer, J Grisar, CW Steiner, JS Smolen, 
R Knobler* and WB Graninger
Department of Rheumatology and *Department of Special
Dermatology, University of Vienna, Vienna, Austria
Objective: T lymphocytes are thought to play an important role in
the pathogenesis of Systemic Sclerosis (SSc). Perivascular accu-
mulations of predominantly CD4+ T-lymphocytes are found at an
early stage of scleroderma skin lesions. Moreover, soluble and
membrane-bound adhesion molecules are elevated in SSc and may
facilitate lymphocyte/endothelial cell contact. To assess the migra-
tion qualities of peripheral lymphocytes, we investigated the in vitro
migration of SSc-lymphocytes through human endothelial cell
monolayers.
Patients and Methods: Endothelial monolayers were formed by
human umbilical vein endothelial cells (HUVEC) in their 3rd to 4th
passage seeded on collagen gels and incubated over night. PBMC
were prepared from 6 patients (5f, 1m, mean age 55±6.5 yr.) fulfill-
ing the ACR criteria for SSc and 6 healthy controls (HC; 5f, 1m,
mean age 55±7.11 yr.). Lymphocyte-migration was measured after
one hour of incubation by fractionated harvest of non-adherent,
bound, and migrated lymphocytes. Changes in the CD4/CD8 ratio
and in the lymphocytic expression of activation markers (CD25,
HLA-DR, CD69) and adhesion molecules (CD11a, CD49d) ex vivo,
during and after migration were investigated by fluorocytometry.
Results:  The percentage of migrated SSc lymphocytes was
increased in each single experiment (Fisher´s exact test P < 0.03)
when compared to HC (9.0±4.4% vs 5.3±2.9%). Compared to
HC, the CD4/CD8 ratio was only slightly higher in SSc when
detected ex vivo (2.71±0.76 vs. 2.22±0.54, P = n.s.), but
increased after migration (3.00±0.57 vs. 1.01±0.38, P < 0.02),
whereas the CD4/CD8 ratio in HC fell. The expression of lympho-
cytic activation markers and adhesion molecules was similar in SSc
and HC ex vivo. Migrated SSc lymphocytes tended to express
higher amounts of CD 25 and CD 49d, but this did not reach statis-
tical significance in our small sample of patients.
Discussion: Lymphocyte migration through a human endothelial
monolayer is increased in SSc and is accompanied by an increase
of the CD4/CD8 ratio. These data suggest that CD4+ SSc cells
are more prone to migration than CD8+ cells and are in line with the
paravascular accumulation of CD4+ lymphocytes.
P64
Autologous dendritic cells stimulate human HSP60
responsive T cells, in the absence of additional
exogenous antigen
MS Lillicrap, MK Matyszak, JC Goodall, JL Young, JSH Gaston
University of Cambridge, Dept. of Medicine, Addenbrookes Hospital, UK
Background:  Animal models and clinical studies of inflammatory
arthritis have shown a potentially protective role for autoreactive T
lymphocytes recognising the 60 kilodalton heat shock protein
(hsp60). The mechanisms of this protection have not been fully char-
acterised. We have previously demonstrated that PBMC from
healthy individuals show proliferative responses to human hsp60,
and clones have been isolated that recognise the self protein. The
objective of the present study was to confirm the autoreactive nature
of these cells and determine whether the endogenous antigen could
be effectively presented by professional antigen presenting cells.
Methods and results: Highly purified recombinant human hsp60
was prepared along with a non-recombinant preparation of mito-
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology Researchchondrial hsp60, derived from human lymphoblastoid cells. To
assess the ability of professional antigen presenting cells to present
the endogenous self hsp60, autologous dendritic cells were iso-
lated from peripheral blood by negative selection, cultured in GM-
CSF and IL-4, and activated with LPS prior to use. Human hsp60
responsive T cell clones from a healthy individual were shown to
proliferate in response to both the recombinant preparation and the
mitochondrial preparation, thereby excluding the possibility of the
clones recognising bacterial contaminants. Furthermore these
clones proliferated in the presence of autologous dendritic cells,
activated with LPS, in the absence of exogenous antigen. The prolif-
erative responses to the activated dendritic cells were titratable and
the data suggested a requirement for additional, presumably apop-
totic, cells to also be present in the culture system.
Conclusions: These experiments demonstrate, at a clonal level, an
autoreactive repertoire in healthy individuals responding to human
hsp60. The ability of these cells to recognise autologous activated
dendritic cells may provide insight into the role of such cells in vivo.
Since activated dendritic cells and increased numbers of apoptotic
cells will both be present at inflammatory foci, local expansion of
potentially immunomodulatory, self hsp60 responsive T cells could
occur at these sites.
P65
Macrophages expressing the scavenger receptor
CD163: a link between immune alterations of the
gut and synovial inflammation in
spondyloarthropathy
D Baeten, P Demetter, C Cuvelier, E Kruithof, N Van Damme, 
M De Vos, EM Veys and F De Keyser
Ghent University Hospital, Ghent, Belgium
Objective: To investigate the presence, phenotype and role of syn-
ovial macrophages in SpA by immunohistochemistry and flowcy-
tometry.
Results: In the synovial lining CD68, CD163 and HLA-DR were
increased in SpA versus RA; in the sublining CD163 and HLA-DR
were also increased. In contrast, costimulatory molecules and den-
dritic cell markers were scarce in SpA versus RA synovium. Interest-
ingly, CD 163 and CD68 were also increased in colonic lamina
propria in SpA. CD163 and HLA-DR in the sublining were corre-
lated with CRP and ESR. CD163+ macrophages expressed high
levels of HLA-DR and could produce TNF-alpha but not IL-10. Anti-
TNF-alpha therapy in SpA induced a decrease of CD163 in both
synovial lining and sublining.
Conclusions: Macrophages expressing the scavenger receptor
CD163 are increased in synovium and colonic mucosa in SpA,
highlighting the relation between joint and gut. The correlation with
inflammatory parameters, the expression of HLA-DR, the production
of TNF-alpha but not IL-10 and the reduction by anti-TNF-alpha
therapy support a role for CD163+ macrophages in synovial inflam-
mation in SpA.
P66
Fully competent dendritic cells as inducers of T cell
anergy in autoimmunity
S Quaratino, LP Duddy and M Londei
Imperial College of Medicine, Kennedy Institute of Rheumatology
Division, London W6 8LH, UK
Mature immunologically competent dendritic cells are the most effi-
cient antigen presenting cells, that powerfully activate T cells and
initiate and sustain immune responses. Indeed, dendritic cells are
able to efficiently capture antigens, express high levels of co-stimu-
latory molecules and produce the combination of cytokines required
to create a powerful immune response. They are also considered to
be important in initiating autoimmune disease by efficiently present-
ing autoantigens to self-reactive T cells that, in this case, will mount
a pathogenic autoimmune reaction. Triggering T cells is not a simple
on-off procedure, as TCR responds to minor changes in ligand with
gradations of T-cell activation and effector functions. These ‘misfit’
peptides have been called Altered Peptide Ligands, and have been
shown to have important biological significance. Here we show that
fully capable dendritic cells may present, upon natural antigen pro-
cessing, a self-epitope with Altered Peptide Ligands features that
can unexpectedly induce anergy in a human autoreactive T cell
clone. These results indicate that presentation of a self-epitope by
immunologically competent dendritic cells does not always mean
‘danger’ and show a novel mechanism involved in the fine balance
between T cell activation and tolerance induction in man.
P67
Dendritic cell subsets in rheumatoid arthritis
K Summers, J O’Donnelland A Rothwell*
Department of Immunology and *Department of Orthopaedic Surgery,
Christchurch Hospital, Christchurch, New Zealand
Distinct myeloid DC and lymphoid DC subsets have been
described, which regulate the nature and magnitude of immune
responses. Therefore DC function must be carefully regulated, oth-
erwise inappropriate responses may result in such chronic inflam-
matory diseases as rheumatoid arthritis (RA). In this study the
composition and activation state of DC subsets was compared
between autologous blood, synovial fluid and synovial tissue of RA
patients using 4-colour flow cytometry. Preliminary results indicated
that RA blood and normal blood had a similar ratio of DC subsets,
both of which exist in a relatively inactivated state. In contrast,
myeloid DC were predominant in RA synovial fluid and synovial
tissue. In synovial tissue these myeloid DC were more highly acti-
vated and localized to lymphoid aggregates. Lymphoid DC were
scarce in both synovial fluid and synovial tissue.
Conclusion: These results suggest that myeloid DC play a key role
in the pathogenesis of RA and supports the view that RA is predom-
inantly a Th1-mediated disease.
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Detection of bacterial components in synovial
tissue from patients with inflammatory arthritis by
using PCR with pan bacterial 23S rRNA and 16S
rRNA primers, and gas chromatography-mass
spectrometry
T Chen*, M Rimpiläinen*, R Luukkainen†, T Möttönen‡, 
T Yli-Jama§, J Jalava* and P Toivanen*
*Department of Medical Microbiology, Turku University, Turku;
†Rheumatology, Satalinna Hospital, Harjavalta; ‡Division of
Rheumatology, Department of Medicine, Turku University Central
Hospital, Paimio; §Turku City Hospital, Turku; Finland
Using PCR for 16S rRNA, the presence of bacterial DNA in synovial
tissue (ST) from a variety of inflammatory arthritides has been
reported. To confirm this, we have applied the PCR with pan bacter-
ial 23S rRNA and 16S rRNA primers, which both methods have
been used successfully for bacterial identification in various clinical
samples.
ST were collected at joint surgery from 81 patients: 42 rheumatoid
arthritis (RA), 31 osteoarthritis (OA), 8 other inflammatory arthri-
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laboratory to prevent contamination. Bacterial DNA could not been
detected by PCR with pan 23S rRNA and 16S rRNA in any of the
samples. The positive controls, including bacterial DNA and human
DNA, were run with each sample, and were always positive. Further,
using the same method, 5/15 (33%) synovial fluid samples from
patients with Chlamydia reactive arthritis were PCR positive. The
PCR sensitivity was 2-20 CFU/reaction determined by mixing the
living bacteria with ST and using exactly the same experimental pro-
cedure as with the patient samples.
Gas chromatography-mass spectrometry has been applied to
detect muramic acid (bacterial cell wall specific chemical compo-
nent) in ST. Preliminary results suggest that low concentration of
muramic acid can be detected in the ST from some patients with
inflammatory arthritis.
Our results show that bacterial DNA in ST from RA and OA could
not been detected by PCR for 23S rRNA and 16S rRNA. Instead,
muramic acid could be detected by gas chromatography-mass
spectrometry. These observations indicate that the presence of
bacterial DNA in ST might not be as prevalent as previously sug-
gested. Nevertheless, the bacterial components may exist in ST.
Poster Discussion E
Autoantibodies in CTDs
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Detection of anti-B/B’ UsnRNP antibodies in
connective tissue disease sera by Western
immunoblot
A Ghirardello, A Doria, S Zampieri, D Villalta*, F Vescovi, PF
Gambari
Division of Rheumatology, Department of Medical and Surgical
Sciences, University of Padova, Italy; *Microbiology and Immunology
Unit, Pordenone, Italy
Introduction: The fine antibody specificity towards protein compo-
nents of uridine-enriched small nuclear ribonucleoproteins
(UsnRNP) may be investigated by several methods including the
Western immunoblot. Crucial in Western blot techniques’ reliability
is the origin and nature of the antigenic source.
Aim: To assess the significance of antibodies to B/B’ proteins
detected by Western immunoblot in connective tissue disease
(CTD) patients.
Methods: Three hundred and forty-eight patients with well diag-
nosed CTD (101 SLE, 51 systemic sclerosis, 53 primary Sjogren’s
syndrome, 27 poly/dermatomyositis, 15 rheumatoid arthritis and
101 overlap CTD) and 31 matched healthy subjects were studied.
In addition, sera from 13 patients with primary Epstein-Barr virus
(EBV) infection (10 in acute primary infection and 3 with anamnestic
past infection) and high titer IgG anti-EBV antibodies were tested.
IgG anti-UsnRNP as well as anti-ribosomal P protein antibodies
were determined by Western blotting on total Raji cell extract (a cell
line transformed by EBV). Antinuclear and anti-dsDNA antibodies
were detected by indirect immunofluorescence on HEp-2 cells and
Crithidia luciliae respectively, anti-ENA by counterimmunoelec-
trophoresis. Statistical analysis was performed by chi-square test.
Results: An unespectedly high frequency of anti-B/B’ antibodies
was found, confined to SLE (54.4%) and overlap CTD with SLE
features (55.2%). Anti-B/B’ antibodies were closely associated with
other anti-UsnRNP antibodies (P < 0.0001), gel precipitating anti-
nRNP antibodies (P < 0.0001) and anti-ribosomal P antibodies (P
= 0.0013). Band patterns unequivocally different from those
obtained with autoimmune sera, were provided by anti-EBV positive
sera. Noteworthy, a peptide with an apparent MW corresponding to
that of B peptide (28kDa) was clearly recognized by 9/10 sera from
active EBV infection but not by anamnestic EBV infection sera.
Conclusions: The Sm spliceosomal complex is one of the most
important targeted autoantigens in SLE. Western immunoblot on
Raji cells provides a reliably sensitive and specific antigenic source
for anti-Sm B/B’ antibodies. Such high immunoreactivity could be
explained by the strong cross-reactive potential of B/B’ proteins and
not by EBV cell transformation. Further studies are in progress to
comparatively evaluate the suitability of other cell lines as an anti-
genic source.
P70
Comparison of different methods for the detection
of the fine specificity of anti-Ro/SSA response
I Cavazzana, F Franceschini, M Quinzanini, P Airò, A Brucato, 
R Cattaneo
Clinical Immunology Unit and Chair, Spedali Civili and University of
Brescia; Division of Medicine, Niguarda Hospital, Milan, Italy
Background: the determination of the fine specificity of anti-
Ro/SSA response is useful in the classification of the risk for the
occurrence of congenital complete heart block (CCHB) in newborn
of anti-Ro/SSA mothers.
Aim of the study: to evaluate different methods for the detection of
anti-52 and 60 kD Ro/SSA antibodies.
Patients and methods: 132 sera (82 from anti-Ro/SSA patients by
counterimmunoelectrophoresis (CIE), 30 from anti-ENA positive/
anti-Ro/SSA negative and 20 from ANA and anti-ENA negative)
were tested by ELISA with recombinant 52 and 60 kD Ro protein
(Pharmacia Upjohn, Germany) and immunoblotting (IB) with human
spleen extract (HSE) as substrate to the aim of determining the fine
specificity of anti-Ro response. In addition, 21 sera from mothers of
CCHB children were tested by CIE, two ELISAs with recombinant
proteins (Pharmacia and Euro-diagnostica, The Netherlands), two
IBs with HSE and with HEp-2 extract as substrates (MarDx, USA).
Results: the total agreement between ELISA (Pharmacia) and IB
(HSE) was 76% for anti-Ro 60 kD and 44% for anti-Ro 52 kD. The
ELISA was more sensitive than IB both for anti-Ro 60 kD (91% vs
84%) and for anti-Ro 52 kD detection (82% vs 51%). Seven sera
positive by CIE were negative by IB (non blotters): six of these sera
were positive for anti-60 kD and 2 for anti-52 kD by ELISA. The
mean antibody titre for anti-60 kD was significantly lower (P <
0.00005) than that of sera detected by IB.
A correlation ranging from 78 to 100% was detected between the
different methods testing the sera from CCHB mothers. The agree-
ment between the IB methods for anti-Ro 60 kD and for anti-52 kD
was 79% and 68.5% respectively while between the ELISAs was
44% and 67% respectively. The best agreement obtained compar-
ing IB and ELISA for anti-Ro 60 and 52 kD was 78% between IB
with HSE and ELISA (Euro-diagnostica).
Conclusions: ELISA seems to be the most sensitive method to
detect the fine specificity of anti-Ro/SSA response. The majority of
IB negative/CIE positive sera (non blotters) were positive for anti-60
kD by ELISA at low titer. IB with HSE as substrate performed
slightly better (p not significant) than IB with HEp-2 cells extract in
CCHB mothers.
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Study of the anti-idiotypic resonse to anti-LA/SSB
autoantibodies using complementary peptides to
B- and T-cell epitopes of La/SSB
JG Routsias*, E Touloupi*, A Moulia† M Sakarellos-Daitsiotis†
H Dotsika‡, C Sakarellos†, HM Moutsopoulos* and AG Tzioufas*
*Department of Pathophysiology, University of Athens, Greece;
†Department of Organic Chemistry, University of Ioannina, Greece;
‡Hellenic Pasteur Institute, Athens, Greece
Autoantibodies to La/SSB are found in sera of patients with primary
Sjogren’s Syndrome (pSS) and Systemic Lupus Erythematosus
(SLE). A large body of these autoantibodies are directed towards
discrete linear epitopes comprising the sequences 289-308 aa and
349-364 aa. Several previous studies have shown that in the
sequence 289-308 aa resides also a T-cell epitope. Based on “mol-
ecular recognition” theory, complementary peptides cpep289-308
and cpep349-364, derived by anti-parallel readings of the non-
coding strand of La/SSB DNA encoding epitopes 289-308 and
349-364 respectivelly, were synthesized. Complementary peptides
cpep289-308 and cpep349-364 presented inverted hydrophobicity
profiles, compared with sense peptides and recognized by 28%
and 51% of anti-La/SSB positive sera respectively. F(ab´)2 frag-
ments were prepared after pepsin enzymatic degradation of affinity
purified anti-pep and anti-cpep specific IgG. Anti-pep IgG found to
specific recognize anti-cpep F(ab´)2 fragment and vice versa, sug-
gesting an idiotype – antiidiotype relation. Homologous inhibition
with soluble anti-pep or anti-cpep F(ab´)2 further confirmed this
relation. In addition soluble pep, cpep or recombinant La/SSB inhib-
ited (65%-85%) anti-pep and anti-cpep interaction indicating that
the idiotype is located within the antigen binding site of anti-La/SSB
antibodies. Anti-pep349-364 antibodies, purified from different
patient sera were all found to recognize the same anti-cpep F(ab´)2
suggesting that a common idiotype exists. Immunizations of BALB-c
non-autoimmune mice with pep289-308 produced anti-pep289-
308 followed by the production of anti-cpep289-308 antibodies 10
days later. In a similar manner immunization with cpep289-308 led
to the appearance of anti-cpep289-308 followed by the formation
of anti-pep289-308 antibodies. In conclusion, antibodies to B-cell
epitopes of La/SSB contain in their antigen binding site a common
idiotype which can be detected using complementary peptides to
these epitopes. Antibodies to La/SSB epitopes are target of an anti-
idiotypic response against this common idiotype. Manipulation of
this Id - anti-Id network may provide potential insights into the
understanding of the molecular mechanisms for autoantibody pro-
duction and therapeutic approaches.
P72
Induction of immune responses in inbreed mice by
immunizations with the complementary 289-308
La/SSB epitope
Å Dotsika*, Ì Papamattheou*, P Tsagozis*, Å Êaragouni*, 
C Sakarellos†, Ì Sakarellos-Daitsiotis†, J Routsias‡, 
HM Ìoutsopoulos‡, ÁG Ôzioufas‡
*Laboratory of Cellular Immunology, Hellenic Pasteur Institute, Athens,
Greece; †Department of Chemistry, University of Ioannina,Greece;
‡Department of Pathophysiology, University of Athens, Greece
It has been recently reported a methodology of manipulating anti-
body and T cell-mediated autoimmune responses via activation of
anti-idiotypic and/or anti-clonotypic networks. This methodology
was based on immunization with the complementary peptide
against antigen receptors on epitope-specific B and T cells. The
region 289-308 of the La/SSB protein is one of the four linear B
cell epitopes which is recognized by sera from patients with primary
Sjogren’s Syndrome (pSS) and by different predictive methods
share also putative T cell epitope properties. The 289-308 epitope
(denoted Po25) and its complemetary form encoded by comple-
mentary RNA (denoted Pcpl25) were conjugated on Sequential
Oligopeptide Carrier (SOCn). SOCn is formed by the (Lys-Aib-
Gly)n sequential motif, where n = 2-7, and the peptide antigens
were anchored to the lysine groups so as they retain their original
structure and they obtain favorable molecular recognition conforma-
tions. Different doses of peptide carrier formulations were adminis-
trated alone or together with Freud’s adjuvant (CFA/IFC) and
specific antibody and lymphoproliferative response were deter-
mined. Both the in vivo and in vitro responses were dose depen-
dent and a demonstrable cross reactivity was observed at the T and
the B cell level. Immunization with Po25-SOC resulted to the induc-
tion of anti-Pcpl25-antibodies and immunization with Pcpl25 led to
the production of anti-Po25 response indicating the regulatory
activity of anti-idiotypic antibodies. On the other hand immunized
mice also primed specific T cell proliferative responses in spleen.
The ability of complementary peptides to prime both anti-idiotypic
and T lymhocyte responses may be central to their potent immuniza-
tion properties in regulating autoreactive B and T cells. With this
approach we aim to shed light to the immunoregulatory mecha-
nism(s) which underline the autoimmune response.
P73
Structure and function of an autoantigen, alpha-
enloase
S Moscato, F Bongiorni, F Pratesi, M Scavuzzo, S Bombardieri
and P Migliorini
Clinical Immunology Unit, Department of Internal Medicine, University
of Pisa, Pisa, Italy
The glycolytic enzyme 2-phosphoglyceratelyase (alpha-enolase) is an
autoantigen in connective tissue disorders, and more frequently in
patients with active renal disease. The enzyme has pleiotropic func-
tions: it is also a structural protein, a stress protein induced by
hypoxia and it acts as transcription factor in the nucleus. Alpha
enolase is encoded by a single copy gene and only one mRNA
species is detected. In order to define a structural basis for these dif-
ferent functions, we analyzed the isoelectric point of the enzyme. On
a kidney extract fractionated by 2D electrophoresis, a mouse anti-
enolase antiserum detects 5 spots of identical molecular weight but
differing in pI. Some autoimmune sera react with all the spots, while
other recognize only the acidic forms of alpha-enolase. We then ana-
lyzed the properties of the membrane form of enolase. Enolase is not
a membrane structural protein, but it is strongly associated with the
membrane, where it acts as plasminogen receptor. Anti-enolase anti-
bodies purified from autoimmune sera react also with the membrane
form of alpha-enolase: by flow cytometry, 7/9 antibody preparations
bind in fact U937 cells, a human lymphomonocytoid cell line that
expresses high density of plasminogen receptors. To investigate the
possible functional role of membrane enolase, we evaluated the
ability of monoclonal anti-enolase antibodies to induce cell damage
or apoptosis. No monoclonal had a cytotoxic effect on U937 cells or
was able to induce apoptosis in the same cell line. We then tested
the ability of monoclonal anti-enolase antibodies to induce Ca2+
influx in U937 cells. One out of 4 monoclonal antibodies induced
release of Ca2+ from intracellular stores.
In conclusion, alpha-enolase exists as multiple isoforms, probably
due to postranslational modifications, which seem to affect recogni-
tion by autoantibodies. It is presently unknown whether these modi-
fications are tissue-specific and/or affect membrane expression of
the enzyme. A possible link between Ca2+ influx and receptor func-
tions of enolase is currently under investigation.
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Recombinant anti-P proteins antibodies isolated
from human autoimmune library: reactivity,
specificity and epitope recognition
S Zampieri, A Ghirardello, A Doria, WH van Venrooij* 
and JMH Raats*
Department of Medical and Surgical Sciences. Rheumatology Division.
University of Padova, Italy; *Department of Biochemistry. University of
Nijmegen. Nijmegen, The Netherlands
Introduction: The ribosomal phosphoproteins P0, P1 and P2 are
targeted by autoantibodies in SLE. The presence in the patient sera
of the anti-P antibodies is highly specific for the disease and corre-
lates with psychiatric, renal and liver involvement. In order to better
characterize these autoantibodies (reactivity, specificity and epitope
recognition), recombinant anti-P monoclonal antibodies were iso-
lated from an human SLE patient derived phage display library.
Methods: Two synthetic peptides were used to select the recombi-
nant anti-P antibody fragments: a synthetic peptide representing the
C-22 common immunogenic region of the three P proteins and the
multiple antigenic peptide (MAP) carrying four copies of the last 13
residues of the C-22. The human library was derived from the bone
marrow lymphocytes of an anti-P positive SLE patient. The selected
anti-P antibodies were tested for reactivity with the C-22, the MAP
and a control panel of recombinant autoantigens in an ELISA assay.
Specificity of the selected antibodies was further analyzed by
immunoblotting and immunoprecipitation assays using Jurkat total
cell extract. Indirect immunofluorescence staining on HEp-2 cells
was also performed. Using different synthetic peptides derived from
the C-22 peptide epitope recognition was further characterized in
an ELISA assay. Sequencing of the selected antibody fragments
was performed and the antibody sequence was compared to the
nearest germ-line sequence. In all the experiments human anti-P
positive control sera were included.
Results: Six recombinant anti-P antibodies were isolated from the
human library when using the C-22 synthetic peptide. Some of the
isolated antibodies reacted specifically with the C-22 antigen in
ELISA, others recognized the ribosomal P proteins on Western blot,
immunoprecipitated the P proteins from the Jurkat cell extract and
showed cytoplasmic staining on HEp-2 cells in an immunofluores-
cence assay. The selected antibodies exhibited features similar to
serum antibodies of the patients with respect to their reactivity,
specificity and epitope recognition.
Conclusions: The phage display technology proofs once again to
be a very useful technique for the production of human monoclonal
autoantibodies and for the characterization of the reactivity and
specificity of these autoantibodies.
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Dominance of hydrophobic reading frames in
complementarity determining region 3 of variable
heavy chain genes from a patient with untreated
SLE
B Yazdani-Biuki, R Brezinschek, T Dörner*, J Hermann, 
H Mitterhammer, G Tilz, U Demel, T Müller, S Eder, J Gretler 
and HP Brezinschek
Department of Internal Medicine University Hospital Graz, Austria;
*Department of Rheumatology, University Hospital Charite Berlin,
Germany
Systemic lupus erythematosus (SLE) is an autoimmune disease
characterized by the production of multiple autoantibodies (AAb),
especially anti-dsDNA Ab. It is not known whether an aberrant V(D)J
recombination process itself predisposes to the generation of
autoreactive Ab, or whether abnormalities in selection influences
can lead to the generation of AAb. Immunoglobulin (Ig) heavy (H)
and Ig light chains of an antibody are generated from variable (V),
diversity (D) and joining (J) gene segments through V(D)J rearrange-
ments. Diversification mechanisms inherent to the rearrangement
reaction ensure that D elements can potentially be used in all
reading frames (RF). In addition, D and J elements of the IgH chains
encode the complementarity determining region (CDR) 3 that con-
stitutes a significant part of the Ig antigen binding site. Since it has
been suggested that the CDR3 of Ab in SLE is different from that
found in normals, we compared the CDR3 obtained from Ab of an
untreated SLE patient with that from normal individuals. D segments
of Ab from normal donors are preferentially used in RF II (26/48, p*
0.001) that most often encodes hydrophilic antibodies. Comparison
of productive and nonproductive rearrangements suggests, that this
is the result of the recombinational process rather than selection. In
contrast, RF II was significantly less often used in SLE Ab (4/17, p*
0.03). In both, normal and SLE Ab, D segments were significantly
less often found utilizing RF that encode stop codons. Similar to the
usage of RF II, in normals this seems to be the result of the recombi-
nation process rather than selection. Because of the low number of
nonproductive rearrangements in the SLE analysis it is not possible
to estimate whether this results from selection or the recombination
process. In contrast to the analysis of the RF, no significant differ-
ence between the length or composition of the CDR3 from SLE
and normal Ab was found.
P76
Comparative analysis of anti-histone and anti-
chromatin antibody specificity in lupus
erythematosus cell-positive and -negative sera and
their relation to disease activity
G Schett*, RL Rubin†, G Steiner*, H Hiesberger*, S Muller‡ and
JS Smolen*
*Division of Rheumatology, General Hospital Vienna, Austria; †The
Scripps Research Institute, La Jolla, California, USA; ‡Institut de
Biologie Moleculaire & Cellulaire, Strasbourg, France
Anti-histone and anti-chromatin antibody responses play a central
role in the autoimmune response of systemic lupus erythematosus
(SLE). Furthermore, anti-histone H1 antibodies are essential for the
formation of the lupus erythematosus cell (LEC) phenomenon. In
this study, the binding properties of LEC+ and LEC– SLE sera to
chromatin-associated nuclear antigens (histones H1, H2A, H2B,
H3, H4; complexes of H2A-H2B, [H2A-H2B]-DNA, H1-DNA; total
and H1-stripped chromatin; native and denatured DNA) were
investigated. In addition, sera from patients with drug-induced
lupus (by procainamide, hydralazine, or quinidine), as well as from
patients with rheumatoid arthritis and osteoarthritis, were
assessed. Enzyme-linked immunosorbent assay was used to
detect specific antibody binding. Mirroring the important role of
histone H1 in the formation of LE cells, anti-histone H1 reactivity
was 8-fold higher in LEC+ sera than in LEC– sera. In addition,
reactivities to most of the other antigens tested, i.e., other histones
and histone-DNA complexes as well as chromatin and DNA, were
significantly higher in LEC+ sera than in LEC– sera. All but 1
serum sample from the patients with drug-induced lupus were neg-
ative for LE cell formation as well as for anti-histone H1 reactivity,
but displayed high antibody reactivities to histone-DNA complexes,
including chromatin. Sera from patients with rheumatoid arthritis
and osteoarthritis did not show significant binding to these anti-
gens. When comparing the clinical features of LEC+ and LEC–
SLE patients, severe organ involvement, including nephritis and
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology Researchcentral nervous system involvement, was common in the LEC+
group, but rare in the LEC– group. A positive LE cell phenomenon
not only correlated with the presence of high anti-histone H1 anti-
body levels in SLE, but also indicated serologically and clinically
active disease with major organ involvement.
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Immuno-serological profile of Systemic Erythemic
Lupus (SLE) patients with neuropsychiatric
manifestations (NP)
L Stojanovich*, V Mircetic†, R Stojanovich†, V Kostich‡
and D Popovich*
*Hospital Center “Bezhanijska Kosa”, Belgrade, Yugoslavia; †Institute
for Rheumatology, Belgrade, Yugoslavia; ‡Institute for Neurology,
Belgrade, Yugoslavia
Introduction: goal of the study was to establish the correlation
between immuno-serological anomalies and the existence of NP in
patients with SLE
Methods: the study included 60 SLE patients (54 female, 6 male),
all with signs of NP. The age of patients varied between 17 and 71
years (42.3 + 13.0). The study consisted of clinical evaluation by
rheumatologist, neurologist, psychiatrist, neuro-ophtalmologist, as
well as electrophysiological (EEG, EP, EMNG) methods. It also
included visualization (NMR) methods for determining pathologies
in the CNS. Different auto-antibodies and other immuno-serological
markers displayed positive results with the following frequency:
ANA (91.7%); anti-dsDNA (40.0%); anti-DNP (48.3%); CIK
(45.0%); low C3/C4 levels (18.3%). Antiphospholipid antibodies
(aPL) were positive: LA in 14.8% pts; aCL (IgG and IgM) in 23.1%
pts. 30 patients were tested for anti-SM, anti-U1RNP, cANCA and
pANCA and were positive in: anti-SM— 20.0%, anti-U1RNP—
50.0%, cANCA— 10.0%, pANCA— 30.0%.
Results: there was no statistically significant correlation between
ANA, anti-dsDNA, CIK, anti-DNP, C3/C4 and the diagnosis of
certain neuro-psychiatric manifestations in our SLE patient group.
Patients with focal cerebral dysfunctions were shown to have a
higher frequency of aPL: LA (P = 0.0111) and aCL (P = 0.0148). A
correlation was found between cANCA (P = 0.0406), pANCA (P =
0.0348), anti-U1RNP (P = 0.0309) and skin vasculitis, as well as
between pANCA and CVI diagnosis in neuro-lupus patients (P =
0.0028).
Conclusion: our study did not show the correlation between auto-
antibodies in SLE patients with NP and certain types of CNS/PNS
lesions, except for the connection between aPL and focal cerebral
dysfunctions, as well as pANCA’s correlation with cerebro-vascular
stroke diagnosis.
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The infectious origin of the antiphospholipid
syndrome: induction by passive transfer of anti-
b b2GPI Abs induced by common bacteria
M Blank*, I Krause*, M Fridkin†, N Keller‡ and Y Shoenfeld*
*Center for Autoimmune Diseases, Department of Internal Med ‘B’,
and ‡Department of Clinical Microbiology, Sheba Medical Center, Tel-
Hashomer, †Department of Organic Chemistry, The Weizmann Institute
of Science, Rehovot, Israel
The antiphospholipid syndrome is characterized by a wide variety of
vaso-occlusive manifestations associated with autoantibodies
directed against b2-glycoprotein-I. The pathogenicity of anti-b2GPI
antibodies has been demonstrated in animal models. The factor(s)
causing production of anti-b2GPI remain unidentified, but several
indirect arguments support the idea that microbial agents might
influence the course of antiphospholipid syndrome and an associa-
tion with microbial pathogens has recently been documented.
Microbes can contain chemical structures that mimic normal host
self-proteins, a phenomenon termed molecular mimicry. Employing
a peptide phage display library, we identified hexapeptides that
react specifically with anti-b2GPI monoclonal antibodies. These
peptides were found to modulate the experimental model for
antiphospholipid syndrome. In the current study we found high
homology between one of the hexapeptides- TLRVYK, and various
bacteria and viruses. We therefore immunized naive mice with a
panel of TLRVYK-corresponding microbial particles to find whether
they posses a pathogenic potential for autoimmunity. We show that
mice which were infused with antibodies derived from mice immu-
nized with tetanus toxoid, haemophilus influenzae or with neisseria
gonorrhoeae developed clinical manifestations of experimental
antiphospholipid syndrome (e.g. mice infused with anti-b2GPI
derived from tetanus immunized developed thrombocytopenia
497±98X10-3cells/dl compared to 1012±214x10-3cells/dl in
control mice, high percentage of fetal resorption 48±3% in compar-
ison to 4±2% and prolonged aPTT 69±4sec in comparison to
23±3sec in mice infused with IgG from Shigella disenteriae immu-
nized mice). The pathogenetic mechanism for anti-b2GI generation
seems to be an epitope mimicry with common bacterial molecules.
P79
Impaired in vitro thrombin generation in 
b b2-glycoprotein I null mice
Y Sheng, SW Reddel, H Herzog, YX Wang, T Brighton, 
MP France and SA Krilis
Department of Medicine and Department of Immunology, Allergy and
Infectious Disease, University of New South Wales, The St. George
Hospital, Sydney, New South Wales 2217, Australia
b2-glycoprotein I (b2GPI) is a target antigen for ‘antiphospholipid’
antibodies. These antibodies are of considerable clinical importance
because of their strong association with thrombosis, recurrent fetal
loss, and thrombocytopenia. Although b2GPI has been shown to
have a number of anticoagulant properties in vitro, its role in vivo is
unknown. The aim of this study was to evaluate the function of
b2GPI in vivo using a b2GPI deficient mouse model. We employed
homologous recombination to disrupt the b2GPI gene in embryonic
stem cells, which led to the generation of mice deficient in b2GPI.
To confirm that the appropriate gene was targeted, nucleotide
sequencing, map location, Northern blot analysis and Western blot
analysis of the expected protein was performed. Following heterozy-
gous (+/-) intercrosses, a total of 336 surviving offspring were
genotyped. Interestingly, only 8.9% of these offspring were homozy-
gous (-/-) for the disrupted allele, suggesting an effect on embryonic
implantation or development. The remaining b2GPI-/- mice pro-
gressed normally to term and the adult mice appeared to be normal
by anatomical and histological analysis. However, in vitro thrombin
generation using a novel chromogenic assay demonstrated that
there was a marked decrease in thrombin generation in -/-
(OD405=0.175) compared to +/- (OD405=0.312) and +/+
(OD405=0.576) (n = 10). This would indicate that b2GPI is likely
to have a prothrombotic role in vivo. This finding is in contrast to
results obtained in in vitro assay system using purified b2GPI which
demonstrate anticoagulant activity for b2GPI . These knockout mice
also provide a valuable in vivo model system for exploring the role of
b2GPI in disease pathogenesis.
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Improving an anti-b b2 2GPI ELISA by reducing the
influence of a blocking agent
A Ambroz
vic
v, B Boz
vic
v, M Hojnik and T Kveder
Department of Rheumatology, University Medical Centre, Ljubljana,
Slovenia
There are still considerable interlaboratory differences in positivity
rate in anti-b2GPI ELISA. We have already shown that BSA as a
blocking agent could introduce a substantial interference effect in
an anti-b2GPI ELISA.
The aim of this study was to validate and possibly reduce an inter-
ference effect of different blocking agents on the detection of IgG
anti-b2GPI antibodies by ELISA.
We used Costar high binding plates coated with affinity purified
human b2GPI and blocked with 1% BSA or 3% gelatin in PBS.
Selected sera (20 NHS, 20 APS sera and 10 sera from children
with atopic diseases) were diluted in PBS containing 0.05% Tween
(PBS-T) or in 0.1% BSA/PBS-T or in 1% gelatin/PBS-T.
When plates were blocked with BSA and samples diluted in PBS-T,
11/50 sera expressed values above the cut-off level in the wells coated
with b2GPI and also substantial binding in sample blanks wells (SB)
mostly exceeding the binding to the antigen, therefore these samples
were considered negative (average SB for all sera = x±SD=63±127
mOD). The specificity of IgG antibodies yielding high background
bindings was confirmed by direct binding to BSA on solid phase (cor-
relation with SB: P < 0.001, R2=0.88) and efficient inhibition by fluid
phase BSA. Further, the sera were diluted in 0.1% BSA/PBS-T, which
resulted in negligible binding to BSA either directly coated on the
plates or used as the blocking agent and hence lowered SB to insignif-
icant levels (SB=13±9 mOD). Following this modification, 3/11 sera
previously found negative due to high SB values, clearly expressed low
positive IgG anti-b2GPI values. The inhibition of anti-BSA with 0.1%
BSA in fluid phase was almost complete in 3 minutes, suggesting that
longer preincubation time may be unnecessary.
1% gelatin/PBS-T as the sample diluent buffer did not prevent the
substantial binding to BSA used as the blocking agent either (SB
for 20 sera with the highest binding to BSA =203±262 mOD). The
same was true even when the plates were blocked with 3% gelatin
and samples diluted either in PBS-T (SB=117±120 mOD) or in
0.1% BSA/PBS-T (SB=127±122 mOD) generating substantial SB
values in 18/38 tested sera. Similarly to BSA, significantly lower
background bindings were reached only when gelatin was used as
the blocking agent and 1% gelatin added to the sample diluent
buffer (SB=30±21 mOD).
To reduce the interference effects of a blocking agent it was essen-
tial to dilute sera in a buffer containing the same agent. Since the
binding to BSA or gelatin was detected in both normal human and
patients’ sera we suggest to follow this general guideline in anti-
b2GPI ELISA to better define the cut-off points and to more accu-
rately verify not only high, but also most of low positive results.
P81
Heterogeneous behaviour of anti-b b2-glycoprotein I
antibodies on different “high binding” microtiter
plates
A Ambroz
vic
v*, T Kveder*, K Ichikawa‡, T Avc
vin†, M Hojnik*, 
B Boz
vic
v*, T Koike‡
*Department of Rheumatology and †Department of Paediatrics,
University Medical Centre, Ljubljana, Slovenia. ‡Department of
Medicine II, Hokkaido University School of Medicine, Sapporo, Japan
We recently identified anti-b2GPI antibodies in a high proportion of
sera from children with atopic dermatitis (AD) and showed that
these anti-b2GPI most probably recognise domain V of b2GPI by
contrast to anti-b2GPI from patients with the anti-phospholipid syn-
drome (APS) which epitopes apparently reside in domain I or IV.
The aim of the present study was to compare the binding of IgG
anti-b2GPI in AD and APS on four representative commercially
available types of high binding microtiter plates.
Selected plates: Costar, Nunc, Linbro and Sumilon C. Randomly
selected sera from 29 children with AD and sera from 43 SLE
patients (24 with secondary APS) were tested by anti-b2GPI ELISA
using affinity purified b2GPI. Assays were calibrated with the HCAL,
chimeric anti-b2GPI monoclonal antibodies with human g1 constant
regions.
The calibration curves for HCAL were practically the same on all
four types of plates. Sera from 7/24 APS patients with medium or
high anti-b2GPI levels showed similar binding properties on all four
plates, while 3/24 sera expressed values either slightly above or
below the cut-off points. On the other hand, anti-b2GPI from AD
sera showed very simmilar binding on Costar, Nunc and Linbro
plates, while only 3/13 positive sera with the highest values on
these 3 types of plates expressed low positive values for IgG anti-
b2GPI on Sumilon C plates (Table 1). Except for one serum (low
positive on Linbro plate) all sera from SLE patients without APS
were negative on all the plates.
Our results point to substantial differences in the binding to b2GPI
coated on different microtiter plates by anti-b2GPI in AD (with no
signs of APS) but not by anti-b2GPI in APS. In contrast to the other
plate types, Sumilon C plates coated with b2GPI bound only mini-
mally antibodies from AD children. If such anti-b2GPI prove non-
thrombogenic, we will be able to increase the specificity of
detecting anti-b2GPI relevant for APS by the use of this type of
microtiter plates. Alternatively, if both anti-b2GPI specificities prove
thrombogenic, we will be able to increase the sensitivity of the
assay system by the use of other less discriminatory types of plates.
Table 1 COSTAR NUNC LINBRO SUMILON C
kR 2 NkR 2 Nk R 2 NkR 2 N
APS (n = 24) 1.00 1.00 8 1.06 0.99 8 1.09 0.95 9 0.84 0.99 9
AD (n = 29) 1.00 1.00 13 1.05 0.97 13 0.87 0.92 13 0.22* 0.63 3*
k, slope of linear regression plot and R2 - determination coefficient:
both compared to Costar. N, number of IgG anti-b2GPI positive
sera in the group. *P < 0.001 (significant difference when com-
pared with Costar, Nunc or Linbro)
P82
Oxidation of b b2- -glycoprotein I (b b2GPI) by the
hydroxyl radical alters phospholipid binding and
modulates recognition by anti-b b2GPI
autoantibodies
J Arvieux, V Regnault, E Hachulla, L Darnige, F Berthou 
and P Youinou
Laboratoire d’Immunologie, Institut de Synergie des Sciences et de la
Santé, CHU Brest, France
We investigated whether b2GPI, the key antigen in the antiphospho-
lipid syndrome, is susceptible to oxidative modifications by the
hydroxyl radical (°OH) that may influence its lipid-binding and anti-
genic properties. We compared the effects on human and bovine
b2GPI of °OH free radicals generated by g-radiolysis of water with
137Cs and by the Fenton system composed of Fe-EDTA, ascorbate
and H2O2. Radiolytic °OH caused a dose-dependent loss of trypto-
phan, production of dityrosine and carbonyl groups, dimerization
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology Researchand/or extensive aggregation of b2GPI. It ensued a reduction in
affinity binding to cardiolipin liposomes and loss of b2GPI-depen-
dent autoantibody binding to immobilized cardiolipin. Patient anti-
b2GPI antibodies segregated into two groups based on the effect in
the  b2GPI-ELISA of b2GPI pretreatment with radiolytic °OH :
enhancement or suppression of IgG binding in groups A (common
type) and B (rare subset), respectively. The avidities of group A anti-
bodies for fluid-phase b2GPI were low but increased in a dose-
dependent manner upon b2GPI irradiation, in relation to protein
crosslinking. Distinguishing features of group B antibodies included
higher avidities for fluid-phase b2GPI that was no longer recognized
after °OH treatment, and negative anticardiolipin tests suggesting
epitope location near the phospholipid binding site. The °OH scav-
engers thiourea and mannitol efficiently protected against all above
changes. In contrast, the Fenton system induced no major alteration
in the structure and functions of b2GPI.
Thus, oxidative modifications of b2GPI via °OH attack of susceptible
amino acids alters phospholipid binding, and modulates recognition
by autoantibodies depending on their epitope specificities. These
findings may be of clinical relevance for the generation and/or reac-
tivity of anti-b2GPI antibodies.
P83
Isolation of b b2GPI by perchloric acid yields three
proteins having different antigenic properties
S C
v
uc
vnik, T Kveder, M Hojnik and B Boz
vic
v
University Medical Centre, Department of Rheumatology, Ljubljana,
Slovenia
The precipitation by perchloric acid is usually the first step in the
isolation of b2GPI used in the ELISA for anti-b2GPI antibodies. Per-
chloric acid inhibits plasmin and denaturates most proteins except
for those being very basic.
The aim of our study was to evaluate the common procedure for the
isolation of b2GPI with special emphasis on the precipitation step
with perchloric acid.
The precipitation by perchloric acid, performed with different timing
(3, 18 or 50 minutes) was followed by affinity chromatography on
heparin, concluded by cationic exchange chromatography. Elution
with the Na+ gradient (linear 0.05-0.65M) led to three distinct
protein peaks. Each peak was isolated and analysed separately by
1./denaturated polyacrylamide electrophoresis, 2./rocket electro-
phoresis with rabbit polyclonal anti-b2GPI and 3./ELISA with 6 SLE
and/or APS patients’ sera, previously determined by the standard
anticardiolipin and anti-b2GPI ELISA. In the ELISA all 9 proteins
were used at the same concentration, determined by colorimetric
reaction.
The protein from the 2nd peak exhibited a molecular weight of 50
kDa, corresponding to both molecular weight markers and refer-
ence b2GPI (Tincani, Brescia Italy). Both the protein from the 1st
and 3rd peak exhibited a molecular weight of about 55 kDa. The
same result was observed after all three different precipitations. In
rocket electrophoresis, the proteins from the 2nd and 3rd but not
from the 1st peak reacted with polyclonal rabbit anti-b2GPI anti-
body. There were no diferences in the activities among the isolates
obtained by the different precipitation timing. In the ELISA, the pro-
teins from the 2nd and 3rd but not from the 1st peak reacted with
human anti-b2GPI antibodies. Differences among the isolates
obtained by different precipitation timing were observed. The
protein from the 2nd peak obtained after 3-minute precipitation
reacted 2 to 10 times stronger with different patients’ sera than the
protein from the 3rd peak (from the same isolation). Proteins
obtained after 18-minute precipitation reacted more weakly than did
the proteins from the isolation after 3-minute precipitation, but the
protein from the 2nd peak gave still 2 to 6 time higher results than
the protein from the 3rd peak. The proteins from the 2nd and 3rd
peaks after 50-minute precipitation reacted almost equally; the
protein from the 3rd peak after 50-minute precipitation reacted
stronger than the same protein either after 18-minute or 3-minute
precipitation.
In conclusion, the precipitation with perchloric acid followed by
affinity purification on heparin and cation exchange chromatography
with linear Na+ gradient (0.05 to 0.65M) yielded three different pro-
teins, out of which one was antigenically nonactive and two were
antigenically active with anti-b2GPI antibodies. The time of precipi-
tation influenced the antigenic properties of the two proteins with
the same antigenic specificity but different molecular weight.
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Antibodies to b b2–glycoprotein I, prothrombin and
antithrombin III as markers of the
antiphospholipid syndrome severity
J Zabek, S Luft, T Reshetniak*, Z Alekberowa*, 
B Wojciechowska, W Karlik†, V Nasonowa*
Institute of Rheumatology, Warsaw, Poland; *Institute of
Rheumatology, Moscow, Russia; †Warsaw Agricultural University,
Warsaw, Poland
Antibodies to b2-glycoprotein I /b2-GP I/, prothrombin /Pt/ and
antithrombin III /AT III/ are not strictly speaking antiphospholipid
antibodies, but they are closely associated with this pool of antibod-
ies. The “marker” and prognostic significance of these antibodies
have been recently widely discussed.
The aim of the presented study was to determine whether the anti-
b2-glycoprotein I, anti-Pt and anti-AT III antibodies possess
“marker” and prognostic value in APS syndrome.
The presence of the serum antibodies to these serum proteins, six
selected phospholipids /including cardiolipin/ and Lupus antycoag-
ulant have been tested and correlated with such clinical manifesta-
tions of the antiphospholipid syndrome /APS/ like: thrombotic
events, fetal loss, trombocytopenia and livedo reticularis. The study
covers 83 sera of the patients with various diagnoses /in 11 SLE,
43 SLE + APS /SAPS/ and 29 in PAPS/. The antibodies to b2-gly-
coprotein I in 21% of the SAPS cases and in 24% of the PAPS
cases have been found and in none of the SLE without APS syn-
drome sera. The antibodies to Pt are present in 20% and to AT III
in 15% of the tested sera. The correlation of antibodies to nega-
tively charged phospholipid, LAC and anti-b2-glycoprotein I seems
to be evident. Also significant increasing of the frequency of the
appearance of selected clinical manifestations in the group of the
anti-b2-glycoprotein I, anti-Pt and anti-AT III – positive sera was
observed, especially fetal loss, livedo reticularis and thrombocytope-
nia. It seems to us the anti-b2-glycoprotein I, anti-Pt and anti-AT III
antibodies are very promising “marker” for APS and possess also
prognostic value.
P85
Differences between active immunoinflammatory
and postinfectious fibromyalgia (FM)
I Wittrup, M Christiansen, B Jensen, H Bliddal, 
B Danneskiold-Samsøe and A Wiik
Parker Research Institute; Frederiksberg Hospital and Departments of
Clinical Biochemistry and Autoimmunology, Statens Serum Institut,
Copenhagen, Denmark
Aim: To study immunological and neurochemical markers in cere-
brospinal fluid (CSF) and serum of FM patients in two subgroups,
one having had a slow onset of symptoms (SO) and the other an
acute onset (AO) of FM after a flue-like attack.
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Available onlinehttp://arthritis-research.com/supplements/3/SAMaterials: Twenty women with SO and 19 with AO FM, matched
as to age and clinical symptoms, were studied for a multitude of
antimicrobial and autoantibodies in serum. Markers of inflammation,
immune activation and nerve cell damage were looked for in CSF
and serum. All patients had longstanding disease.
Results: More patients with AO FM had IgM antibodies to
enteroviruses, but PCR amplification showed no signs of enteroviral
genome in CSF. All other antimicrobial and autoantibodies were
similar in the two groups. However, in the SO FM patients we found
strongly increased intrathecal IgA production as shown by extended
indices but normal albumin ratio indicating normal blood/CSF
barrier function. Intrathecal IgM production was increased in a few
SO FM patients but IgG production was normal in all FM patients.
Myelin basic protein (MBP) levels were normal in CSF of AO FM
patients but very low in the SO patient group.
Conclusions and discussion: In FM characterized by an insidious
onset of symptoms an immunoinflammatory mechanism involving
IgA production in the brain may be a driving pathogenetic mecha-
nism. Patients having experienced an acute onset of FM after a flue-
like episode are likely to suffer from sequelae after earlier
encephalitis, showing no signs of immune activation. The abnor-
mally low MBP levels in the CSF of SO FM patients are yet unex-
plained. Our findings strongly support the concept that FM is a
result of brain abnormalities that lead to disordered sensory pro-
cessing and widespread allodynia.
P86
Disorders of the system of hemostasis and
biochemical parameters of NZB/NZW F1 mice
AV Arshinov*, OA Nazarova†, GN Pleskovskaya‡ and VV Redko*
*Medical Academic Yaroslavl; †Medical Academy, Ivanovo; ‡Institute of
Rheumatology, Moscow, Russia
Object of a research. A research of interaction of coagulation and
biochemical parameters of NZB/NZW F1 mice with spontaneous
explicating lupus like disease.
Methods: 120 female mice of a line NZB/NZW F1 3 months age
were investigated. Coagulation tests were used: counting platelets,
activated partial thromboplastin time (APTT), throbmin time (TT),
prothrombin time (PT), concentation of fibrinogen, soluble fibrin
monomer complexes (SFMC); pararmeters of platelet aggregate
(spontaneous and induced with ristocetin, collagen and ADF). Bio-
chemical parameters of serotonin and cortisol were investigated. An
electronic microsocopy of microvessels was investigated also.
Results: Significant (more than twice) decreasing the amount of
platelets of NZB/NZW F1 mice, elongation of parameters of the
coagulation tests (APTT 40,0 ± 2,7 sec, control 27,6 ± 2,5 sec) (P
< 0,01), decreasing the concentration of fibrinogen (1,1 ± 0,2 g/l,
control 5,2 ± 0,6 g/l), increasing the level SFMC (28,1 x 10-2 ± 1,6
g/l, control 8,9 x 10-2 ± 1,03 g/l), increasing the parameter of spon-
taneous platelets aggregate (20,3 ± 1,96 %, control 2,5 ± 0,6 %)
and aggregate of platelets with ADF (12,8 ± 1,3 %, control 9,0 ±
0,8 %) decreasing the aggregate with collagen (4,4 ± 0,6 %, contol
9,3 ± 0,8 %) were registered. The concentration of “plasma” sero-
tonin was increased (0,065 mcg/ml, control 0,042 mcg/ml), the
level of cortisol was considerably reduced (0,4 ± 0.09 mcg/ml,
control 1,03 mcg/ml). The correlation between increasing the con-
centration of “plasma” serotonin, increasing the parameter of the
spontaneous aggregate of platelets, increasing the concentration of
SFMC, elongation of the coagulation tests and decreasing the con-
centration of “platelet” serotonin were marked. By the electronic
microscopy the distrophy of endothelium is registered.
Conclusion: Thus the endothelial damage of NZB/NZW F1 mice
was accompanied by the expressed activation of a system of hemo-
stasis, amplifying the aggregate of platelets and increasing the
release of serotonin from them. At the same time the significant
decreasing the concentration of cortisol was found. These disorders
of hemostasis are typical for DIC syndrome. Therefore, it is possible
to use NZB/NZW F1 mice as an animal model for study of disorders
of hemostasis, including DIC syndrome, for the patients with SLE.
Poster Discussion F
Innovative Therapies
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Adenoviral gene transfer of tissue inhibitors of
metalloproteinases (TIMPs) reduces the invasive
behaviour of rheumatoid fibroblast-like
synovicytes
WH Van der Laan*†, L Huisman*, E Pieterman†, PHA Quax*, 
JM TeKoppele*, FC Breedveld†, JH Verheijen* and TWJ Huizinga†
*Division of Vascular and Connective Tissue Research, TNO
Prevention and Health, Leiden; †Department of Rheumatology, Leiden
University Medical Center, Leiden, The Netherlands
In rheumatoid arthritis (RA), an excess of proteolytic enzymes
secreted at the synovium-cartilage junction results in the invasion of
the articular cartilage by synovial cells. The aims of the present
study were to investigate the effects of overexpression of TIMP-1
and TIMP-3 on: 1) the invasive behaviour of rheumatoid fibroblasts-
like synoviocytes and 2) cell proliferation and apoptosis.
The day before the experiments, the synoviocytes were infected
with adenoviral vectors encoding TIMP-1 or TIMP-3 or with a
control vector (AdLacZ). A Transwell system was used to study
invasion of the cells. After 3 days, the invaded cells were counted
using a microscope. Proliferation was assessed by measuring 3H-
thymidine incorporation and cell counting. Apoptosis was assessed
at 1-4 days after transduction using an Annexin V-FITC kit.
Both TIMP-1 and TIMP-3 overexpression resulted in a significant
reduction, respectively 60% (P < 0.001) and 80% (P < 0.001), of
invasiveness of the synoviocytes as compared to the AdLacZ-trans-
duced cells. In all cases, TIMP-3 was superior to TIMP-1 (P = 0.02).
Cell proliferation was significantly reduced by TIMP-3 overexpres-
sion (40%; P < 0.05) and to a lesser extend by TIMP-1 (20%; P <
0.05) as compared to AdLacZ. There were little differences in % of
apoptotic cells between the non-transduced, AdTIMP-1, AdTIMP-3
or Ad LacZ transduced cells up to 4 days after transduction. A
maximum of 15% of the AdTIMP-3 transduced cells were in apopto-
tis as compared to a maximum of 12% in the other conditions.
These results show that the invasive behavior of RA-FLSs can be
strongly inhibited by overexpression of TIMPs. Both MMP inhibition
and a reduction of proliferation appear to contribute to this effect.
The superior effect of TIMP-3 may be due to a stronger effect on
proliferation or to differences in the inhibitory profile of TIMP-1 and
TIMP-3. To limit joint destruction in rheumatoid arthritis, inhibition of
cartilage invasion by the pannus tissue by TIMP overexpression may
be a useful approach.
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Adenoviral-based overexpression of TIMP-1
reduces tissue damage in the joints TNF-
transgenic mice
G Schett*, S Hayer*, Q Xu†, M Tohidast-Akrad‡, G Kollias§, G
Steiner*‡ and J Smolen*‡
Division of Rheumatology, Department of Internal Medicine III,
University of Vienna, Vienna; Institute for Biomedical Aging Research,
Austrian Academy of Sciences, Innsbruck; ‡Ludwig Boltzmann-
Institute for Rheumatology and Balneology, Vienna, Austria;
§Department of Molecular Genetics, Hellenic Pasteur Institute, Athens,
Greece
Introduction: Rheumatoid arthritis is a prototype of a destructive
inflammatory process. Inflammation triggered by the overexpression
of TNF-a is recognized as a driving force of the disease process and
mediated tissue destruction. The particular impact of TNF-a-depen-
dent pathways in tissue destruction is unknown.
Materials and methods: Herein, the effect of an overexpression of
tissue inhibitor of metalloproteinases (TIMP)-1, a physiological
antagonist of metalloproteinases, was studied in the arthritis model
of TNF-a-transgenic mice. Systemic treatment was carried out by
replication defective adenoviral vectors for TIMP-1 (AdvTIMP1, n
=7) or b-galactosidase (AdvLacZ, n = 6) or phosphate buffered
saline (PBS, n = 7), which were injected once intravenously at the
onset of arthritis. Clinical, serological, radiological and histological
outcomes were assessed 18 days after treatment.
Results: The AdvTIMP1 group showed a significantly improved clin-
ical outcome as measured by paw swelling and grip strength than
the two control groups, whereas total body weight, TNF-a and IL-6
levels were similar in all groups. Tissue destruction as assessed by
X-ray and histology of hind paws was significantly lower in the
AdvTIMP1 group than in the AdvLacZ- and PBS- control groups.
Finally, the formation of arthritis-specific autoantibodies to hnRNP-
A2 was not observed in the AdvTIMP1 group but were present in
the two control groups.
Discussion: These results indicates a central role of metallopro-
teinases in TNF-a-mediated tissue damage in vivo and a promising
therapeutic role of TIMP-1.
P89
Serum levels of matrixmetalloproteinases MMP1
(collagenase) and MMP3 (stromelysin) before and
after treatment with leflunamide in patients with
rheumatoid arthritis
H Mangge, P Gratze and S Hermann*
Departments of Laboratory Diagnosis and *Internal Medicine,
University Graz, Austria
Objective: Leflunamide has been proven to be efficient in reducing
joint inflammation and destruction in patients with rheumatoid arthri-
tis (RA). This study was conducted to examine effects of leflu-
namide on serum levels of matrixmetalloproteinases MMP1 and
MMP3 in patients with RA.
Methods: In a prospective clinical trial, we measured in 24 patients
suffering from RA, as defined by ACR criteria, serum activities of
MMP1 and MMP3 by means of ELISA. Analysis of MMPs was per-
formed before and after a treatment period of approximately 3
months (84 + 14 days, mean + SD) with leflunamide. Additionally,
conventional inflammatory parameters (CRP, ESR) and clinical data
of RA activity were determined.
Results: Leflunamide treatment lead to a highly significant reduc-
tion of MMP1 serum activity (p < 0.001), whereas MMP3 values
were not influenced. Furthermore, the number of painful (p < 0.01)
and swollen (p < 0.05) joints decreased significantly as well as clin-
ical inflammatory joint activity scores (GLASS, p < 0.001) and
levels of CRP (p < 0.05).
Conclusion: In accordance with recent data, leflunamide is effec-
tive in reducing the clinical inflammatory activity of RA, and in
decreasing the activity of matrix-degrading factors like MMP1. The
differential effect of this immunomodulative drug on MMP1 and
MMP3 will be explored in further investigations.
P90
Altered migratory capacity of polymorphonuclear
leucocytes as an effect of TNF-alpha blockade in
patients with rheumatoid arthritis
H Mitterhammer, J Hermann, G Tilz, R Brezinschek, U Demel, 
B Yazdani-Biuki, T Müller, J Gretler, S Eder and HP Brezinschek
Department of Internal Medicine, Auenbruggerplatz 15, A-8036 Graz,
Styria, Austria
Rheumatoid Arthritis (RA) is associated with progressive joint
destruction, functional disability and decreased life expectancy.
Althought the underlying cause of RA is unknown, TNF-alpha, a
proinflammatory cytokine, contributes to the pathogenesis of synovi-
tis and joint destruction. Anti-TNF-biological response modifiers,
such as Etanercept a recombinant human TNF receptor fusion
protein, suggest that TNF-alpha-inhibition is a viable approach to
control disease activity in RA.
Considering the pivotal role TNF alpha plays in the first line defense
against bacterial and fungal infections by polymorphonuclear leuco-
cytes (PMN) it seems important to focus on the PMN function in RA
patients, treated with Etanercept. Since a 29% increase in infec-
tions of the upper respiratory tract under TNF-alpha blockade has
been reported, we investigated inflammatory parameters related to
PMN-activity in 6 RA-patients, before and after 3-months of Etaner-
cept treatment without altering their methotrexate and/or glucocorti-
coid-medication. The migration of the neutrophils was measured
with a standardized whole blood membrane filter assay with and
without stimulation by the chemoattractant fMLP. The percentage of
migrating PMN (total migration index,TMI) and the relative penetra-
tion depth into the filters (distribution characteristics, DC) served to
characterize the migratory behaviour of neutrophils. To estimate in
vivo granulocyte activation, neutrophil elastase was measured in
plasma from RA patients. In addition, PMN-blood count and C-
reactive protein as a marker of disease activity, were analysed. TNF-
alpha blockade significantly (p < 0,03) reduced the spontaneous
and fMLP stimulated median TMI (15.2 vs. 10.9 and 16.5 vs. 11,4,
respectively). Moreover the spontaneous and the fMLP-stimulated
median DC was reduced under Etanercept–treatment ( 21.1 vs.
5.9, P < 0.03 and 20.5 vs. 6.6, P < 0.06 respectively). Interestingly,
these values were still within the normal range of migratory activity.
Furthermore, TNF blockade significantly reduced the median
plasma elastase levels ( 252 vs. 108, p <0,04), as well as the
median C reactive protein levels ( 21 vs. 7 P < 0,035) and the
median number of polymorphonuclear leucocytes ( 7.73 vs. 4.58, P
< 0.0001). Of note, plama elastase levels as a sign of systemic
PMN-activation were still above the normal range. During the
observed treatment period all patients showed an improvement in
the inflammatory symptoms of RA ( 2 had a 70% ACR-response, 3
a 50% and 1 a 20% ACR response). No patients had signs of bac-
terial or fungal infections. In conclusions, TNF alpha blockade did
not suppress PMN migratory activities to levels that are assosciated
with higher incidences of infections.
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Development of a doxycycline inducible AAV
vector for long term in vivo viral IL-10 gene transfer
in rheumatoid arthritis
F Apparailly*, D Noël*, V Millet*, C Jacquet*, J Sany*†
and C Jorgensen*†
*INSERM U475, †Immunorhumatologie, CHU Lapeyronie, Montpellier,
France
Objectives. The recent development of AAV vectors (adeno-associ-
ated virus) offers new perspectives for cytokine gene transfer in RA
as they are non pathogenic and allow long term transgene expres-
sion in vivo. Moreover, we propose to regulate vIL-10 expression
with tetracycline derivative (tetON system). The purpose of this study
was to assess the potential long-term gene expression regulation of
a recombinant AAV vector expressing vIL-10 in human rheumatoid
synovial tissue and its efficiency in collagen-induced arthritis (CIA).
Methods. The AAV-tetON-vIL10 vector contains two transcriptional
units oriented in opposite directions, with a central bi-directional
SV40 polyA. Sequences encoding the transcriptional activator rtTA,
which confers doxycycline transgene induction, is inserted down-
stream a retroviral LTR promoter. A minimal human CMV promoter,
flanked with tetracycline operator motifs, controls the transcription
of vIL-10. Human RA synoviocytes were infected in vitro with AAV-
tetON-vIL10 (500 MOI) and vIL-10 secretion was assessed by
ELISA after addition of 5 mg/ml doxycycline (dox). Therapeutic effi-
ciency of the vector was achieved after intra-muscular injection (1.5
x 109 pi) in DBA1 mice with CIA in the presence of doxycycline in
the drinking water (0.2 mg/ml).
Results. Viral IL-10 secretion by RA synoviocytes was increased
40-fold in presence of dox (233 ng/ml/106 cells) and returned to
basal level 24 hr after dox removal. In CIA, serum vIL-10 increased
to 0.38 ng/ml, 5 weeks after gene transfer in animals under diet dox.
RT-PCR analysis showed vIL-10 transcription in the muscle up to
14 weeks, without diffusion in other organs. We observed a
decrease of CIA incidence (30% versus 89% in AAV-GFP injected
control group) and of paw swelling (1.68±0.04 versus 1.81±0.15
on day 35 post-immunization, P < 0.0003).
Conclusions. AAV vectors conferred safe and inducible long-term
expression of vIL-10. These data support AAV-tetON-vIL10 as a
therapeutical tool for gene therapy in RA.
P92
IL-18 blockade is a potential disease-modifying
therapy for rheumatoid arthritis
C Plater-Zyberk§, LAB Joosten*, MMA Helsen*, P Sattonnet-
Roche§, C Siegfried§, S Alouani§, FAJ van de Loo*, P Graber§, 
S Aloni†, CA Dinarello‡, WB van den Berg* and Y Chvatchko§
§Serono Pharmaceutical Research Institute, 14 chemin des Aulx, 1228
Geneva, Switzerland; *Rheumatology Research Laboratory, University
Medical Center St-Radboud, Nijmegen, The Netherlands; †InterPharma
Laboratories, Nes Ziona, Israel; ‡Department of Medicine, Division of
Infectious Diseases, University of Colorado Health Sciences, Denver,
Colorado, USA
Introduction: Interleukin-18 (IL-18) has been demonstrated as pro-
moting the development of a TH1 response in vivo in synergy with
IL-12. Significant levels of IL-18 and IL-12 have been detected in
the joints of patients with rheumatoid arthritis (RA).
Aim: To define the therapeutic potentials of IL-18 blockade in RA by
investigating the effect of neutralising endogenous IL-18 in the
experimental CIA mouse model.
Methods: Two distinct IL-18 neutralising strategies, i.e., a recombi-
nant human IL-18 binding protein (rIL-18BP) and a polyclonal anti-IL-
18 IgG, were used to treat CIA mice in a therapeutic protocol (after
disease onset). The effect on disease severity (visual scores) as well
as parameters of cartilage and bone destruction were evaluated.
Results:  Clinical scores were significantly reduced after IL-18
blockade (rhIL-18BP 1 mg/kg, P < 0.001, n = 13; rhIL-18BP 0.25
mg/kg, P < 0.05, n = 7; anti-IL18 IgG, 2 mg, P < 0.05, n = 9, Mann
Whitney test, treated versus placebo groups). Histological examina-
tion showed cartilage protection (decrease erosion scores, P <
0.05) that was accompanied by significantly reduced levels of
serum cartilage oligomeric matrix protein (an indicator of cartilage
turnover) and VDIPEN expression (a neoepitope present after
digestion by matrix metalloproteinases). X-ray analysis of joints pro-
vided evidence of reduced bone erosion. Serum IL-6 levels were
diminished in the treated animals.
Conclusions: These results clearly demonstrate that blocking
endogenous IL-18 is therapeutically efficacious in the CIA model
and support the use of IL-18 neutralisation as a novel cartilage and
bone protective therapy for the treatment of destructive arthritis.
Recombinant hIL-18BP could therefore represent a new disease-
modifying anti-rheumatic drug that warrants testing in clinical trials
in patients with rheumatoid arthritis.
P93
Digital vasculitis in a patient with rheumatoid
arthritis: good response on anti-TNF blockade
F van den Hoogen, A den Broeder, M Zandbelt and L van de Putte
Department of Rheumatology, University Medical Center St. Radboud,
Nijmegen, The Netherlands
Rheumatoid arthritis (RA) may be complicated by vasculitis. Vasculi-
tis usually affects small vessels of the skin causing nailfold infarcts,
but may also affect larger vessels and cause severe damage to
internal organs. In such cases, treatment with high doses of corti-
costeroids or other immunosuppressive drugs may be necessary.
TNF-alpha blockade has been shown to be an effective and safe
treatment for RA, but thus far no reports have addressed the effect
of TNF-alpha blockade on extra-articular manifestations of RA, such
as vasculitis. We report a patient with RA and nailfold infarcts which
repeatedly disappeared for several weeks following monthly i.v.
injections with an anti-TNF alpha receptor fusion protein.
A 46 year old woman was diagnosed as having rheumatoid factor
positive, erosive RA in 1982. Due to the uncontrollable disease she
was included in 1994 in a study with Ro 45-2081, a fusion protein
combining two p55 TNF receptors with the Fc component of an IgG
human antibody (Roche, Basel, Switzerland, sTNFR:Fc). After a three
months placebo controlled phase she was treated with 50mg
sTNFR:Fc every four weeks. Clinical response was impressive with
swollen joint counts decreasing from 32 to 5 and C-reactive protein
CRP levels declining from 95 at baseline to 20 after the first injection.
Low disease activity was sustained for the following years. Besides
sTNFR:Fc her medication consisted of oral prednisone 5 mg a day
and occasionally paracetamol 500 mg. In the spring of 1999 she first
noticed nailfold infarcts on the fingers of both hands. These lesions
disappeared after every injection of sTNFR:Fc and reappeared three
weeks thereafter when the clinical effects of sTNFR:Fc were decreas-
ing. This effect on the digital vasculitis has been well documented
during several cycles of sTNFR:Fc administration.
Conclusion:  The prompt disappearance of nailfold infarcts after
sTNFR:Fc administration observed in our patient strongly suggests
a therapeutic effect of sTNFR:Fc on active vasculitis. This observa-
tion raises the question whether blocking of TNF-alpha might also
be effective in more severe forms of vasculitis and possibly other
extra-articular manifestations of RA, some of which are life threaten-
ing and are currently treated with high doses of corticosteroids and
immunosuppressive drugs.
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Effect of osteoprotegerin and pamidronate
treatment in transgenic mice overexpressing
human TNF
K Redlich*, A Maier†, S Hayer*, G Kollias‡, CR Dunstan§, 
M Tohidast-Akrad*, S Lang#, W Woloszczuk**, G Steiner*, 
JS Smolen* and G Schett*
*Department of Internal Medicine III, Div. of Rheumatology,
†Department of Radiology, #Department of Pathology, **Ludwig
Boltzmann-Institute of Experimental Endocrinology, Vienna, Austria;
‡Department of Molecular Genetics, Hellenic Pasteur Institute, Athens,
Greece, §Department of Pathology, Amgen, Inc., CA, USA
Rheumatoid arthritis (RA) is characterized by progressive joint
destruction resulting from chronic inflammation. Recent studies
suggest that bone-resorbing osteoclasts formed in the synovium
play an important role in bone destruction in RA. We studied the
effect of anti-resorptive treatment with osteoprotegerin and/or
pamidronate compared to TNF blockade with infliximab on the
development of erosions in TNF overexpressing mice. Systemic
treatment with osteoprotegerin (OPG), pamidronate, both osteopro-
tegerin and pamidronate, infliximab or phosphate buffered saline
(PBS) was carried out by intravenous injection . Treatment was initi-
ated at the time of onset of arthritis and continued over 35d. Clini-
cal, serological, radiological and histological outcomes were
assessed after treatment. Clinical improvement, as assessed by
reduction in paw swelling was only seen in the infliximab treated
group. X-Rays of the hind paws were performed to quantify erosive
changes. Erosions were detectable in each joint compartment
Grading of erosions was performed analogous to the Larsen score.
There was a marked and significant (P < 0.05) reduction in the
Larsen scores of mice treated with OPG (-54%), OPG and
pamidronate (-64%) and infliximab (-66%). Microscopic examination
of decalcified joint tissue sections using a semiquantitative method,
revealed a significant (P < 0.05) reduction in the extent of erosions
in all treatment groups (OPG: -56%; pamidronate: -53%; OPG +
pamidronate: -81%; infliximab –46%) when compared to controls.
These data suggest that anti-resorptive treatment may have a signif-
icant potential in TNF-mediated bone destruction.
P95
Induction of a rapid progessive cartilage
destruction in SCID mice by intraarticular
application of a murine fibroblast like cell line
U Sack, A Hirth, B Funke, K Wiedemeyer, S Konrad, J Lehmann
and F Emmrich
Institute of Clinical Immunology and Transfusion Medicine, University
of Leipzig, Germany
Background: In pathogenesis of rheumatoid arthritis, fibroblasts are
considered to be a crucial cell population for disease progression
as well as joint destruction. Following intraarticular injection into
SCID mice, isolated human rheumatoid synovial fibroblasts have
been shown to induce a destructive arthritis (hu/mu SCID arthritis).
Although exclusively human synovial fibroblasts were able to induce
this arthritis, cartilage destruction was caused by murine fibroblast
like cells in this model. Therefore, we have isolated a murine
destructive fibroblastoid cell line and established a cartilage
destruction model.
Material and methods: LS48 cell line was examined for morpho-
logical, ultrastructural, immunological, and functional parameters.
Furthermore, cartilage destruction was induced by intraarticular
application of LS48 cells into SCID mouse knee joints. Mice were
monitored for joint swelling, serological parameters and by radiolog-
ical methods. Finally, immunohistochemistry and histology were
used to characterize morphology of cartilage destruction.
Results: LS48 was shown to present characteristics of a fibroblast-
like cell. Secretion of interleukin-6 and tumor necrosis factor-alpha
revealed similarities to human invasive rheumatoid synovial mem-
brane fibroblasts. Installation of 5 x 10^5 cells into SCID mouse
knee joints caused a rapid progressive process causing cartilage
destruction within 10 days. Morphology revealed infiltration of
fibroblast like cells into the cartilage.
Conclusions:  Induction of cartilage destruction by intraarticular
application of these murine fibroblast like cells is a rapid and highly
reproducible model for investigation of cartilage destruction in
arthritic joints. This provides an excellent possibility to investigate
relevant processes and new therapeutic strategies for rheumatoid
arthritis in an easy-to-handle animal model.
P96
Infiltrate analysis of rheumatoid synovial tissue
before and after high does chemotherapy and
autologous stem cell transplantation
RJ Verburg, R Flierman, EWN Levahrt, F van den Hoogen*, 
FC Breedveld and JM van Laar
Departments of Rheumatology, Leiden University Medical Center and
*University of Nijmegen, The Netherlands
Objective: To investigate the effects of high dose chemotherapy
(HDC) and autologous stem cell transplantation (ASCT) on the syn-
ovial infiltrate in rheumatoid arthritis.
Methods: 8 patients with erosive, refractory, progressively rheuma-
toid arthritis, were treated with HDC (cyclophosphamide 200
mg/kg) and CD34 enriched selected ASCT. Biopsies of synovial
tissue from a clinically involved knee were obtained by arthroscopy
before and three months after HDC and ASCT. Immunohistochem-
istry was performed and blindly scored on a five point scale (0-4)
using MoAbs specific for the following markers: CD3, CD4, CD8,
CD25, CD27, CD45RA, CD45RO, CD45RB, CD19, CD20,
CD22, CD38, CD5, CD68, HLA-DR, CD62L, CD62E, CD56 and
CD55.
Results: There were no statistical significant differences (Wilcox-
on’s signed rank test) when the results before and after transplanta-
tion were compared. However when patients were divided in clinical
responders (ACR > 50%, n = 5) and non-responders (ACR < 20%,
n = 3) statistically significant differences with respect to several T-
cell markers were found (Table).
Responders Non-responders
Before After Before After P*
CD 3 2.8 ± 0.5 1.3 ± 2.3 1.0 ± 1.4 1.7 ± 2.1 0.06
CD27 3.0 ± 0.8 0.3 ± 0.6 1.0 ± 0.8 1.7 ± 2.1 0.05
CD45RA 2.3 ± 0.9 0.7 ± 1.2 0.5 ± 1 1.6 ± 2.1 0.03
CD45RO 3.4 ± 0.5 0.7 ± 1.2 1.8 ± 1.6 2.0 ± 2 0.04
CD45RB 3.2 ± 0.8 1.0 ± 1.7 2.0 ± 1.6 2.0 ± 2.0 0.05
Mean Histological Score ± STDEV. * Mann-Whitney U test. Clinical and
immunohistochemical responses were predicted by CD27 (P = 0.016), CD45RO
(P = 0.003) and CD45RB (P = 0.047) infiltration before treatment.
Conclusions: There was a statistically significant difference (P <
0.05) between clinical responders and non-responders with respect
to a decrease in infiltration of CD45RA+ and CD45RO+ cells after
HDC and ASCT. CD27, CD45RO and CD45RB appear to be
useful markers to predict clinical response.
c
o
m
m
e
n
t
a
r
y
r
e
v
i
e
w
r
e
p
o
r
t
s
m
e
e
t
i
n
g
 
a
b
s
t
r
a
c
t
s
p
r
i
m
a
r
y
 
r
e
s
e
a
r
c
h
Available onlinehttp://arthritis-research.com/supplements/3/SAP97
Newer immunmodulating drugs in rheumatoid
arthritis may precipitate glomerulonephritis
H Nielsen, E Kemp, LJ Petersen, AN Gam, J Dahlager, T Horn, 
S Larsen and S Olsen
Department of Rheumatology/Nephrology/Pathology, Herlev and
Glostrup University Hospitals of Copenhagen and Department of
Internal Medicine, Roskilde Hospital, Denmark
Three patients with rheumatoid arthritis on newer immunmodulating
therapy, developed acute glomerulonephritis. Two of the patients
were treated with tumour necrosis factor blockade ( Etanercept, 25
mg sc. twice a week) and one with leflunomide (Arava, 20mg daily)
in addition to the conventional medical treatment. All of the patients
developed unexpected blood and urinary abnormalities, two of them
after treatment with Etanercept for eleven- and one months respec-
tively. Renal biopsies showed in, the patients with long term Etaner-
cept treatment, focal proliferative glomerulonephritis with cellular
crescents in 30% of all glomerular sections. The biopsy showed
mesangial deposits of IgA. This patient was suspected clinically for
subacute bacterial endocarditis, however all data were negative. In
the other patient treated with Etanercept for only four weeks slightly
diffuse mesangial proliferative glomerulonephritis was demon-
strated. Electron microscopy of this biopsy showed distinct mesan-
gial matrix changes “moth-eaten” appearance. In the patient treated
with Arava during four weeks, biopsy showed focal proliferative
glomerulonephritis with cellular crescents in 7% of all glomerular
sections and with IgA mesangial deposits.
Two of the patients thus had IgA glomerulonephritis. The diagnosis
of the third one was inconclusive, as regard the present of IgA , but
pathology could represent IgA glomerulonephritis in resolution.
The relation in time of sign of renal disease to the treatment with
Etanercept and Arava makes it probable that renal disease was
related to these drugs. It is generally assumed that IgA glomeru-
lonephritis is caused by the deposition of immune complexes, but
details of antigen(s) are in these cases unknown. We finally regard it
as a possibility that the immunmodulation caused by these new
drugs may facilitate silent infection and subsequently development
of IgA glomerulonephritis. At least in long term treated patients this
aetiology could not be excluded.
P98
The use of Ribomunyl® in the immunomodulatory
treatment of rats with adjuvant arthritis
J Rovenský, K Svík and M Stanciková
Research Institute of Rheumatic Diseases, Pieštany, Slovakia
Immunomodulatory therapy of inflammatory rheumatic diseases,
especially in refractory forms of systemic lupus erythematosus
(Rovensky  et al.) and rheumatoid arthritis (Mateicka et al.) has its
tradition. The very immunosuppressive therapy may induce the
development of resistance and to participate in recurrent secondary
infections in patients suffering from systemic diseases of the con-
nective tissue. Alternatives of immunomodulatory therapy are there-
fore sough for that would eliminate some adverse effects of
immunosuppressive agents on the cell-mediated and non-specific
immunity function, and would favorably affect the clinical condition
of the patient.
To verify our working hypothesis concerning the appropriateness of
immunomodulatory therapy with Ribomunyl® , the adjuvant arthritis
model in rats was chosen. Following drugs and their combinations
were orally administered to animals in a long-term prophylactic
course: Cyclosporine A (CyA, 2,5 mg/kg/day), methotrexate (MTX,
0,3 mg/kg, 2 times a week), Ribomunyl® (25 mg/kg 4 times a
week), CyA+MTX, CyA+Ribomunyl®, MTX+Ribomunyl®, and the
three-combination of CyA+MTX+ Ribomunyl®. When given in com-
bination, both the doses and the frequency of administration were
the same as when the drugs were administered alone. The following
markers of inflammation and arthritic process were measured:
serum albumin, joint X-ray, hind paw swelling, and on day 40 of the
study, bone mineral density (BMD) and bone mineral content
(BMC).
Our results showed that Ribomunyl® alone has no marked effect on
markers of inflammation and arthritis in animals with adjuvant arthri-
tis. When combined with the immunosuppressive drugs CyA and
MTX, a similar and/or better therapeutical effect was observed than
with the basic drug without Ribomunyl®. However, the effect of the
three-combination of CyA+MTX+Ribomunyl® was rather remark-
able. This combination had the most pronounced therapeutical
effect on rats with adjuvant arthritis. It significantly inhibited inflam-
matory and arthritic markers as well as BMD and BMC reductions.
Our results obtained using the adjuvant arthritis model suggest that
immunomodulatory procedures are promising. These result there-
fore need to be verified in additional animal models and markers of
cell-mediated immunity and/or cytokines involved in the induction of
this therapeutic effect should be investigated.
Rovensky J. et al.: Levamisole treatment of systemic lupus erythe-
matosus. Arthitis Rheum 1982; 24: 470-471.
Mateicka et al. : Immunomodulatory treatment with Biostim (Roussel
Uclaf) in patients with rheumatoid arthritis (Preliminary follow-up of
group with 10 patients). Rheumatologia 1992;6: 129-133.
P99
Thymosin beta4 sylphoxide: potential role in
resolution of inflammation?
JD Young, JA Gracie, RD Stevenson, AJ Lawrence, FY Liew* 
and IB McInnes
Centre for Rheumatic Diseases, University Department of Medicine,
Royal Infirmary, Glasgow, G31 2ER and *Department of Immunology,
University of Glasgow, Glasgow, G11 6NT, UK
Background: Thymosin beta 4 sulphoxide (Tb4so) has previously
been shown to be produced by glucocorticoid-treated monocytes
(1). This highly conserved intracellular peptide possesses ‘moon-
lighting’ functions in the modulation of inflammatory responses, and
may represent a natural down-regulator of inflammation in vivo. We
have investigated the mechanisms of action of Tb4so primarily on
neutrophils by studying its effects on in vitro and in vivo models.
Methods: Effect of Tb4so on assays of neutrophil function included
chemotaxis and respiratory burst. Apoptosis was measured as
Annexin-V/PI binding by FACS and macrophages were stained for
phagocytic uptake of apoptotic neutrophils by the presence of neu-
trophil-specific myeloperoxidase. In vivo, the effect of administration
of Tb4so on carrageenan-induced inflammation was eplored.
Results: Tb4so significantly inhibited fMLP-induced chemotaxis (P
< 0.005) and respiratory burst of human neutrophils in a dose
dependent manner (100% vs 23%, P < 0.05). Further, it increased
the rate of apoptosis in neutrophils (20.5 ±1.9%, P < 0.05) and
their subsequent phagocytic uptake by macrophages. In vivo,
Tb4so was a potent inhibitor of neutrophil mediated carrageenan-
induced inflammation in BALB/c mice (1.2mm vs 0.6mm P < 0.001
at 24h).
Conclusions: Tb4so is an anti-inflammatory peptide that down-reg-
ulates neutrophil mediated inflammation. The mechanism of action
appears to be, at least in part, via induction of neutrophil apoptosis
and their clearance by phagocytic macrophages. These results
suggest therapeutic potential for Tb4so.
1. Young et al 1999 Nature Med. 5:1424
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New antirheumatic effects of biphosphonate
treatment
L Konenkova, E Zonova, A Sizikov, M Korolev, S Tsareva 
and V Kozlov
Institute of Clinical Immunology SB RAMS, Novosibirsk, Russia
Recently, secondary osteoporosis therapy has been as new strat-
egy for combination treatment rheumatic disease. We have stadied
the efficacy of pamidronate treatment in the contexst of combination
therapy rheumatic disease.
The complex chek up of 27 patients with rheumatic disease:
(rheumatoid arthritis (RA) - 15, systemic lupus erythematosus (SLE)
- 3, ankylosing spondilitis (AS) - 2, Reiter syndrome (RS) - 2, sis-
temic sclerosis (SS) - 1), average age 46,2 year.
In all of them the decrease of bone mineral density were revealed.
Patients had standart non-change cytotoxic therapy, were treated
with «Aredia» (pamidronate, Novartis pharma, 30 mg i.v. infusion).
The control clinical and laboratory examination were carry out after
3 and 6 month. In 24 (88,9%) patients significant improvement was
observed: decrease the tender-joint count and swollen-joint count
of 25 percent; erythrocyte sedimentation rate decreased by 11,5
mm per hour; serum level of antiphospholipide antibodies
decreased (P < 0,05), Ig G serum levels and of cyrculating erithroid
precursors decreased (P < 0,05); CD 3+, CD 4+, CD 8+, CD 20+
levels were normalysed. The regulary pamidronate infusion may
benefit from optimisation of the antirheumatic therapy for patients
with secondary osteoporosis.
P101
Follow-up study of the effect of a three-month
course of ciprofloxacin on the late prognosis of
reactive arthritis
T Yli-Kerttula*, R Luukkainen†, U Yli-Kerttula‡, T Möttönen*, 
M Hakola§, M Korpela‡, M Sanila†, A Toivanen*
Department of Medicine, *Turku University, †Satalinna Hospital,
‡Tampere University Hospital and §Jyväskylä Central Hospital, Finland
Methods: In a randomised, double blind, placebo controlled trial,
between 1992 and 1996, 71 patients with acute reactive arthritis
(ReA) triggered by a gastrointestinal or an urogenital infection were
randomly assigned to receive ciprofloxacin or placebo twice daily
for three months. There were no statistically significant differences
in any variables during the 12-month follow-up. The aim of the
present study was to evaluate the effect of ciprofloxacin on the late
prognosis of ReA. We reviewed the long-term outcome in 56 (79%)
of 71 patients 4-8 years after the acute phase of ReA. The patients
suspected to have inflammatory back pain (IBP) were further evalu-
ated using the MRI of the sacroiliac joints. Six of the 10 patients
with chronic spondyloarthropathy (SpA) were assessed by Tc-
labelled leucocyte scintigraphy to search for the association
between gut inflammation and SpA.
Results: Two patients (7%) in the active treatment group and 10
patients (36%) in the placebo group had developed chronic
disease. Ankylosing spondylitis (AS) was diagnosed in 3 patients
(11%) in the placebo group. One patient (4%) in the active treat-
ment group had psoriatic arthritis. None in the active, 4 (14%) in the
placebo group were assessed as having undifferentiated spondy-
larthropathy (USpA, ESSG, Amor’s criteria). Three of these USpA
patients had sacroiliitis, 1 had chronic oligoarthritis and one male
patient had chronic oligoarthritis and bilateral sacroiliitis. Two
patients (7%) in the placebo group suffered from chronic enthe-
siopathy (achilles tendon). Seronegative rheumatoid arthritis was
diagnosed in one female patient in the active treatment group. One
patient (4%) in the placebo group had recurrent anterior uveitis.
MRI indicated sacroiliitis in 3 out of 5 patients with suspected IBP
(2 bilateral, 1 unilateral). Scintigraphy revealed mild (grade 1/4)
bowel inflammation in only 2 patients out of 6 with chronic SpA.
Discussion: The result is somewhat surprising considering that
antibiotics did not show any beneficial effect in the first phase of the
study. In this follow-up the occurrence of chronic development or
late sequelae was clearly more prominent in the placebo group.
P102
Early treatment of recent-onset rheumatoid
arthritis patients impairs the effect of HLA class II
antigents on the progression of joint destruction
LR Lard*, JMW Hazes*, FC Breedveld*, GMTh Schreuder†, 
RRP de Vries†, E Zanelli† and TWJ Huizinga*
Departments of *Rheumatology and †Immunohematology and Blood
Transfusion, Leiden University Medical Center, the Netherlands
Introduction: HLA class II antigens influence disease progression
as measured by extend of joint destruction in RA. This effect is sup-
posed to be caused by formation of autoreactive T-cells after pre-
sentation of (auto)antigens in the context of HLA class II. To
investigate whether in patients with recent-onset RA early DMARD
treatment could prevent the involvement of autoreactive T cells, we
analyzed the association of HLA class II and joint damage in 110
patients with early RA that were treated according to the pyramid
strategy with DMARDs and 98 patients with early RA that were
promptly treated with DMARDs at two weeks after the first visit.
Methods: DNA isolation, DRB1 typing and subtyping and DQB1
typing were performed. Extend of joint damage was measured by
the modified Sharp score of the radiographs of hand and feet.
Results: In the early treatment group the increase in the median
Sharp score in the SE+ group was 1.0 to 5.0 in contrast to 1.0 to
3.0 in the SE- group (P>0.5). However, in the pyramid group the
increase in joint damage was 0.0 to 16.0 in the SE+ group in con-
trast to 0.0 to 5.0 in the SE- group (P < 0.005). On the other hand,
in the RF+ group of the early treatment group the increase in joint
damage was 1.0 to 6.5 in contrast to 1.0 to 1.0 in the RF- group (P
< 0.005). In the pyramid group the increase in joint damage was 0.5
to 17.0 in the RF+ in contrast to 0.0 to 3.0 in the RF- group (P <
0.005).
Conclusion: This study shows that early anti-rheumatic drug treat-
ment abolishes the effect of HLA class II alleles on extend of joint
damage in early RA patients.
G. Genetics, apoptosis and miscellaneous
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The shared epitope revisited: shared epitope
negative HLA-DR alleles influence susceptibility to
rheumatoid arthritis
D Reviron, A Perdriger, E Toussirot, D Wendling, N Balandraud, 
S Guis, G Semana, P Tiberghien, P Mercier and J Roudier
INSERM EMI9940, Rheumatology Ward La Conception and EFS
Histocompatibility, Marseille, France; Rheumatology Ward and EFS
Histocompatibility Rennes, France; Rheumatology Ward and EFS
Histocompatibility, Besançon; France
We propose to classify HLA-DRB1 alleles into 3 groups: shared
epitope positive (SE), shared epitope negative with a positively
charged HLA-DR P4 pocket (XP4p)and shared epitope negative
with a negative or neutral HLA-DR XP4 pocket (XP4n). Using this
classification to analyse 3 different French populations, we find that:
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develop RA.
-XP4p/XP4p or SE/XP4n genotypes are neutral
-XP4p/XP4p or XP4n/XP4n genotypes are protective with respect
to the development of RA.
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Positivity of HLA-DRB1 rheumatoid epitope does
not predict the course of juvenile idiopathic
arthritis in Czech children
O Cinek, P Vavrincová, P Drevínek, M Suková, Š Rádová* 
and J Vavrinec
2nd Paediatric Department, 2nd Medical Faculty, *University Hospital
Motol, Prague, Czech Republic
Aims: Association of juvenile idiopathic arthritis (JIA) with HLA class
II still remains unresolved. Our study investigated whether presence
of the HLA-DRB1 amino acid 70-74 rheumatoid epitope (RE) is a
predictive factor of the disease course.
Patients and methods: We analysed 74 consecutive patients with
JIA diagnosed and classified according to ILAR criteria, aged 11.2
± 4.2 (mean ± SD), 35 boys and 39 girls. The numbers of children
having oligoarticular, polyarticular, and systemic form of JIA were
24, 40, and 10, respectively. HLA-DRB1 alleles carrying the
QRRAA, QKRAA, and RRRAA motifs of RE were typed for using
PCR with sequence-specific primers.
Results and Conclusions: There were no significant differences in
frequency of the RE, or its particular motifs, among the three forms
of JIA.
JIA JIA JIA
oligo. poly. systemic Total P value
RE negative  16 25  6  47  N.S.
RE positive 8 15  4  27  N.S.
Total 24 40 10  74
The 2x2 table were tested using chi2 test with Yate’s correction, or Fisher exact
test where appropriate.
We therefore conclude that simple positivity of the DRB1 rheuma-
toid epitope is not a likely predictive factor of the JIA course in
Czech children.
P105
In Marseille, Southern France, HLA-B2702 carries
higher risk than HLA-B2705 to develop ankylosing
spondylitis (AS)
S Guis, W Nielsen, G Boetsch, O Dutour, P Mercier, D Reviron
and J Roudier
Rheumatology Ward La Conception, INSERM EMI9940, EFS Alpes
Provence Histocompatibility, Anthropology UMR6578, Marseille, France
HLA-B27 subtypes were defined by molecular typing in 45 patients
with AS and 90 controls from Marseille. We subdivided patients
and controls in 2 subgroups, according to the birth place of their
grandparents: 19 patients and 38 controls constituted the
Spanish/North African subgroup; 26 patients and 52 controls con-
stituted the “French” subgroup. In patients from the Spanish/North
African subgroup, the frequency of B2702 was higher (74%) than
in controls from the same area (21%)pc<0.01 and the frequency of
B2705 was lower in patients (25%) than in controls (79%)
pc<0.01. In patients from the French group, the frequency of
B2702 was higher (7%) than in controls (2%)(N.S.).
Thus, in the population of Southern France, B2702 seems to carry
higher risk to develop AS than B2705.
P106
Juvenile idiopathic arthritis is associated to a
functionally active polymorphism in the SH2D2A
gene
A Smerdel, K-Z Dai, B Flato, R Ploski*, O Forre and A Spurkland
IMMI, The National Hospital, Songsvannsveien 20,0027 Oslo,
Norway; *Institute of Rheumatology, Warsaw, Poland
Objective: T cell specific adapter protein (TSAd) is involved in the
negative control of T cell activation. The SH2D2A gene encoding
TSAd is located on chromosome 1q21 which has been implicated
in susceptibility to experimental autoimmune disorders in the mouse
(chronic allergic encephalomyelitis and collagen-induced arthritis).
Recently we found that short alleles of the SH2D2A gene promoter
are associated with multiple sclerosis (MS). The aim of our study
was to investigate whether the SH2D2A promoter polymorphism
contributes to the genetic susceptibility to develop juvenile idio-
pathic arthritis (JIA).
Methods: DNA from 212 Norwegian patients with juvenile arthritis
(categorized as systemic (n = 18), poly- RF+ (n = 12), poly- RF- (n
= 61), oligo- (n = 87) and extended oligoarthritis (n = 31)) and 279
healthy unrelated Norwegian controls were genotyped for a func-
tional GA repeat polymorphism in the promoter region of SH2D2A
gene using an ABI automatic sequencing machine (ABI PrismTM
XL377)
Results: The frequencies of the two shortest alleles GA13 and
GA16 were increased among the JIA patients compared to the
control; the GA13 significantly so (0.098 vs 0.053, OR=1,97, P =
0,0063). When we divided patients into subgroups only in the RF-
positive polyarthritis group of patients there was no increases of any
of the short alleles. All other subgroups of JIA showed an increased
frequency of GA13, however only in the patients with oligoarthritis
the increased frequency of GA13 allele reached significance
(0.103, P = 0.017). When we analyzed the frequency of short
alleles in relation to the occurrence of chronic iridiocyclitis (CIC) in
the group of patients with oligoarthritis (n = 14), we found that 57%
of the these patients carry at least one short allele compared to
46% of the patients without CIC (n = 73).
Conclusion: Our data indicate that the short alleles of the SH2D2A
promoter associated with JIA patients could contribute to the
genetic susceptibility of JIA, similar what we have observed in MS. It
is possible that the short allele is a marker for particular clinical pre-
sentations. This we will investigate in further details.
P107
Analysis of VH and VL mRNA in single synovial
and peripheral B/plasma cells of patients with
rheumatoid arthritis
S Ruzickova*‡, J Vencovsky*, O Krystufkova*, Z Cimburek*, 
J Sinkora†, O Horvath‡ and T Doerner§
*Institute of Rheumatology and Laboratory of Gene Expression,
†Division of Immunology and Gnotobiology, ‡Department of
Immunology, Institute of Microbiology CAS, Prague, Czech Republic;
§Department of Rheumatology and Clinical Immunology, Charite
University Hospital, Berlin, Germany
Introduction: Synovial tissue in rheumatoid arthritis displays a
complex infiltration of many cell types like T and B lymphocytes,
plasma cells, folicular dendritic cells, macrophages etc. Presence of
B and plasma cells results in secretion of large amounts of multiple
pathologic autoantibodies.
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology ResearchAim: To analyze immunoglobulin VH and VL gene usage on the
level of mRNA from a single B or plasma cell isolated from synovium
and peripheral blood of patients with RA, in order to determine a
clonality and a molecular structure of produced antibodies.
Materials and methods: RA synovial tissue obtained during syn-
ovectomy was enzymatically digested and single synovial B/plasma
cells were sorted using immunofluorescent staining with anti-CD19
or anti-CD138. Peripheral B cells were isolated in the same way
without enzyme treatment. cDNA library from each single B and
plasma cell was generated. Two stage polymerase chain reaction to
analyse VH and VL genes was performed. VH, DH and JH or VL
and JL gene segments were assigned and somatic mutations deter-
mined by comparison with germline sequences on the V
BASE/Genbank data base. As a control peripheral B lymphocytes
from healthy donors were screened.
Results: Analysis of RA synovial mRNA transcripts revealed preva-
lence of C gamma recombinants that contained rearranged VH1,
VH3, VH4, VH5 and VH6 genes. Utilization of VH segments was
similar between RA patients and normal subjects, but the accumula-
tion of somatic mutations was elevated in RA synovial and periph-
eral B cells. We also found preferential utilization of a limited
number of VH and DH gene segments. There was increased fre-
quency of kappa light chains containing unusually long CDR3 when
compared to normal peripheral B cells.
Conclusions: Our findings are consistent with hypothesis that B cell
response RA synovium is probably antigen driven and oligoclonal.
The project was supported by grant VS96129 from Ministry of Edu-
cation, Youth and Sport in the Czech Republic.
P108
Disparate associations of the FcgammaRIIIa 158/V
variant with RA in two diverse populations
A Milicic*, R Misra†, MA Brown* and BP Wordsworth*
*Wellcome Trust Centre for Human Genetics, Headington, Oxford, UK;
†Sanjay Gandhi Institute of Medical Sciences, Lucknow, India.
Rheumatoid Arthritis (RA) is typically associated with the presence
of rheumatoid factors (RF), autoreactive immunoglobulins capable
of complexing with IgG. Receptors for IgG may play a key role in
clearance of immune complexes and the genes encoding Fcgam-
maR are potential candidates in RA.
A single nucleotide polymorphism (559 T/G) in FcgammaRIIIa
results in an amino-acid substitution (Phe/Val) at position 158
which has functional significance: 158Val has a higher affinity for
binding some IgG allotypes than 158Phe. Published studies of
associations of this polymorphism with autoimmune diseases have
given variable results.
To investigate this in RA, we have analysed this polymorphism in
two genetically diverse populations: UK Caucasians (398 RA cases
and 289 healthy controls) and Northern Indians (63 RA cases and
93 controls). Reliable typing of the 559 T/G polymorphism is greatly
hindered by the high homology between FcgammaRIIIa and the
neighbouring FcgammaIIIb, which has an invariant G at position
559. A rigorous review of the published typing methods revealed an
average error rate of over 10% of genotypes obtained by a single
method. The typing in this study was therefore done by comple-
menting two different approaches: PCR-RFLP and allele specific
PCR.
A significant reduction in the frequency of the rare GG genotype
was seen among the Indian RA cases (RR=0.2 [0.05-0.7], P <
0.02), although the allele frequencies were similar to those found in
the control cohort (see table). Among the UK Caucasians, no signif-
icant differences were found for either the allele or genotype fre-
quencies (the study had 95% statistical power to detect a genotype
relative risk of 2 and an allelic association with OR of 1.6).
We conclude that the 158Phe/Val functional polymorphism in the
FcgammaRIIIa gene does not predispose to RA in Caucasians,
although there may be an effect among Indians. Further studies will
be required to confirm this.
UK Caucasian TT TG GG Phe Val
Controls (n = 420) 172(41%) 213(51%) 35(8%) 66% 34%
RA cases (n = 401) 165(41%) 189(47%) 47(12%)  65% 35%
Indian TT TG GG Phe Val
Controls (n = 93) 44(47%) 35(38%) 14(15%) 67% 33%
RA cases (n = 63) 36(57%) 25(40%) 2(3%) 72% 28%
P109
The exchange of one single amino acid at position
71 of the DR4 b b-chain leads to significant
differences in antigen processing and presentation
of a human autoantigen chaperoned by a member
of the HSP70 family
S Roth*, N Willcox†, MP Mayer‡ and I Melchers*
*Clinical Research Unit for Rheumatology, University Medical Center,
Freiburg, Germany; †Neurosciences Group, Institute for Molecular
Medicine, University of Oxford, UK; ‡Institute of Biochemistry and
Molecular Biology, University Freiburg, Germany
The immune response to protein antigens depends on processing
by antigen presenting cells and subsequent presentation of pep-
tides to specific T cells by molecules of the MHC. In rheumatoid
arthritis (RA) there is much evidence implicating a positive genetic
association of the disease with several alleles of the DRB1 gene,
characterised by a common amino acid sequence at position 70-74
(“shared epitope”). The most frequent of these alleles is
DRB1*0401 with the sequence QKRAA, which is also present in
the E. coli protein DnaJ. DnaJ and DnaK, a member of the HSP70
family, or their homologs in other species, together form an impor-
tant chaperone machinery in bacteria and higher organisms, includ-
ing man. It was proposed that the motif QKRAA might be involved
in binding between DnaJ and DnaK, and also in binding of QKRAA-
containing DR $-chains to the human heat shock cognate protein
HSC70. We used a T cell clone with a restriction pattern similar to
the genetic association of RA, being specific for an epitope of the “-
chain of the human acetylcholine receptor (AChR). It reacted with
synthetic peptides presented by murine P388.D1 expressing the
human DRA and DRB1*0401 (71Lys) or DRB1*0408 (71Arg), with
slight preference for 0408. In contrary, the recombinant “-chain (r1-
437) or AChR obtained from human muscle extracts were much
better presented by 0401. This preference depended entirely on
the presence of E. coli DnaK or human HSC70 in the antigen
preparations; the response was lost, if HSP70 molecules were
removed, and reconstituted by their addition. We conclude that effi-
cient processing of the long protein requires the presence of a
member of the HSP70 family, which besides protecting the epitope,
interacts intracellularly well with 0401, but less well with 0408 $-
chains, and thus participates in the process of peptide loading. This
mechanism might be of importance for immune responses against
foreign antigens (advantage of DRB1*0401) as well as against
autoantigens (disadvantage of DRB1*0401).
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Time to lupus nephritis: impact of gender and
ethnicity
VA Seligman, H Li, JL Olson and LA Criswell
Department of Medicine, UCSF, San Francisco, CA 94143-0633;
Department of Human Genetics, UCD, Davis, CA 95616, USA
Objective:  There is a paucity of literature regarding the time to
development of nephritis among SLE patients. Our goal was to
define this important parameter for a large multi-ethnic cohort, with
an emphasis on the impact of gender and ethnicity.
Methods: 779 SLE patients with disease satisfying the ACR criteria
were classified as non-nephritis or definite nephritis patients based
on questionnaire and comprehensive medical record review.
Patients classified with definite nephritis fulfilled the criteria of pro-
teinuria (> 0.5 g per 24 hrs), active sediment, or renal biopsy con-
sistent with SLE. 716 (92%) were female. The ethnic distribution
was: Caucasian 453 (58.2%), Hispanic 123 (15.8%), Asian 97
(12.4%), African American 75 (9.6%), and other 36 (4.6%). The
annual rates of developing nephritis among different gender and
ethnic subgroups were derived using Kaplan-Meier estimates.
Results: The table shows gender and ethnicity based Kaplan-Meier
estimates of the proportion of patients with nephritis at designated
time intervals. The curves are significantly different for males vs.
females and Caucasians vs. non-Caucasians based on the log-rank
test. The curves for Hispanic, Asian and African American sub-
groups did not differ significantly.
Proportion with nephritis at intervals after SLE diagnosis
1 year 2 years 3 years 5 years 10 years P value *
Male .47 .51 .51 .54 .57
Female .20 .23 .24  .25 .30 8.16 x 10-7
Caucasian .15 .17 .17 .18 .20
Non-Cauc .33 .37 .40 .41 .49 6.23 x 10-14
* P value for log-rank test
Conclusions: These results are a significant contribution to the
data regarding time to development of nephritis in SLE, and empha-
size the important influence gender and ethnicity.
P111
Increased apoptosis level in late stages of
rheumatoid arthritis correlates with macrophage
number
AI Catrina, A-K Ulfgren, L Gröndal*, S Lindblad, L Klareskog
Department of Medicine, Unit of Rheumatology, Karolinska Hospital,
Stockholm; *Department of Orthopaedic Surgery, University Hospital,
Uppsala, Sweden
Introduction: Rheumatoid arthritis (RA is a chronic inflammatory
disease characterized by synovial hyperplasia and excessive
mononuclear infiltration. Altered apoptosis was proposed as a pos-
sible mechanism for cell accumulation. In vitro experiments showed
that monokines are able to inhibit synovial apoptosis in a dose
dependent manner. In this study we aim to investigate synovial
apoptosis with respect to disease duration, inflammatory cell type
and monokines expression.
Materials and methods: Synovial biopsy speciments from eleven
patients with longstanding RA (mean disease duration 21 years)
and eight with early RA (mean disease duration 5 months) have
been investigated. Samples were evaluated for apoptosis (TUNEL
method combined with morphologic analysis), cell surface markers
(CD3, CD68) and monkine expression (IL1a, IL1b, TNFa and IL6).
Tissue sections were then microscopically analysed using comput-
erised image analysis. Statistical analysis was done using Mann-
Withney test, Spearman correlation test and linear regression.
Results: Apoptosis level in RA synovium is signficiantly higher in
late cases compared with early ones (P = 0,001), while
macrophage population significantly decreases during disease
progession (P = 0,003). Macrophage score is negatively correlated
with apoptosis level (R=-0,618; P = 0,0088). In contrast, no corre-
lation could be observed between apoptosis and monokine expres-
sion or T cell score.
Discussion: Low level of apoptosis in early RA cases suggests an
ineffective cell death mechanism that ultimately contributes to cell
accumulation into the joint and propagation of the inflammatory
response. Apoptosis is restored during disease progression, in par-
allel with a decrease of the macrophage number. These findings
suggest apoptosis as a possible marker for early RA and a promis-
ing therapy target.
P112
Protein kinase C inhibition dephosphorylates the
ribosomal P proteins while inducing apoptosis in
Jurkat cells and peripheral human T cells
X Wu, S Schatt* and P Hasler
Forschungslabor, Rheumatologische Universitätsklinik, Felix Platter
Spital; *Pränatale Forschung, Universitätsfrauenklinik, Kantonsspital,
Basel, Switzerland
The control of phosphorylation of CK2 target sites has long been a
matter of controversy. We have demonstrated that phosphorylation of
the ribosomal P protein CK2 sites is reliably measurable by 2D
western blotting of whole cell lysates. Physiologically, phosphorylation
of the CK2 sites of the P proteins is necessary for the elongation
phase of protein translation, which can be used as an indirect para-
meter of P protein function. Based on previous data showing that
crosslinking of CD95 and hyperthermia lead to the dephosphorylation
of the ribosomal P protein CK2 phosphorylation sites and decreased
protein synthesis, which was associated with the induction of apopto-
sis in Jurkat cells, we examined whether similar mechanisms are initi-
ated when apoptosis is induced by inhibition of the PKC pathway. In
Jurkat cells and freshly isolated peripheral blood T cells, rapid dephos-
phorylation of the ribosomal P proteins P0, P1 and P2 was induced
by low concentrations of chelerythrine, a specific inhibitor of PKC.
Neither of the specific PKC activators thymeleatoxin or PMA were
able to prevent the dephosphorylation. Inhibition of intracellular Ca2+
release by TMB-8 also induced dephosphorylation of the P proteins,
which is compatible with the requirement of intracellular Ca2+ for
classical PKC isozyme activity. Chelerythrine also induced apoptosis
in Jurkat cells, which was prevented by zVAD-fmk and ZnCL2, though
these agents did not inhibit the dephosphorylation of the P proteins.
The effects of chelerythrine were not due to altered CK2 activity, and
there was no evidence that the cAMP-dependent PKA, ornithine
decarboxylase, or protein phosphatase 2A pathways were involved in
signaling leading to P protein dephosphorylation. The dephosphoryla-
tion of the P proteins was accompanied by markedly reduced whole
cell protein synthesis, which, in parallel with dephosphorylation of the
P proteins, was not affected by zVAD-fmk or ZnCl2. Freshly isolated
peripheral blood T cells showed the same pattern of responses as
Jurkat cells, with the exception that chelerythrine did not induce apop-
tosis in resting T cells.
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology ResearchOur results demonstrate that inhibition of Ca2+ dependent PKC
activity decreases the phosphorylation of the P protein CK2 sites
and protein synthesis. The failure of caspase inhibition to prevent
the dephosphorylation and decreased protein synthesis due to PKC
inhibition indicates early divergence of PKC and caspase-depen-
dent signaling in T cells and Jurkat cells.
P113
Nucleosome binding by serum amyloid P
component from SLE patients
NHH Heegaard, L Rahbek and C Recke
Department of Autoimmunology, Statens Serum Institut, Copenhagen,
Denmark
There is evidence in favor of apoptosis dysfunction being involved in
the pathogenesis of SLE. Since mice deficient in the nucleosome-
binding protein: serum amyloid P component (SAP) develop antinu-
clear immunity and nephritis it is possible that impaired clearance of
nuclear material from apoptotic cells is the key defect. We therefore
developed a solid-phase assay for the binding of SAP to nucleo-
somes and investigated the nucleosome binding characteristics of
SAP from 20 different SLE patients as compared with normal
donors. We could not demonstrate any significant differences
between the groups and therefore the functions of other pentraxins
(such as C-reactive protein) or DNA binding molecules (such as
C1q) will be examined in future studies.
P114
Nucleosome is a necrosis inducer for lymphocytes:
consequences in systemic lupus erythematosus
P Decker and HG Rammensee
Institute for Cell Biology, Department of Immunology, Auf der
Morgenstelle 15, D-72076 Tübingen, Germany
Nucleosome is a major autoantigen in systemic lupus erythemato-
sus. It is composed of DNA (multiple of 180 bp) and the five his-
tones H1, H2A, H2B, H3 and H4. Previous works have shown the
presence of circulating nucleosome in sera of lupus patients, which
could be due to increased apoptosis or impaired phagocytosis,
both resulting in secondary necrosis and release of nucleosome.
On the other hand, it was shown that nucleosome could bind to the
surface of cells, such as lymphocytes. In order to better understand
the role of this circulating complex, we analysed the effect of puri-
fied nucleosome on living murine lymphocytes. Here we show that
nucleosome induces necrosis of cells, and not apoptosis, as
assessed by different techniques. Similar results were obtained with
mono-, di-, tri- and poly-nucleosomes. Moreover, this effect is time
and dose dependent, is impaired when nucleosome is heat-inacti-
vated and is not observed with other non related purified proteins.
Finally, we analysed in more details the sensitivity of B and T cells to
nucleosome. These results suggest that nucleosomes released by
apoptotic cells could induce necrosis of neighbouring cells, thus
allowing the release of cell contents in high amounts. This phenom-
enon would act as an “amplification loop” and could explain how the
peripheral tolerance is broken and is in agreement with inflammatory
responses which are normally not associated with apoptosis.
P115
Anti-Fcg g receptor (Fcg gR) autoantibodies (Ab) delay
apoptosis of polymorphonuclear cells (PMN) in
systemic autoimmune diseases by inducing the
production of G-CSF and GM-CSF
V Durand, Y Renaudineau, J-O Pers, P Youinou and C Jamin
Brest University Medical School, Brest, France
FcgRIIIb is expressed by PMN, and cell-free receptor has also been
found circulating in body fluids. We have examined 222 patients
with rheumatoid arthritis (RA), systemic lupus erythematosus and
primary Sjögren’s syndrome and classified anti-FcgR auto-Ab into
three groups, based on the results of an indirect immunofluores-
cence (IIF) test and an ELISA : IIF+/ELISA+ (group A), IIF+/ELISA-
(group B) and IIF-/ELISA+ (group C). PMN-binding Ab, i.e. groups
A and B, prolonged the survival of PMN by delaying spontaneous
apoptosis, and reduced adhesiveness and respiratory burst of these
cells. Interestingly, recombinant non-glycosylated and purified gly-
cosylated FcgR produced similar effects as the related auto-Ab.
To delineate the mechanism(s) by which the PMN life span is pro-
longed, we studied the response of PMN to F(ab’)2 fragments of
anti-FcgR (CD16) monoclonal Ab. CD16 engagement decreased
apoptosis and prevented the up-regulation of b2 integrins, particu-
larly CD11b which is the a chain of complement receptor 3, and
CD18 which is its b chain.
The expression of mRNA for G-CSF and GM-CSF was induced.
Release of these chimiokines followed CD16 stimulation, suggesting
an autocrine involvement of survival factors in the rescue of PMN.
The levels of G-CSF and GM-CSF paralleled the amounts of CD16
monoclonal Ab used to stimulate the cells. This set off a partial
reduction of caspase 3 activity and was associated with down-
expression of Bax. It was shown that anti-G-CSF and anti-GM-CSF
Ab inhibited these events, while anti-TNFa was ineffective.
Overall, apoptosis of aged PMN can be modulated by signalling
through FcgR, which may occur in patients with PMN-binding auto-
Ab. This might be particularly relevant in the synovial fluid of patients
with RA.
P116
Phage display as a tool to study human
autoantibodies and autoantigens in systemic
autoimmune disease. Selection of recombinant
(auto)-antibodies specific for human autoantigens
in rheumatic disease (RA, SLE, SSc) from human
autoimmune-patient and immunized chicken
derived phage display libraries
J Raats*, W Degen*, S Litjens*, I Bulduk*, G Mans*, E Wijnen*, 
S Zampieri*, W Roeffen†, F Van den Hoogen‡
and WJ van Venrooij*
*Department of Biochemistry, University of Nijmegen, P.O. Box 9101,
6500 HB Nijmegen, The Netherlands; †Department of Medical
Microbiology, Section Parasitology, University Hospital of Nijmegen,
P.O. Box 9101 6500 HB, Nijmegen, The Netherlands; ‡Department of
Rheumatology, University Hospital of Nijmegen, P.O. Box 9101, 6500
HB, Nijmegen, The Netherlands
One important property of the immune system is its ability to dis-
criminate between self and non-self antigens. The unresponsive-
ness of the immune system to self-antigens is called self-tolerance,
loss of this property results in immune reactions against own or
autologous antigens. Such reactions often are associated with an
autoimmune disorder and eventually may contribute to clinical mani-
festations. The humoral immune response plays a crucial role in the
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mune diseases are associated with distinct profiles of autoantibod-
ies. During the last five years there has been a growing interest in
finding possible connections between apoptosis and autoimmunity.
It has been hypothesized that the recognition, uptake, processing,
or presentation of modified self-antigens may promote autoantibody
production. At present, many autoantigens have been found that are
modified (i.e. cleaved, phosphorylated or dephosphorylated) during
apoptosis. Using autoimmune patient sera in immunoprecipitation
and Western blotting assays with cell extracts derived from non-
apoptotic and apotptic cells, we identified sera reactivities specific
for (novel) modifications of autoantigens.
In this paper we give an overview of our studies on human recombi-
nant autoantibodies derived from patients suffering from rheumatic
diseases. Furthermore, we describe the generation of recombinant
chicken antibodies specific for human autoantigens that will also be
used to study these antigens and (apoptotic) modifications thereof
in more detail.
We selected human recombinant antibodies from patient phage
display scFv combinatorial antibody libraries (complexity of 107 or
higher) derived from peripheral blood or bone marrow lymphocytes
of patients with rheumatoid arthritis (RA), systemic lupus erythemato-
sus (SLE), and scleroderma (SSc). Next to the human patient
libraries we also used chicken libraries made from spleens of animals
immunized with 7 human (auto)antigens simultaneously. Screening
of both patient and animal derived libraries with recombinant or puri-
fied autoantigens resulted in several recombinant monoclonal human
and chicken (auto)-antibodies. From our SLE patient libraries,
autoantibodies against U1snRNP components U1-A, U1-C, U1-70k
and U1-RNA were selected. Moreover, from our SLE libraries we
selected anti Ro52 and anti ribosomal P protein antibodies, and from
both our SLE and scleroderma libraries we selected anti-La and anti
a-fodrine recombinant antibodies. From our RA patient libraries anti-
bodies specific for RA related peptides were obtained. All human
scFv clones obtained were characterized by ELISA, immunoprecipi-
tation assays, western blotting, epitope mapping and of some clones
the affinities were measured and competition experiments with
patient sera were performed. Sequence analysis was performed to
study the germline usage. All chicken clones were sequenced and
analyzed by LIA, Western blot and ELISA.
We will discuss characteristics of some of the selected scFv’s i.e.
epitope mapping, germline gene usage, and competition experi-
ments with patient sera.
The phage autoantibodies selected from autoimmune patient
libraries were also analyzed for their specificity for (apoptotically)
modified forms of their target autoantigens by Western blotting and
immunprecipitation assays using apoptotic cell-extracts. Some anti-
La, anti-70K and anti-RA peptide scFv’s recognized (apoptotically)-
modified forms of their target antigens.
Conclusions: The use of antibody phage display proves to be an
extremely helpful technique in studying autoantibodies and autoanti-
gens. Modifications of autoantigens (by apoptosis and/or necrosis)
seem to play a major role in the ontogeny of autoimmune diseases.
Currently, by using antibody phage display libraries in combination
with patient sera we continue our search for possible modifications
of autoantigens involved in the ontogeny of autoimmune disease.
P117
Diagnostic value of synovial fluid analysis in
pigmented villonodular synovitis (PVS)- a proposal
of diagnostic criteria.
I Zimmermann-Górska, M Puszczewicz 
and G Bialkowska-Puszczewicz
Department of Rheumatology and Rehabilitation, Karol Marcinkowski,
University of Medical Sciences, Poznañ, Poland
PVS is an idiopathic lesion that affects the synovial
joints,tendons,sheats and bursea through the production of tumour-
like growths. Diagnosis of PVS is difficult. Arthroscopy and biopsy
together with microscopic examination are usually a base. Accord-
ing to our experience, cytologic features of synovial fluid are a very
useful diagnostic tool in PVS.
Material and methods: Synovial fluids (SF) from the joints of 14
patients with biopsy-proven PVS were examined. Moreover in all the
patients features of the disease were confirmed in surgical spec-
imes. Synovial fluids were divided into three samples, for physico-
chemical analysis, bacteriological and cytologic findings, and
placed in sterile tubes. For cytological examination MGG staining
was used.
Results: SF analysis had revealed an inflammatory character of effu-
sion. In all the cases synovial fluids were bloody and fragments of
synovial villi in their sediments were observed as well as multinucle-
ated giant cells, pseudomalignant cell, macrophages with phagocy-
tized hemosiderin , foam cell and a few synoviocytes. Moreover the
fat crystals were seen, under polarized light.
Conclusion: Cytological features of synovial fluid in PVS are in par-
allel with results of microscopic examination of joints tissues. In our
opinion SF analysis should be the first step in the diagnopstic pro-
cedure in PVS. We propose the following criteria:
Major:
1. the presence of bloody fluid with fragments of synovial villi in sed-
iment
2. macrophages containing hemosiderin
3. pseudomalignant cells
Minor:
1. multinucleated giant cells
2. foam cells
3. fat crystals
The diagnosis of PVS can be establish if all the major and at least
one of the minor criteria are fulfilled.
P118
Analysis of anti-Ro52 antibodies in sera of healthy
subjects
C Zimmermann, G Fabini, E Höfler, JS Smolen and G Steiner
2nd Department of Internal Medicine, Lainz Hospital and 
3rd Department of Internal Medicine, University of Vienna, Vienna,
Austria
Anti-Ro/SSA antibodies (ab) are directed to two proteins, Ro60
and Ro52. While anti-Ro60 aab are predominantly found in patients
with SLE or primary Sjögren´s syndrome, anti-Ro52 ab can be
detected also in sera of healthy subjects. These antibody escape
detection by ELISA or immunoblotting and can be found only in
immunoprecipitation assays. Recently, an unexpected interaction of
Ro52 with IgG has been reported which appeared to occur inde-
pendently of the antigen binding site. To investigate this unusual
interaction, serum IgG was covalently bound to protein A sepharose
(PAS) or an anti-IgG argarose column was used and incubated with
HeLa cytoplasmic extracts and various Ig fractions as competitors
(IgG1-4, IgM, Fab, F(ab)2, Fc, pFc¢, Fc¢, C1q). Proteins bound to
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology Researchimmobilized IgG were detected by immunoblotting using anti-Ro/La
positive patients sera and a monospecific anti-Ro52 antibody for
identification of bound proteins.
In these assays Ro52 only was bound to the column-IgG complex.
Binding of Ro52 was inhibited by total IgG and Fc, but not Fab,
F(ab)2 or C1q.
In another experiment IgG anti-IgM was complexed with PAS and
Ro52 binding was demonstrated. This binding was partly inhibited by
IgM, suggesting an unspecific interaction of Ro52 with the IgG-Fc.
This antigen/antibody reaction is seen in all IgG subclasses binding
to the PAS, namely IgG1, IgG2 and IgG4, with IgG2 reacting very
strongly with the Ro52.
In conclusion, these data show an interaction of Ro52 with all types
of IgG of healthy persons. This interaction appears therefore to be
substantially different from normal antigen-antibody interaction. The
biological function of this interaction is unclear.
Abstracts of invited lectures
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The impact of DNA chip technology on molecular
medicine
KK Wilgenbus
Boehringer Ingelheim R&D, Austria
The recent popularity of DNA chip technology has been fostered by
the increasing demand for new tools, which allow the simultaneous
analysis of large numbers of nucleic acid hybridization experiments
in a timely fashion. The development of DNA chip-based assays has
been strongly driven by modern approaches aiming at the compre-
hensive analysis of multiple gene mutations and expressed
sequences. The broad range of current DNA chip applications
include the detection of pathogens, the measurement of differences
in the expression of genes between different cell populations as
well as the analysis of genomic alterations such as sequence or
copy number alterations of disease related genes or single
nucleotide polymorphisms. A brief overview of the impact of DNA
chip technology on the field of Molecular Medicine will be provided,
followed by a more detailed presentation on DNA chip technology
for large-scale differential expression profiling.
L2
Protein microarray characterization of the
autoantibody response in systemic lupus
erythematosus and related diseases
W Robinson*, C DiGennaro*, W Hueber*‡, D Fong*, B Haab*, 
D Hirshberg*, S Muller#, GJ Pruijn†, WJ van Venrooij†, 
JS Smolen‡, PO Brown*, Lawrence Steinman*, and Paul J. Utz*
*Stanford University, School of Medicine, Stanford, CA, USA; #Institut
de Biologie Moleculaire et Cellulaire, Strasbourg, France; †Katholieke
Universiteit Nijmegen, The Netherlands; ‡University of Vienna, Austria
Systemic lupus erythematosus (SLE) is the prototypical systemic
autoimmune disease characterized by production of autoantibodies
against a wide range of nuclear self-antigens. These antigens
include DNA, histone and several constituents of the RNA splicing
complex. Binding of autoantibodies to their specific antigens leads
to tissue injury, ultimately resulting in end-organ damage. Individual
SLE patients are known to have considerable variability in their spe-
cific autoantibody response patterns, and this in part correlates with
their clinical manifestations. We have refined protein microarray
technology and utilized it to study variation in the autoantibody
response between individual SLE patients. We have further
extended these studies to other diseases including primary biliary
cirrhosis, rheumatoid arthritis, scleroderma, mixed connective tissue
disease, multiple sclerosis, diabetes mellitus, and the myositides.
Protein microarrays are produced by the application of thousands of
proteins and peptides to the surface of a glass microscope slide
using a robotic arrayer. We have developed an array containing the
major SLE antigens including dsDNA, ssDNA, Sm, Ro, La, histones,
and Sm/RNP, along with several other common disease-specific
autoantigens. Arrays are probed with serum from disease or control
patients, followed by incubation with fluorescently labeled, anti-
human secondary antibody. Our array analysis reveals distinct
autoantigen response patterns in individual SLE patients. ELISA,
immunoprecipitation, and western blot analysis validate our array
results. Protein autoantigen arrays represent a powerful tool which
may be used to perform comprehensive studies of the breadth of
epitope spreading, as well as the fine specificity of the autoantibody
response. The large scale of our protein arrays allows us to examine
reactivity patterns against a much wider range of autoantigens than
was previously possible with more traditional methods. Our ability to
distinguish autoantibody specificity patterns using autoantigen
microarrays will provide further insight into the role of autoantibod-
ies in disease progression and pathogenesis in subsets of SLE
patients with distinct autoantibody responses.
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L5
The integration of functional genomics,
combinatorial chemistry and nanotechnology into
a miniaturized drug discovery process
M Auer
Novartis Forschungsinstitut GmbH, Dermatology, Fluorescence based
HTS-Technology Program, Vienna, Austria
Future concepts in miniaturized HTScreening technologies will con-
centrate on making optimal use of the two emerging technologies,
combinatorial chemistry and functional genomics. To effectively
exploit compounds from highly-parallel combinatorial synthesis and
the high number of new target proteins from functional genomics,
Novartis and Evotec BioSystems developed the CONA-BSP (con-
focal nanoscanning – bead scanning picking technology) as a novel
high throughput – low hit-rate HTS process. In combination with the
Novartis proprietary AIDA-Technology, quantitative on-bead confo-
cal fluorescence screening can be combined with off-bead confir-
mation via a series of fluorescence techniques such as
fluorescence anisotropy, or rotational correlation time applied to
equilibrium binding studies.
Single molecule fluorescence spectroscopy and confocal
nanoscanning/AIDA technology provide an optimal combination for
a miniaturized automated uHTS process with high mechanistic res-
olution in functional and coupled assay systems.
References
Fluorescence correlation spectroscopy: Lead discovery by miniatur-
ized HTS
M. Auer, Keith J. Moore, F-J. Meyer-Almes, R. Guenther, A. J. Pope,
K. A. Stoeckli. Drug Discovery Today, 1998, 3, 457-465, Review.
Auer M and Gstach H. Fluorescent dyes (AIDA) for solid phase and
solution phase screening. United States Patent, WO 00/37448
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Available onlinehttp://arthritis-research.com/supplements/3/SAMeyer-Almes FJ. and Auer M. Enzyme inhibition assays with fluores-
cence correlation spectroscopy: A new algorithm for the derivation
of kcat/Km and Ki values at substrate concentrations lower than the
Michaelis Menten constant. Biochemistry 2000; 39(43): 13261-
13268.
The integration of single molecule detection technologies into minia-
turized drug screening: Current status and future perspectives.
C. Bühler, K. Stöckli, and M. Auer
Review in press: Fluorescence Spectroscopy: Valeur/Brochon,
Trends in Fluorescence Spectroscopy (Springer Verlag, 2001).
L6
DNA therapeutics: a feasible option for treatment
of inflammatory diseases?
E Wagner
Boehringer Ingelheim Austria, Dr Boehringer Gasse 5-11, A-1121
Vienna, Austria
Recombinant proteins can be very potent, but their therapeutic
application can be strongly hampered by inappropriate distribution,
dosage, kinetics or toxic effects. Targeted delivery of proteins such
as cytokines would be strongly desirable.
DNA therapeutics comprise the delivery of genetic information on a
piece of DNA as therapeutic prodrug. This prodrug can be tran-
scribed and translated into a protein (the actual drug) within the
target cells, preferably in a tissue-specific and bio-regulated fashion.
Basically, two types of nonviral gene transfer systems [1] have been
developed: particle-based systems, with DNA packaged into
cationic lipids or polymers; and physical techniques which are
based on combining DNA with a physical device. Intramuscular
administration of naked DNA has already proven as interesting
concept for vaccination [2], despite the low efficiency of the
method. Two physical device technologies, electroporation and the
gene gun, were found to enhance gene expression levels up to
1000- fold over injection of naked DNA alone. This enhancement
has also recently been shown by several groups to trigger immune
responses against defined antigens in several species [3].
We have generated particle-based systems that can target gene
delivery and expression into distant target tissues. We use DNA
polyplexes conjugated with cell-binding ligands such as transferrin
for receptor-mediated endocytosis. The surface charge of com-
plexes is masked by covalent coating with polyethylenglycol (PEG).
Tumor targeting has been demonstrated in mouse models after sys-
temic administration. With systemically applied tumor necrosis
factor (TNF) alpha gene, tumor necrosis and regression of tumors
was observed, but no systemic TNF-related side effects. Opportuni-
ties to apply local or systemic DNA therapeutics for inflammatory
diseases will be discussed.
References
1 L. Huang, M.C. Hung, E. Wagner (Eds), "Non-Viral Vectors for
Gene Therapy", Academic Press (1999).
2 Wang R, et al. Induction of antigen-specific cytotoxic T lympho-
cytes in humans by a malaria DNA vaccine. Science 282 (1998)
476-480.
3 Widera G, et al. Increased DNA vaccine delivery and immuno-
genicity by electroporation in vivo. J. Immunol. 164 (2000) 4635-
4640.
4 Kircheis R, et al. Polycation-based DNA complexes for tumor-tar-
geted gene delivery in vivo. J. Gene Medicine 1 (1999) 111-120. 
L7
Chromosome segregation one hundred years after
Mendel´s rediscovery
K Nasmyth
IMP, Dr. Bohr-Gasse 7, A-1030 Vienna, Austria
In eukaryotic cells, replicated DNA strands remain physically con-
nected until their segregation to opposite poles of the cell during
anaphase. This “sister chromatid cohesion” is essential for the align-
ment of chromosomes on the mitotic spindle during metaphase.
Cohesion depends on a multisubunit protein complex called
cohesin, which possibly forms the physical bridges that connect
sisters. Proteolytic cleavage of cohesin’s Scc1 subunit at the
metaphase to anaphase transition is essential for sister chromatid
separation and depends on a conserved protein called separin. We
show here that separin is a cysteine protease related to caspases
and that it alone can cleave Scc1 in vitro. By replacing one of
Scc1’s cleavage sites by that for a different site specific protease,
we show that cleavage of Scc1 in metaphase arrested cells is suffi-
cient to trigger the separation of sister chromatids and their segre-
gation to opposite cell poles.
L8
Genetic analysis of the pentraxin genes in SLE
AI Russell, CA Roberton, S Chadha, DS Cunninghame Graham
and TJ Vyse
Imperial College, Hammersmith Hospital, Du Cane Road, London
W12 0NN, UK
The aetiology of systemic lupus erythematosus (SLE) is unknown.
However, there is good evidence to support a genetic contribution
in lupus, including a number of mouse strains that are genetically
predisposed to develop lupus. Several groups have published
genome-wide mapping studies on multi-case families. More than 15
intervals have been linked with SLE – they are large enough to
contain several hundred genes; the aetiologic polymorphisms con-
tained within them remain to be established.
We are establishing a large collection of single case nuclear fami-
lies with the aim of fine mapping the aetiologic polymorphisms.
Using a candidate gene approach, we have examined several
genes, which lie within the linked intervals. First, we identified
genetic markers in the candidate genes. The inheritance of the
markers in our nuclear families was then tested using the program
TRANSMIT which compares the observed and expected rates of
transmission of marker alleles (or haplotypes) from parents to off-
spring. A marked distortion away from random segregation indi-
cates association with disease.
We have hypothesised that genetic variation in the pentraxin genes,
C-reactive protein (CRP) and serum amyloid component P (SAP)
predisposes to SLE. These two genes are tightly linked on chromo-
some 1q21-23, a region linked to human SLE. Other evidence
implicating these includes the defective CRP response in SLE and
the presence of antinuclear autoimmunity in Sap knockout mice. We
identified five novel single base pair polymorphisms (three in CRP
and two in SAP) and tested these for evidence of association. Indi-
viduals from 354 families were studied.
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology ResearchTable. Transmission of Markers across CRP and SAP to SLE Probands
Marker Allele Observed Expected Chi square P value
CRP C1122T 1 461 460 0.01 > 0.05
2 183 183
CRP G1979A 1 416 428 2.6 > 0.05
2 222 219
CRP G808C 1 359 361 0.74 > 0.05
22 52 2
SAP G-246A 1 490 491 0.06 > 0.05
2 146 144
SAP G902T 1 354 356 0.47 > 0.05
22 82 6
These data provide no evidence for a genetic contribution to human
SLE from the pentraxin genes. When haplotypes across this locus
were examined there was similarly no evidence of association. The
defective CRP response in human SLE is unlikely to be related to
variation at the CRP locus itself.
L9
The role of DNA in the pathogenesis of SLE
DS Pisetsky
Duke University Medical Center, USA
Systemic lupus erythematosus (SLE) is a prototypic autoimmune
disease characterized by antibodies to DNA. These antibodies
serve as markers of diagnosis and prognosis as well as serological
markers of disease pathogenesis. While designated as autoantibod-
ies, SLE anti-DNA target sites that are widely conserved among
DNA of both self and foreign origin. This crossreactivity, a feature
that appears common among SLE antinuclear antibodies, raises the
possibility that immune responses to DNA may arise from stimula-
tion by foreign DNA. This possibility has gained credence from
observations that DNA from bacteria has potent immunological
properties. These properties include polyclonal B cell activation and
induction of cytokines such as IL-12. Furthermore, sera of normal
human subjects contain anti-DNA antibodies which selectively bind
to DNA from certain bacterial species. Immunization experiments in
mice fully support the possibility that bacterial DNA can initiate or
sustain SLE anti-DNA production. Recently, studies in mice have
demonstrated that self DNA has immunological activity and is not
inert as has been widely assumed. As shown in in vitro experiments,
DNA from mammalian species including human and bovine, can
inhibit cytokine production induced by bacterial DNA and, in certain,
systems, the cytokine response to LPS. As such, self DNA may play
a regulatory role in immunity, inhibiting response in settings of tissue
inflammation or destruction where self antigens are released from
cells. These considerations suggest that anti-DNA responses in
SLE could result from a crossreactive response to foreign DNA or
an aberrant response to self DNA in which the inhibitory signals of
mammalian DNA are insufficient or overcome. In either instances,
models of SLE must take into account that DNA plays an active role
in immune responses and, depending upon species and base com-
position, may be stimulatory or inhibitory.
L10
Gene expression analysis of Th1 and Th2 cells:
clues to homing in inflammation
F Sinigaglia
Roche Milano Ricerche, Milan, Italy
Many pathological processes, including rheumatoid arthritis, are
associated with the presence of specialised subsets of T helper
cells at the site of inflammation. Understanding the genetic program
that control the functional properties of Th1 versus Th2 cells may
provide insight into the pathophysiology of inflammatory diseases.
We compared the gene expression profiles of human Th1 and Th2
cells using high-density oligonucleotide arrays with the capacity to
display transcript levels of 6000 human genes. This approach
resulted in the identification of more than 200 differentially
expressed genes, including genes controlling the different steps of
lymphocyte migration and homing1. A subset of these genes was
further upregulated by exposure of differentiated Th1 cells to IL-12.
Functional assays and in vivo expression of selected genes have
validated the biological relevance of this study. Our results provide
novel insight into the transcriptional program controlling the differ-
ential ability of T helper subsets to traffic and localise to sites of
inflammation.
1Rogge et al. 2000. Nature genetics 25:96-101
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From perinuclear factor to citrulline, a target
structure for autoantibodies in rheumatoid
arthritis
G Serre
Department of Biology and Pathology of the Cell, INSERM CJF 96-02
IFR30, Purpan School of Medicine, Toulouse III University, Toulouse,
France
Antiperinuclear factor (APF) and the so-called “antikeratin antibod-
ies” (AKA), have been described 37 and 22 years ago, respectively.
Now, their diagnostic value in Rheumatoid Arthritis (RA) was con-
firmed on thousands of patients.
In the past few years the molecular targets of these RA-specific
serum IgG antibodies were identified : first those of AKA were
shown to be acidic variants of filaggrin in human epidermis and
(pro)filaggrin-related proteins in rat oesophagus epithelium ; secon-
darily the target of APF in human buccal mucosa cells was demon-
strated to correspond to tissue-specific forms of (pro)filaggrin. APF
and AKA were proved to constitute two overlapping subgroups of
antibodies belonging to a same family of antifilaggrin autoantibodies
(AFA).
All these AFA-targetted proteins were demonstrated to be deimi-
nated i.e. having their arginyl residues (arginines involved in peptidic
bonds) transformed into citrullyl residues (citrullines). This post-
translational enzymatic modification is due to a peptidyl-arginine
deiminase. AFA are unreactive with native recombinant human filag-
grin but become highly reactive after enzymatic deimination of the
protein. Moreover synthetic peptides derived from the human filag-
grin sequence are reactive with AFA only when their arginyl
residues have been substituted by citrullyl residues (citrullinated
peptides). Therefore AFA are directed to peptidic epitopes in which
citrullyl residues play a pivotal role, nevertheless the neighbouring
residues are important since certain are permissive and participate
to generation of AFA epitopes whereas others are non-permissive
and make the reactivity with AFA impossible.
Identification of the molecular targets of AFA allowed the develop-
ment of new tests for their detection, using either (pro)filaggrin
extracted from epithelia or deiminated recombinant filaggrins and/or
filaggrin-derived citrullinated peptides. Several of these new tests
prove to be highly efficient in the diagnosis of RA and largely more
performant than the reference APF and AKA tests. They show that
at least 2 out of 3 RA patients develop the very specific antifilaggrin
B autoimmunity.
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Available onlinehttp://arthritis-research.com/supplements/3/SAIn rheumatoid synovial tissue, (pro)filaggrin was confirmed to be
absent, however several deiminated proteins were detected.
Among them, only two proteins were highly reactive with AFA. They
were identified as the alpha and beta chains of fibrin. Deiminated
fibrin therefore appears as the major synovial target of AFA and
probably correspond to their genuine target.
In RA patients, the proportion of AFA among IgG was recently
found to be largely higher in the synovial interstitium than in synovial
fluid and serum, moreover AFA were shown to be secreted by
plasma cells of the rheumatoid pannus.
These results strongly suggest that the chronic conflict between the
locally secreted AFA / antifibrin autoantibodies and the fibrin
deposits particularly prominent in the RA synovium, play a central
role in the pathophysiology of RA.
L13
Anti-inflammatory activity of statins: potential use
in the anti-phospholipid syndrome
PL Meroni
Department of Internal Medicine, IRCCS Istituto Auxologico Italiano,
University of Milan, Italy
Background: Hydroxymethylglutaryl Coenzyme A reductase
(HMGCoA-red) inhibitors are cholesterol lowering drugs which
display pleiotropic effects on several cell types including endothelial
cells (EC). Patients with antiphospholipid syndrome (APS) are char-
acterized by the persistent presence of antiphospholipid antibodies
(aPL) and by a high incidence of recurrent thrombotic events. aPL
have been demonstrated to bind and activate cultured human EC
thus contributing to a prothrombotic state. We evaluated the ability
of HMGCoA inhibitors to affect the EC activation induced in vitro by
aPL and in particular by antibodies reacting with the PL-binding
protein b2 glycoprotein I (b2GPI). Both human monoclonal IgM and
polyclonal IgG anti-b2GPI antibodies were used. EC activation was
evaluated as adhesion molecule (ADM) expression and cytokine
production.
Methods: ADM expression was evaluated by a cell ELISA. EC were
incubated with human recombinant (hr) IL-1b (50 U/ml), hr TNFa
(10 ng/ml), LPS (20 ng/ml) or with human anti-b2GPI antibodies
(100 mg/ml) for 4 hr for E-Selectin expression and for 20 hr for
ICAM-1 evaluation. Cytokine production was investigated by using
the RiboQuantTM in vitro transcription assay to measure IL-6 mRNA
expression. As control, EC monolayers were incubated with irrele-
vant monoclonal or polyclonal antibodies or medium alone. The
same experiments were carried out with EC monolayers pre-incu-
bated overnight with fluvastatin or simvastatin (1-10 mM) in the
absence or presence of mevalonate (100 mM). E-Selectin specific
NFkB expression was also evaluated by the gel-shift assay.
Results: Both statins inhibited in a concentration dependent-
manner the ADM expression induced by anti-b2GPI antibodies as
well as those induced by the other agonists, being fluvastatin more
efficient than simvastatin. Fluvastatin also down-regulated the
mRNA expression specific for IL-6 and significantly inhibited E-
Selectin NFkB DNA-binding. The simultaneous addition of meval-
onate to fluvastatin completely prevented the drug inhibitory effect.
Conclusions: These data demonstrates for the first time that statins
(and particularly fluvastatin) are able to inhibit an endothelial pro-
adhesive and pro-inflammatory phenotype induced by different
stimuli including anti-b2GPI antibodies or pro-inflammatory
cytokines. Altogether these findings suggest a potential usefulness
for statins in the prevention of the APS pro-atherothrombotic state.
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The place of mitochondria in apoptosis
G Kroemer
CNRS-ULR1599, Institut Gustave Roussy, F-94805 Villejuif, France
Apoptosis research has recently experienced a change from a para-
digm in which the nucleus determined the apoptotic process to a
paradigm in which caspases and, more recently, mitochondria con-
stitute the center of death control. Mitochondria undergo major
changes in membrane integrity before classical signs of cell death
become manifest. These changes concern both the inner and the
outer mitochondrial membranes, leading to the dissipation of the
inner transmembrane potential and/or the release of intermembrane
proteins through the outer membrane. An ever increasing number of
endogenous, viral, or xenogeneic effectors directly act on mitochon-
dria to trigger permeabilization. At least in some cases, this is
achieved by a direct action on the permeability transition pore
complex (PTPC), a multi-protein ensemble containing proteins from
both mitochondrial membranes which interact with pro- and anti-
apoptotic members of the Bcl-2 family. At present, it is elusive
whether opening of the PTPC is the only physiological mechanism
leading to mitochondrial membrane permeabilization. Proteins
released from mitochondria during apoptosis include caspases
(mainly caspases 2, 3 and 9), caspase activators (cytochrome c,
hsp 10, Smac/DIABLO), as well as a caspase-independent death
effector, AIF (apoptosis inducing factor). Apoptosis inducing factor
(AIF) is encoded for by one single gene located on the X chromo-
some. AIF is ubiquitously expressed, both in normal tissues and in a
variety of cancer cell lines.
The AIF precursor is synthesized in the cytosol and is imported into
mitochondria, The mature AIF protein, a flavoprotein (prosthetic
group: FAD) with significant homology to plant ascorbate reduc-
tases and bacterial NADH oxidases, is normally confined to the
mitochondrial intermembrane space. In a variety of different apopto-
sis-inducing conditions, AIF translocates through the outer mito-
chondrial membrane to the cytosol and to the nucleus. Ectopic
(extra-mitochondrial) AIF increases the permeability of the outer
mitochondrial membrane, thereby triggering the release of the
caspase activator cytochrome c. Moreover, AIF induces nuclear
chromatin condensation, as well as large scale (~50 kbp) DNA frag-
mentation. Thus, similar to cytochrome c, AIF is a phylogenetically
old, bifunctional protein with an electron acceptor/donor (oxidore-
ductase) function and a second apoptogenic function. In contrast to
cytochrome c, however, AIF acts in a caspase-independent fashion.
The molecular mechanisms via which AIF induces apoptosis, as
well as the phenotype of AIF knock-out cells will be discussed.
L17
New approaches to inhibiting TNF production in
rheumatoid arthritis: is pathological TNF regulated
in the same way as protective TNF?
M Feldmann, B Foxwell, R Maini and F Brennan
Kennedy Institute of Rheumatology Division of Imperial College School
of Medicine, London, UK
The success of antiTNF therapy of rheumatoid arthritis with inflix-
imab (Remicade) and etanercept (enbrel) has prompted us to seek
other ways of inhibiting TNF production, and to seek to determine
the cellular and molecular mechanisms underlying the excess and
prolonged TNF synthesis in RA.
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology ResearchWe have studied spontaneous synovial TNF production and found it
to depend on the function of synovial T cells. These T cells behave
like cytokine activated T cells and not antigen activated T cells from
normal individuals. This was determined by comparing the TNF
response to inhibitors of PI3Kinase and of NFkB in Dayer type Tcell-
macrophage cocultures, using the 3 types of T cells.
This result has important implications, at several levels. First, it ends
the controversy concerning the role of T cells in late RA, they are
involved, but their function is atypical. Second, it demonstrates that
the synovial T cells which resemble cytokina activated T cells are a
goog target for therapy. As these cells are not present in acute pro-
tective immune responses, it predicts that if it turns out that the risk
of infection increases with prolonged use of TNF inhibitors, target-
ting TNF indirectly by this approach, for example with a monoclonal
antibody, might be a safer approach.
L18
Cytokine signalling: new insights and new
opportunities for therapeutic intervention?
JJ O’Shea
Lymphocyte Cell Biology Section, Arthritis and Rheumatism Branch,
National Institute of Arthritis, Musculoskeletal and Skin Diseases, NIH,
Bethesda, MD 20892-1820; USA
It is well documented that cytokines have critical functions in regu-
lating immune responses and remarkably, the number of cytokines
continues to expand. One large family factors that includes many
interleukins and interferons binds related receptors termed the Type
I and Type II families of cytokine receptors. These receptors activate
Janus kinases (Jaks) and Stat family of transcription factors. The
essential and specific function of Jaks and Stats is particularly well
illustrated by human and mouse mutations. For instance, mutations
of human Jak3 results in severe combined immunodeficiency. These
mutations are of interest in that they provide clues to Jak
structure/function. Additionally, patients with mutations that allow
for partial expression of the protein may have nonclassical clinical
presentations in which autoimmune features are prominent. There
are also a number of mechanisms by which cytokine signaling is
attenuated. One important family of inhibitory molecules is the
SOCS family. The possibility that the various components of the
cytokine signaling pathway could be targeted to produce novel
immunosuppressive compounds will be discussed.
L19
The pathogenesis of vasculitis
CGM Kallenberg
Department of Clinical Immunology, University Hospital Groningen,
P.O.Box 30.001, 9700 RB Groningen, The Netherlands
In the secondary vasculitides, associated with infectious disorders,
connective tissue diseases and other conditions, immune com-
plexes play a major immunopathogenic role. Immune complexes are
absent in most of the primary vasculitides. T-cells are, probably,
involved in the large vessel vasculitides, particularly giant cell arteri-
tis, whereas the small vessel vasculitides are associated with anti-
neutrophil cytoplasmic autoantibodies (ANCA). Clinical
observations, in vitro experimental findings, and in vivo data from
animal experiments suggest that ANCA in those diseases, which
are directed to proteinase 3 (PR3) or myeloperoxidase (MPO), are
involved in their pathogenesis.
Most in vitro studies have focussed on ANCA-induced neutrophil
activation. More recently the interaction between ANCA, neutrophils
and endothelial cells has been studied in flow systems. ANCA
appear to activate integrin-mediated adhesion of neutrophils and
adhesion-dependent degranulation. ANCA-induced monocyte acti-
vation has been studied to a lesser extent. The role of ANCA-specific
T-cells is still under investigation. Epitope analysis showed T-cell
reactivity to peptides from PR3 but no specific PR3 sequence could
be identified that was preferentially recognized by T-cells of vasculitis
patients compared to controls. In vivo experimental studies, in which
an MPO-directed autoimmune response is generated, show the
phlogistic potential of this response. Apoptotic neutrophils may,
under certain circumstances, induce the induction of ANCA. Data
from clinical and experimental studies suggest that ANCA alone are
not sufficient to induce disease. Exogenous factors, in particular car-
riage of Staphylococcus aureus and silica exposure, may be involved
as well. S. aureus products may elicit antibody responses resulting in
focal immune complex deposition, e.g. in the kidneys. ANCA may
aggregate the inflammatory response resulting in destruction of com-
plexes and the development of severe necrotizing glomerulonephritis
without immune deposits.
Taken together, the interplay between genetic and exogenous
factors may induce autoimmunity to myeloid enzymes which, in
concert, lead to the clinical expression of the ANCA-associated vas-
culitides.
L20
The pathogenesis of osteoarthritis: potential
targets for therapy
S Abramson
Department of Rheumatology & Medicine, Hospital for Joint Diseases,
New York, USA
It is likely that the excessive production of cytokines, inflammatory
mediators and growth factors by the inflamed synovium and acti-
vated chondrocytes play an important role in the pathophysiology of
osteoarthritis. IL-1b and TNF-a can stimulate their own production
and induce chondrocytes and synovial cells to produce other
cytokines such as IL-8, IL-6, LIF, as well as stimulate proteases,
nitric oxide (NO) and prostaglandin E2 (PGE2) production. NO and
PGE2 are spontaneously produced by human osteoarthritis-
affected cartilage. The excessive production of nitric oxide inhibits
matrix synthesis and promotes its degradation. Furthermore, by
reacting with oxidants such as superoxide anion, nitric oxide pro-
motes cellular injury and renders the chondrocyte susceptible to
cytokine-induced apoptosis. Although PGE2 is the predominant
eicosanoid produced by OA cartilage, PGI2, PGD2, TXA2 and
LTB4 are also spontaneously produced. These specific eicsoanoids
exert diverse effects on matrix metabolism and gene expression that
require detailed elucidation. Differential gene product analysis also
reveals increased expression of osteopontin (OPN) and fibronectin
(FN) mRNA in human osteoarthritis-affected. Osteopontin inhibits
the spontaneous production of inflammatory mediators such as NO
and PGE2. Therefore, inflammatory and anti-inflammatory molecules
produced by OA chondrocytes can be targeted in future therapeu-
tic stategies of OA.
L21
The role of “nurse-like cells” in bone resorbtion
observed in patients with RA
T Ochi
Osaka University Medical School, Osaka, Japan
Synovial stromal fibroblastic cells were histologically suggested to
be derived from the mesenchymal fibroblastic cells migrating from
the ajacent bone marrow space. The membrane structures, cytokine
productions, and other bioligical charactceristics are very similar
among those fibroblastic cells derived from these two origins. These
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Available onlinehttp://arthritis-research.com/supplements/3/SAcells were found to have a characteristic biological function; holding
lymphocytes underneath and supporting the development and pro-
liferation of these cells. This function named “pseudoemperipolesis”
was originalily found by Dr Wekerle (1980) in thymus cells of rats
and mice, and those fibroblastic cells were named as nurse cells.
We established the mesenchymal fibroblastic cell lines from syn-
ovial tissue and bone marrow cells in RA patients, and found the
pseudoemperipolesis in these fibroblastic cells (nurse-like cells;
NLC) just like nurse cells .
We isolated monocytes from the peripheral blood of healthy donors,
and incubated with NLC from RA patients (RA-NLC) . After 4 weeks
of culture, TRAP- positive mononuclear cells with larger cytoplsma
appeared. Monocytes cultured in medium alone died within 6 weeks.
These TRAP- positive mononuclear cells differentiated into the multi-
nucleated giant cells by incubating with some cytokines even in the
absence of RA-NLC. These multinucleated giant cells showed the
bone-resorbing activity by culturing on dentine slices. Considering
that the significantly higher number of TRAP- positive mononuclear
cells and the much more nucleated giant cells with higher bone-
resorbing activity could be obtained from the iliac bone marrow of
patients with more erosive disease group, RA-NLC could be consid-
ered to play important roles in highly activated bone destruction
(including severe secondary osteoporosis) of RA patients.
L22
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Molecular events in cartilage formation and
remodeling
Dick Heinegård
Department of Cell and Molecular Biology, Lund University, BMC -
Plan C12, SE-221 84 Lund, Sweden
Cartilage extracellular matrix contains a major component of highly
anionic proteoglycan contributing fixed charges creating and
osmotic environment and a swelling pressure important for resisting
pressure load. Another key element is a network of fibers with colla-
gen 2 as the major constituent providing tensile properties and an
ability to take up load.
In forming the cartilage matrix the cells produce the macromole-
cules that constitute the building blocks. These are assembled into
the structures of the tissue outside of the cells in a number of spe-
cific interactions. An example is the fiber network where collagen
molecules form fibrils by interactions where a variety of matrix mole-
cules act as catalysts/chaperons or inhibitors.
Examples of molecules interacting with collagen are particularly
found among the leucine rich repeat proteins (LRRP). These include
decorin, fibromodulin, lumican and biglycan all with known capacity
to bind collagens and influence fibrillogenesis in vitro. This binding
occurs via the LRR-domain. Furthermore, the molecules have an
additional functional domain, that in the case of decorin carries der-
matan sulfate chains capable of interacting with other constituents
in the matrix including other collagen fibers thereby crossbridging
and creating a fibrillar network covering large parts of the tissue.
In the case of decorin, lumican and fibromodulin, mice with inacti-
vated genes show alterations in collagen fibril assembly indicative of
roles at different stages of the process. PRELP binds collagen via
its repeat domain and heparan sulfate via a characteristic N-terminal
extension. This includes binding heparan sulfate at the cell surface.
Chondroadherin binds cells via their a2b1 integrin. The molecule
can actually be isolated from cartilage bound to collagen 2 mole-
cules after activation of endogenous proteinases.
COMP represents a different class of molecules with five identical
subunits held together in their N-terminal end. The C-terminal end of
each chain has a structure allowing tight and specific interactions with
triple helical collagen. There are four sites along the collagen mole-
cule each with a KD of 10-9. COMP in vitro has a marked effect in
catalyzing the correct assembly of collagen fibers, while not binding to
the completed fiber. Thus, the molecule act as a chaperon.
Interestingly COMP is upregulated in early phases of osteoarthritis,
where a repair attempt of the damaged tissue is likely to be a com-
ponent. The molecule or fragments thereof released to synovial fluid
and blood, actually serves as an indicator of processes in the carti-
lage leading to its destruction.
In processes in cartilage remodeling, many of the constituents in the
matrix are degraded and lost to surrounding body fluids. This degra-
dation is likely to be a response to remodeling following material
fatigue, altered load or growth. It may also occur as part of a patho-
logical process. It is likely that it is coupled to attempts at repair
laying down new matrix constituents to produce an adequately func-
tioning matrix. In disease it is apparent that the imbalance between
breakdown and adequate repair leads to progressive changes in
cartilage composition characteristic for the various stages of the
disease.
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The molecular mechanism of osteoclastogenesis:
ODF/RANKL-dependent and independent
pathways
T Suda*†, N Takahashi*, N Udagawa* and C Miyaura‡
*Showa University School of Dentistry, Tokyo 142; †Medical Culture,
Tokyo 171; ‡Tokyo University of Pharmacy and Life Sciences, Tokyo
192, Japan
It is well established that osteoblasts and bone marrow stromal cells
express osteoclast differentiation factor (ODF, also called RANKL)
in response to several bone-resorbing factors to support osteoclast
differentiation from their precursors. Osteoclast precursors which
express RANK, a TNF receptor family member, recognize ODF/
RANKL through cell-to-cell interaction with osteoblasts/stromal
cells, and differentiate into osteoclasts in the presence of M-CSF.
Osteoclastogenesis inhibitory factor (OCIF, also called OPG) acts
as a decoy receptor for ODF/RANKL. ODF/RANKL is responsible
for inducing not only differentiation, but also survival and activation
of osteoclasts.
IL-1 and TNFa also play a major role in the pathogenesis of bone
resorption induced by inflammation. IL-1 induced osteoclast differ-
entiation by a classical ODF/RANKL-dependent mechanism, indi-
cating that osteoblasts are essential for IL-1-induced osteoclast
formation. In contrast, mouse TNFa strongly stimulated differentia-
tion of M-CSF-dependent bone marrow macrophages (M-BMMf)
into osteoclasts without any help of osteoblasts/stromal cells.
Osteoclast formation by TNFa was inhibited by antibodies against
TNF receptor type 1 and 2 (TNFR1 and TNFR2), but not by
OPG/OCIF, indicating that differentiation of M-BMMf into osteo-
clasts by TNFa occurs by a mechanism independent of the
ODF/RANKL-RANK interaction. IL-1 failed to induce differentiation
of M-BMMf into osteoclasts.
More recently, we found that lipopolysaccharides (LPS)-induced
bone loss did not occur in knockout mice of EP4, a subtype of PGE2
receptor. This indicates that EP4 signals are involved in the LPS-
induced bone resorption. LPS appeared to induce osteoclast forma-
tion by two different pathways: one is an ODF/RANK-independent
pathway involving TNFa. LPS induces TNFa production through toll-
like receptor 4 (TLR4) in macrophages, which in turn directly acts on
osteoclast progenitors through TNFR1 and TNFR2 to induce osteo-
clast differentiation. In this pathway, osteoblasts did not appear to be
Arthritis Research    Vol 3 No 2 Abstracts of the 21st European Workshop for Rheumatology Researchinvolved. The other pathway is the classical ODF/RANKL-dependent
pathway. In the classical pathway, LPS induces PGE2 production
through TLR4 in osteoblasts and macrophages, which in turn
induces ODF/RANKL through EP4 in osteoblasts. ODF then binds
ODF receptor (RANK) in osteoclast progenitors by cell-cell contact,
which stimulates osteoclast differentiation.
We conclude that osteoblasts/stromal cells are involved in not only
physiological, but also pathological bone resorption via
ODF/RANKL.
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Normal and pathological bone development
controlled by the AP-1 transcription factor complex
EF Wagner et al.
I.M.P., Dr. Bohr-Gasse 7, A-1030 Vienna, Austria
c-Fos is a key regulator of bone development, since transgenic mice
expressing exogenous Fos develop bone tumors, whereas mice
lacking c-Fos are osteopetrotic due to a differentiation block in bone
resorbing osteoclasts. We are interested to study how c-Fos and its
related protein Fra-1, which is c-Fos inducible, control osteoblast
proliferation and osteoclast differentiation (1). We recently found
that Fra-1 is an essential gene for mouse development (2) and
transgenic mice overexpressing Fra-1 develop the bone disease
osteosclerosis, which is due to increased bone formation (3). To
test whether Fra-1 can substitute for c-Fos, we generated knock-in
mice that express Fra in place of c-Fos. Fra-1 rescues c-Fos depen-
dent functions in bone development which appeared to be gene
dosage dependent (4). However, Fra-1 failed to substitute for c-Fos
in inducing expression of target genes in vitro. We are using these
systems to identify novel Fos target genes by microarrays and with
the help of bone-specific conditional alleles of c-Fos and Fra-1, we
are studying the molecular mechanisms how Fos proteins govern
bone cell development and differentiation.
Since Fos proteins need Jun proteins to activate transcription, we
investigated the function of c-Jun in bone cells using the cre/loxP
system. Chondrocyte-specific inactivation using col2A1-cre trans-
genic mice results in severe scoliosis caused by failure of intevertebral
disk formation and abnormal vertebral arch development, suggesting
that c-jun is a novel regulator of sklerotomal differentiation.
1. Matsuo, K., Owens, J.M., Tonko, M., Elliot, C. Chambers, T.J. and
Wagner, E.F. (2000) Osteoclast differentiation by the c-Fos target
gene Fra-1, Nature Genetics 24, 184-187.
2. Schreiber, M., Wang, Z.Q., Jochum W., Fetka, I. Elliott, C. and
Wagner, E.F. (2000). Placental vascularization requires the AP-1
component Fra1. Development 127, 4937-4948.
3. Jochum, W., David, J.P., Elliot, C., Wutz, A., Plenk, H., Matsuo, K.
and Wagner, E.F. (2000) Increased bone formation in transgenic
mice expressing the transcription factor Fra-1, Nature Medicine 6,
980-984.
4. Fleischmann, A., Hafezi, F., Elliott, C., Remé, C.E., Rüther, U. and
Wagner, E.F. (2000). Fra-1 replaces c-Fos-dependent functions in
mice. Genes & Development 14, 2695-2700.
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Interphase fluorescence in situ hybridization
analysis of fibroblast-like synoviocytes of patients
with rheumatoid arthritis and osteoarthritis
HP Kiener, J Ackermann, K Redlich, I Radda, CW Steiner, 
P Bitzan, JS Smolen, J Drach
University of Vienna, Vienna, Austria
Synovial stromal cells (e.g. fibroblast-like synoviocytes, FLS) are
thought to play an essential role in the pathogenesis of inflamma-
tory joint diseases, in particular in the destructive aspects of
rheumatoid arthritis (RA). Recent evidence indicates that chromo-
somal alterations have a profound impact on cellular behavior, even
in non-transformed cells. We therefore investigated whether or not
alterations in chromosome number occur in FLS of patients with
RA and osteoarthritis (OA).
Synovial tissue was collected at the time of joint surgery from 21
patients with RA and 22 patients with OA. Synoviocytes were iso-
lated by enzymatic dispersion. Interphase fluorescence in situ
hybridization (FISH) analysis of freshly isolated synoviocytes and
stimulated or unstimulated cultured FLS was performed using DNA
probes specific for chromosome 17, 8, 11, 6, 7 centromeres and
the p53- (17p13), c-myc- (8q24), and the retinoblastome gene-1-
(13q14) gene locus.
In all the patients studied, both RA and OA, concordant signal
numbers with the probes recognizing chromosome 17, 8, 11
centromeres, 17p13, 8q24, and 13q14 were obtained (dual color
FISH), indicating that allelic losses or gains of p53, c-myc, or the
retinoblastoma gene-1 are not prevalent in fibroblast-like synovio-
cytes. Using a-satellite DNA probes specific for chromosome 6 or
7, alterations in chromosome number were identified in synovio-
cytes derived from some patients with both RA and OA.
In fibroblast-like synoviocytes, alterations in chromosome number
and subsequent selection of chromosomally altered cells may
occur in the joints of patients and contribute to the perpetuation of
synovitis.
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